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showing various abnormalities. Clockwise from top center:
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The 23rd Annual Stoneburner Lecture Series
Symposium on Hematologic Disorders
Glucose-6-Phosphate Dehydrogenase
Deficiency*
DANIEL N. MOHLER

Department of Internal Medicin e,
University of Virginia School of Medicine,
Charlottesville 22901

Major attention was first focused on the problem of
acute hemolytic anemia in the early 1950's, during
the Korean War. Large numbers of American Negroes
stationed in Korea developed this anemia after taking
primaquine for treatment or prophylaxis of malaria.
A study group was formed in Chicago under the direction of Alving; it was this group of investigators
who contributed much of the early information which
has led to our understanding of this type of anemia
(Dern, et al, 1954; Dern, Beutler and Alving, 1954;
Beutler, Dern and Alving, 1954). This also resulted in
an upsurge of interest in red cell metabolism, and led
to many of the advances we are hearing about in this
lecture series.

usual hematologic studies were normal and were of
no help in detecting the susceptible individual. The
first significant clue came when Heinz bodies were
noted on supravital staining of the peripheral blood
smear during the acute hemolytic episode. This gave
rise to the first in vitro test for detecting primaq uinesensitive individuals, the Heinz body test devised by
Beutler (Beutler, Dern and Alving, 1955). In this test
blood is incubated with the oxidant drug, acetylphenylhydrazine, and then observed for the presence of Heinz
bodies. Fig 2 shows that the red cells from a susceptible individual, on the left, have many small Heinz
bodies; while normal red cells, on the right, have one
or two large Heinz bodies.

Clinical Course
The clinical course of primaquine-induced hemolysis is illustrated in Fig 1. Acute intravascluar hemolysis occurs two to four days after exposure to the drug,
and is accompanied by hemoglobinuria. The hematocrit continues to fall for seven to 12 days and approximately 30 to 50 percent of the red cell mass is destroyed (Dern et al, 1954; Dern, Beutler and Alving,
1954). As the reticulocyte response reaches its peak
in around ten to 12 days, the hematocrit begins to rise
again and gradually returns to normal levels in four to
five weeks, even though primaquine is continued.
Radioiron red cell labeling studies have shown that it
is the older population of red cells that is most susceptible to primaquine hemolysis while young erythrocytes
are relatively resistant (Beutler, Dern and Alving,
1954). However, if the dosage of primaquine is increased sufficiently even the younger cells are hemolyzed.
At the time of the Korean War, the only way to
detect a primaquine-sensitive soldier was to challenge
him with the drug, which was not without danger. The

Mechanism of the Anemia

* Presented at the 23rd Annual Stoneburner Lecture
Series, February 19, 1970, at the Medical College of Virginia, Richmond.
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The formation of Heinz bodies is of major importance in the pathogenesis of this type of hemolytic
anemia. The importance of deformability of the red
cell as it travels through the microcirculation has been
stressed throughout this lecture series. Heinz bodies,
which represent precipitated denatured hemoglobin,
are rigid bodies which hamper pliability of the red
cell and interfere with its ability to traverse the microcirculation, particularly in the spleen. Rifkind (1965 ;
1966) has demonstrated this very nicely with electron
microscopy of red cells containing Heinz bodies in the
spleen. Fig 3 shows several red cells with Heinz bodies.
One red cell is completely devoid of hemoglobin except for the Heinz bodies which are firmly attached to
the red cell membrane. In Fig 4 a red cell is shown
going from a splenic cord into a sinus. It is apparent
that the Heinz body in the tail will prevent either the
entire red cell or a portion of it from making it through.
Although the Heinz body test was useful in detecting
primaquine-sensitive individuals, it shed no light on
the underlying biochemical defect. The first biochemical lead was the observation that red cell reduced
glutathione (GSH) was lower in affected individuals
than in normals. This difference was slight when fresh
blood was used, but when blood was incubated for
MCV QUARTERLY 6(2): 42-49, 1970
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Fig. 1-Clinical course in primaquine-induced hemolytic anemia. (From Alving AS, Johnson CE, Tarlov AR: Mitigation of the
haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the chesson strain of plasmodium
by intermittent regimens of drug administration. Bull WHO 22 : 625, 1960. Reprinted with permission.)
two hours with acetylphenylhydrazine there was a
marked fall in GSH levels in primaquine-sensitive red
cells with nearly no fall in normal cells (Beutler,
1957). (Fig 5) This formed the basis for the glutathione stability test for detecting susceptible individuals.
This observation focused attention on erythrocyte
glutathione metabolism and eventually led to the delineation of the basic red cell defect. Glutathione re-

ductase was studied first. When this proved to be normal, glucose-6-phosphate dehydrogenase ( G6PD) was
assayed and found to be deficient (Carson, et al,
1956) .
The importance of the G6PD-glutathione system in
protecting the red cell from oxidative injury can be
summarized in a series of interrelated reactions (Table
l) .

Table 1
Interrelated Reactions of the G6PD-glutathione System in Protecting the Red Cell from Oxidative Injury
gl utathione
I . Red Cell + oxidant

----~

H20 2

3. GSSG + NADPH +

H+----~

2GSH + NADP +

reductase
glutathione
2. H20 2 + 2GSH

G-6-P
2H,O + GSSG 4. G-6-P + NADP +

peroxidase

6-PG + NADPH + H +
dehyi;lrogenase

/
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When the red cell is subjected to oxidative stress
through exposure to some drug or infectious agent,
hydrogen peroxide is generated. Although the erythrocyte is rich in catalase, which decomposes H,O,, glutathione peroxidase seems to be more important in the
reduction of H,0 2. An hereditary deficiency in catalase
(Aebi, Heiniger arid Suter, 1963) is not associated
with hemolytic anemia while a deficiency of glutathione peroxidase is (Steinberg, Brauer and Necheles,
1970).
For glutathione peroxidase to remain effective in reducing H,O, to H,O a continuous supply of GSH must
be available. This is accomplished by the reduction of
GSSG to GSH by glutathione reductase, which in turn
requires NADPH as a cofactor. A deficiency of glutathione peroxidase, glutathione reductase or glucose-6phosphate dehydrogenase, or the inability to synthesize
glutathione all lead to defective reduction of H 20,
and hemolytic anemia. When H,02 accumulates, hemoglobin is irreversibly oxidized and precipitated as
Heinz bodies (Mills and Randall, 1958; Cohen and
Hochstein, 1961).

Tests to Detect G-6-PD Deficiency
We have mentioned the Heinz body and glutathione
instability tests as methods to detect G6PD deficiency,
but they are somewhat cumbersome, indicating a need
for simple screening tests for large populations. We
have found the methemoglobin reduction test (Brewer,
Tarlov and Alving, 1960) to be simple and reliable.
This test is based on the fact that there are two methemoglobin reductases in the red cell-one using
NADH as a cofactor, and the other using NADPH
which is derived from the G6PD reaction in the pentose phosphate pathway. Blood is incubated with sodium nitrate which oxidizes oxyhemoglobin to methemoglobin. Methylene blue is also added to stimulate
the pentose shunt which leads to more efficient methemoglobin reduction. When there is G6PD deficiency
the shunt is not stimulated, NADPH is not generated,
and methemoglobin is not reduced properly. After
two hours the brown color of methemoglobin remains,
rather than the red color of oxyhemoglobin which is
present after two hours incubation of normal blood. :
This test is simple to perform, requires only a few·

Fig. 2- Heinz body formation after incubation with acetylphenylhydrazine. Primaquine-sensitive red cells on the left, normal red
cells on the right. (From Beutler E, Dern RJ, Alving AS: The hemolytic effect of primaquine. VI. An in vitro test for sensitivity
of erythrocytes to primaquine. J Lab Clin Med 45: 43, 1955. Reprinted with permission.)
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Fig. 3- Electron micrograph of red cells containing Heinz bodies in the spleen. Cell 3 is devoid of hemoglobin except for Heinz
bodies attached to the membrane. (From Rifkind RA:' Heinz body anemia: an ultrastructural study. II. Red cell sequestration
and destruction. Blood 26: 438, 1965. Reprinted with permission.)

common reagents, and can be read visually. However,
it often gives equivocal results if carried out during an
acute hemolytic episode, and is poor in picking up
female heterozygotes.
The cyanide-ascorbate test of Jacob and Jandl
( 1966) is another simple screening test which can be
read visually. This test has an advantage in that it is
usually positive in the face of acute hemolysis and will
usually detect female heterozygotes. The ascorbic
acid causes generation of H.O,, which stresses the
system described previously; the cyanide inhibits
catalase. Thus, not only a deficiency in G6PD but a
deficiency in the other enzymatic steps in the system
also gives a positive test.
A young man whom we worked up recently for an
hereditary hemolytic anemia provided a good example
of the usefulness of this test. The methemoglobin reduction test was negative for G6PD deficiency; the
cyanide-ascorbate test was positive, which immediately
focused attention on the glutathione system. Enzyme
assays for G6PD, glutathione reductase, and glutathione peroxidase were all normal or increased; but

the level of GSH was found to be only ten percent
of normal. Further studies showed that the patient had
a deficiency of glutathione synthetase, which was responsible for his hemolytic anemia. The patient was
homozygous for the deficiency, while his parents were
heterozygous and had a lesser degree of red cell glutathione synthetase deficiency (Mohler et al, 1970).
Although several families with this type of enzyme
deficiency have been reported in Europe, this was the
first such report in America. For the reasons enumerated, we now believe that the cyanide-ascorbate test
is the most satisfactory screening test.
Variants of G6PD Deficiency

Although in the United States G6PD deficiency is
seen primarily in the Negro (ten to 13 percent of
Negro males) , the deficiency occurs in many ethnic
groups and over 50 mutations have now been described
(Carson and Frischer, 1966; Kirkman, Kidson and
Kennedy, 1968).
The enzyme has been purified and found to have a
molecular weight of approximately 240,000 consisting
45
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Fig. 4-Electron micrograph of a red cell passing from a splenic cord, below, to a splenic sinus above. The tail of the cell contains several large Heinz bodies which are impeding its progress. (From Rifkind RA: Heinz body anemia: an ultrastructural study.
II. Red cell sequestration and destruction. Blood 26: 436, 1965. Reprinted with permission.)
of six peptide subunits weighing 40,000. There are
two major electrophoretic patterns which are designated A and B. Table 2 shows which electrophoretic
type occurs in various population groups. Normal
Caucasians have only type B, while 82 percent of normal Negroes have type B and 18 percent have type A.
Most Caucasians have G6PD deficiency type B, while
in the Negro the common deficiency type is A and
rarely B.
Yoshida (1968) and his colleagues have shown that
the only difference between types A and B G6PD is
that type A has aspartic acid while type B has asparagine. A great many biochemical comparisons in terms
of enzyme kinetics have been made between normal
and defic;ient type A in Negroes. The only difference
which has been found is that the enzyme is degraded
more rapidly in the deficient erythrocyte than in the
normal (Yoshida, 1968). This explains why older red
cells are more susceptible to oxidant stress than
younger cells, since the G6PD content falls rapidly as
46

the red cell ages. This also explains why it is only the
mature red cell which shows a deficiency of G6PD in
the Negro, as white cells have a short life span.
However, in G6PD deficiency in Caucasians from
the Mediterranean, type B, the deficiency is noted in
leukocytes as well as erythrocytes. Also, a kinetic difference has been observed when comparing the normal and deficient enzyme; the latter has a weaker affinity for its substrate, glucose-6-phosphate (Yoshida,
1968).
Fig 6 shows the world distribution of G6PD deficiency. It has been estimated that over 100 million people have this enzyme deficiency (Carson and Frischer,
1966; Beutler, 1966). Since the distribution follows
mainly tropical areas where there is a high incidence
of malaria, it has been proposed that the enzyme deficiency affords some protection against infection with
the malarial parasite and accounts fer its increased
prevalence in such areas. However, malnutrition and
other diseases with a similar geographic distribution,
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Fig 5-Content of GSH in primaquine-sensitive and normal red cells before and after incubation with acetylphenylhydrazine. (From Beutler E: The glutathione instability of drug-sensitive red cells. J Lab Clin Med 49: 89,
1957. Reprinted with permission.)

TABLE 2
Variants of Glucose-6-Phosphate Dehydrogenase
Amino Atid
Electrophoretic
Population
Type
Substitution
Normal Caucasian
Normal Negro
Deficient Caucasian
Mediterranean
Chinese
Deficient Negro
Common
Rare

B+
B+ (823 )
A+ (18 3 )

Aspartic acid for
asparagine

BBAB-

such as plague, might also play a role (Carson and
Frischer, 1966).
Negroes and Caucasians from the Mediterranean
area with G6PD deficiency are not anemic and do not
display overt hemolysis unless exposed to the oxidant
stress of some drug or infection. In contrast, Caucasians from Northern Europe and some other parts of
the world have a congenital nonspherocytic hemolytic
anemia secondary to their G6PD deficiency. Less than
one percent of Caucasians of Northern European origin have this deficiency. The anemia is usually fairly
mild, with hematocrits in the mid 30's, and becomes
much worse upon exposure to oxidant drugs.

Fig 7 shows a family which we have reported (Mohler and Crockett, 1964) in which two first cousins were
affected. The gentic transmission here, as in all cases
of G6PD deficiency, is sex linked; the hemizygous
sons show the full effect of the deficiency, and the
heterozygous mothers show variable expression. In
our two patients there was no measurable red cell
G6PD activity and the mothers had borderline low
values.
Fig 8 shows a comparison of G6PD levels in various
groups. In our laboratory normal G6PD activity ranges
from four to seven units. The patients with higher than
normal levels had a variety of hemolytic anemias with
reticulocytosis, the increased number of young red
cells accounting for the elevated G6PD activity. The
second column shows deficient Negroes who had about
ten percent of normal activity. The last column shows
three Caucasians with no measurable activity, and
includes the two patients shown in Fig 7 plus a man of
Turkish ancestry. The values in the top part of that
column represent the relatives of the two cousins depicted in Fig 7, and again illustrate the borderline
levels of the mothers.
Causes of Acute Hemolytic Episodes in a G6PD
Deficient Individual
Table 3 lists some of the most common oxidant
drugs; more complete lists are also available (Carson
and Frischer, 1966; Beutler, 1966). Most of these
drugs are aromatic amines; all of them act as electron
carriers, hence having the ability to generate H.O. and
act as oxidants. Some are potent oxidants, such as the
sulfonamides and nitrofurans. Others, such as aspirin
and chloramphenicol, are relatively weak and cause
hemolysis only in Caucasians with very low G6PD
levels or when they are used in high dosages.
It is well known that a variety of drugs produce
acute hemolysis in a G6PD deficient patient, but it has
not been sufficiently emphasized that infections alone
also cause hemolysis. Burka and his associates (Burka,
Weaver and Marks, 1966; Burka, 1969), reviewing a
large number of hemolytic episodes in G6PD deficient
patients seen at Columbia-Presbyterian Hospital, found
that infections alone were a more common cause of
hemolysis than drugs alone. Acute hemolytic episodes
occurred after bacterial pneumonia and a variety of
viral infections, particularly viral hepatitis.
They also pointed out in their study that many
women had hemolytic episodes. Approximately two
percent of Negro women are homozygous for G6PD
deficiency and would be expected to react to oxidant
stress; but heterozygous female carriers, or about 20
percent of Negro women, were not thought to be
susceptible. This study pointed out that there is enough
variation in enzyme levels in female heterozygotes, in
keeping with the Lyon hypothesis, that a significant
47
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number will hemolyze when exposed to the oxidant
stress of drugs or infection.
In summary, G6PD deficiency should be suspected
and tested for not only in Negro men who are taking
oxidant drugs, but also in Negro women and during
acute infections whether drugs are used or not.
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Sulfonamides
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Salicylazosulfapyridine (Azulfidine @)
N itrofurans
Nitrofurantoin (Furadantin ®)
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Nitrofurazone (Furacin ®)
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CONGENITAL NONSPHEROCYTIC HEMOCYTIC ANEMIA

~ DIED AT AGE 10 YRS. OF UNKNOWN TYPE OF BLOOD DISORDER

*
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UNITS OF GLUCOSE-6- PHOSPHATE DEHYDROGENASE ACTIVITY

F ig 7-Pedigree of a Caucasian family with erythrocyte
G6PD deficiency. (From Mohler DH, Crockett CL:
Hereditary hemolytic disease secondary to glucose-6phosphate dehydrogenase deficiency: report of three cases
with special emphasis on ATP metabolism. Blood 23: 429,
1964. Reprinted with permission.)
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Fig 8-Glucose-6-phosphate dehydrogenase activity of red
cells from normal subjects, and from enzyme deficient
Negro and Caucasian individuals.
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New Thoughts on Hereditary
Spherocytosis* t
ROBERT I. WEED

Department of M edicin e,
University of Rochester Sch ool of M edicine and D enistry,
Rochester, New Y ork 14620

This discussion could be abbreviated by saying that
if you take out the spleen, you can cure the patient
with hereditary spherocytosis (HS) . However, that is
a clinical cure, and we know that careful measurements still demonstrate some shortening of red cell life
span though well within the limits of normal marrow
compensation. With the exception of intercurrent infections which may occasionally depress the marrow,
patients with HS are usually asymptomatic after
splenectomy. Having dealt with the treatment, however, there is much to be learned from examining the
pathologic physiology of HS.
The HS erythrocyte is a fascinating cell whose
pathologic changes provide us with insights into physiology of the normal red cell.
When one incubates hereditary spherocytes in a test
tube, as in the autohemolysis test, for example, the
changes are mimicked by normal red cells if you incubate the latter for a longer period of time. The shape
change, from a disc to a sphere, which is already under way in the circulation of the patient with HS, occurs in normal blood when incubated to Adenosine
Triphosphate (ATP) depletion in a test tube. The cells
lose potassium and gain sodium. There is an initial
period of swelling followed by shrinkage, and ultimately loss of membrane lipid and development of
irreversible changes in shape. Although these changes
all occur earlier in HS cells than in normal cells (Weed
and Bowdler, 1966) , many of the changes of this sort
studied in the test tube take a period of time. However,
the hereditary spherocyte is compromised within the
circulation even as we find it in a sample of fresh
blood . So, although in vitro changes are all of considerable interest, the time sequence is a matter of
concern. Perhaps we have not really been examining
the fundamental problem, since many of the in vitro
alterations are late changes.

* Presented at the 23rd Annual Stoneburner Lecture
Series, February 19, 1970, at the Medical 'college of Virginia, Richmond.
t This work was supported in part by USPHS Grant
#HE-06241 and in part by contract with the US Atomic
Energy Commission at the University of Rochester Atomic
Energy Project, Rochester, New York and has been assigned publication #UR-49-1286.
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Fig 1-Fine structure of the red pulp of the spleen.
A) Terminal arteriole
B) Red cell in the splenic cord
C) Red cell traversing lumen in basement membrane

D) Splenic sinus.
(From Weiss, Amer J Anat 113: 91 , 1963, with permission)

Role of the Spleen in HS

posed at A. Here, the high endothelial cells and the
terminal arterioles deliver the first geometric requirement for deformation of the red cell. The cell must be
very deformable and squeeze out in between the endothelial cells, which line the terminal arterioles just as
they break up into the splenic pulp. The red cells must
make their way through the cord itself. The cord is a
potential space, rather than an actual anatomic space.
The large hungry phagocytes which lie in the pulp
(the cords) actually touch one another until they are
pushed apart by the red cells making their way down.
Many never make it, and get engulfed as they pass. If
they are able to slip by these phagocytic cells, then the
final anatomic hazard is the basement membrane (C)
separating spl -n;c cord from sinus. Here the cells
must migrate through openings which are as small as
from 0.5 to 5 microns in diameter. The red cell has a
normal greater diameter of 8 microns but it must be
able to change its shape rather dramatically to pass

Let us look and comment on why removing the
spleen is such a useful maneuver in the management
of hereditary spherocytosis and examine why the
splenic environment is particularly hostile to HS cells.
The first point I would like to make is related to the
anatomy of the spleen. As the blood enters the splenic
artery, lymphocytes are filtered off into the white pulp,
and the red cells which are much more deformable
pass on into the red pulp. In the pulp, red cells have
two possible pathways. One is a direct route from
arteriole into splenic venous sinus, by-passing the pulp
proper. The other is to pass through the terminal
arterioles, out into the splenic cords, and then back
into the sinuses and return to the general circulation.
Fig 1 is a diagramatic representation of splenic
ultra-structure. As we go from A to D and follow the
red cells as they make their way through the splenic
pulp, we see the first hazard of the splenic circulation
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through these small openings. Therefore, the first message that we can infer from looking at splenic architecture is the requirement for red cell deformation.
Determinants of Red Cell Deformability
What are the determinants of this deformability?
First, the discoid red cell shape is very important with
its excess of surface area in relation to volume. Any
decrease in surface area or increase in volume, will
produce a more spherical cell which is less able to deform. If the osmotic fragility is increased, it implies
either decrease in surface area, increase in cellular
osmotic contents, or cell volume in plasma. In addition
to shape, the intrinsic deformability of the cell is critical. Cell contents must be fluid as illustrated by sickle
cells in which hemoglobin becomes paracrystalline or
crystalline under conditions of low oxygen tension. In
the sickle cell, the contents and .the overlying membrane become very rigid. In hereditary spherocytosis
the intrinsic deformability of the membrane itself is
altered as well as the shape, although contents appear
unchanged in their viscosity.

Regarding shape, as mentioned, in order to develop
sphering of a biconcave cell, there must either be an
increase in the cell volume (which might be the consequence of abnormal permeability with swelling) without any change in surface area or, alternatively, a
change in surface area (a loss of membrane material),
or a change in the effective surface area by a conformational change in the membrane without any
change in volume. Any one or combination of these
leads to sphering and an increase in the osmotic
fragility test.
Whether the H S cell swells or shrinks has been a
matter of some discussion. The fact is that it does
both. In terms of the autohemolysis test, which is read
at 48 hours, the HS cell is in fact shrinking at the
time it is hemolyzing. Fig 2 is from work done in
1940 by Drs. Ham and Castle. The volume changes
and hemolysis of normal cells and those from a patient
with hereditary spherocytosis are plotted against hours
of incubation. Both normal and HS cells swell initially.
The normal cell actually swells to about 120 percent
of its zero time volume, and then shrinks. Even after
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ginning to swell sooner than normal, but do not swell as
much and are shrinking when hemolysis begins.
(Reproduced through the courtesy of Dr. T. H. Ham and
Dr. W. B. Castle).
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about 48 hours, there is minimal hemolysis of the
normal red cells. However, the HS cell swells only
about 12 percent to begin with, and by 24 hours it is
back to the starting volume. Yet, it is at this time that
hemolysis begins, and continues as the cells continue
to shrink. Thus, it is clear that hemolysis cannot be
attributed to increase in volume of the hereditary
spherocyte; it must be due to a decrease in the parameter which we will call effective surface area.
Nakao, Nakao and Yamazoe (1960) showed that
normal red cells undergo a shape change from bicqncave disc to sphere upon depletion of their ATP, but
that if ATP is regenerated the shape change is reversible. This phenomenon can be seen in both normal
and HS red c;ells after shorter periods of time (Weed
and Bowdler, 1966) . ATP depleted cells are virtually
all either crenated spheres or smooth spherocytes. If
one regenerates intracellular ATP with adenosine,
within two hours the cells reassume their biconcave
disc shape. These shape changes occur without any
significant loss of membrane lipid or other membrane
materials, implying a rearrangement of the cell membrane material. The process is independent of the addition of ouabain, so it is not a function of the sodiumpotassium pump.

Fig 3-Peripheral blood from patient with hereditary
spherocytosis, post-splenectomy. Note presence of biconcave discs, crenated discs, crenated and smooth spheres.

Fig 4-Phase photomicrograph of hereditary spherocytosis blood incubated 5 hours in absence of glucose. Note fragmentation.
(From J Clin Invest 45: 1137, 1966, with permission).
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Hereditary spherocytes, when incubated with adenosine, will also revert to a normal shape. Fig 3 is a
smear from a patient with hereditary spherocytosis.
In addition to the typical microspherocytes which we
anticipate, one also sees biconcave discs. In fact, HS
cells begin their lives as biconcave discs. The discsphere transformation seen in normal red cells when
they are severely ATP-depleted, is already underway
in the peripheral blood of the HS patient- in blood
which has normal mean ATP levels. Although many
attempts have been made to try to find a metabolic defect in the hereditary spherocyte, no glycolytic defect
has been clearly demonstrated. Thus, we have to look
elsewhere, and for this reason it has been suggested
that the intrinsic defect is in the membrane itself.
If one observes HS blood from the standard autohemolysis test, in addition to the shape changes that
are occuring, one can begin to see that the cell actually
begins to fragment off pieces of membrane. The biochemical correlate of this is loss of membrane lipid as
illustrated in Fig 4. The same phenomenon occurs in
normal red cells after a much longer period of depletion. Thus, there is shape change initially, followed by
this loss of pieces of membrane which may range in
size from sub-microscopic aggregates of lipid, all the
way up to pieces that may be as large as platelets. The
consequence of breaking off pieces like this without
losing contents or changing volume, is progressive increase in sphering. Decrease of surface area in relation
to a constant volume leads to further sphering and the
sphere so produced cannot negotiate narrow circulatory channels because of its shape. In patients who
have severe hemolytic hereditary spherocytosis, Langley and Felderhof (1968) have demonstrated that
there may be as much as a 40 percent decrease in
membrane lipid. This is what has been called "conditioning" by the spleen. We would suggest that splenic
conditioning may come about because cells that are already somewhat rigid are fragmented to some extent
during their passage through the spleen, and as a result they actually suffer a real loss of surface area.
They may be markedly more spherocytic when they reemerge in the general circulation and only pass around
the circulation once or twice more. To recapitulate,
the HS cell undergoes an accelerated shape change as
a result of ATP depletion as an early phenomenon.
Secondly, fragmentation loss of membrane surface
area contributes to the shape change, further limiting
in vivo and in vitro survival.
Turning to intrinsic deformability of the HS cell
apart from shape, there is no evidence for any loss of
fluidity of cell contents in hereditary spherocytes; but
there are changes in the intrinsic deformabili:y of the
membrane itself. One can measure the viscosity or loss
of jilterability of a packed washed cell suspension; both
increase very dramatically with ATP depletion.
However, these are relatively gross ways of evaluat54
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ing the problem since both filterability and viscosity
depend in part on shape and state of cell contents while
our interest has been in the properties of the membrane
itself. My colleague, Dr. LaCelle (Weed, LaCelle and
Merrill, 1969; LaCelle, 1969) has used a micropipette
to measure the pressure necessary to deform the
membrane. With that technique, one can look at individual cells rather than the mean behavior of the
population, as we do when we assay for enzymes, for
example.
Normal cells will pass with ease into a 2.9µ. pipette.
The analogy in the microcirculation is to capillaries
which have a length of about 14µ. or longer. If there
is a shorter length to be negotiated, the cell can get
through a narrower diameter. Thus, a normal cell can
negotiate the ·o.5µ. openings in the spleen, if the length
of the passage is short enough. Capillaries in the
general circulation range from 3 to 12µ. in diameter, so
some challenge of this kind is imposed throughout the
general circulation. Canham and Burton (1968) have
calculated that normal individuals or patients with
hereditary spherocytosis, when the spleen is still present, have red cells in their circulation which can negotiate a hole 3 microns in diameter. This means that
only smaller cells can persist in hereditary spherocytosis. When the spleen is removed, there is a 30 percent
lessening of this requirement, so that they .need only
• be able to negotiate a 4 micron diameter. It is clear
that the spleen imposes a striking geometric requirement within the circulation.
The bone marrow, interestingly enough, has a similar
architectural requirement. The openings between the
hematopoietic cords and the sinuses in the marrow are
of essentially the same dimensions (Weiss, 1965) , and
the architecture bears important similarities to splenic
ultrastructure. The marrow ultrastructure imposes the
first hazard to red cell survival; that is, the requirement
to get out into the circulation in the first place. Since
splenectomy is essentially curative, it implies that the
hereditary spherocyte starts out life pretty normal,
and as pointed out above, HS cells are biconcave
discs when they enter the circulation. They escape
from the marrow without any difficulty but are altered
and destroyed after circulating. Many other cells which
are more rigid at the beginning, eg, thalassemic ce_lls,
may undergo intramarrow hemolysis to a great extent
probably because they cannot negotiate the narrow
dimensions to begin their transit in the circulation.
Fig 5 illustrates two different kinds of information to
be learned from micropipette measurements. If we
think about the capillaries in the circulation, and
the narrow passages in the spleen, the parameter that
is designated P, (or the negative pressure required to
pull the whole cell into the pipette) is the appropriate
measurement. This measurement, however, reflects
shape and intrinsic deformability of the membrane;
also if the cell contents are rigid they will be reflected
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blood bank conditions and restoration of P, with incubation in 30 mM adenosine. (From Transfusion 9: 239,
1969, with permission).
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by an abnormal P , value. P, allows us to predict
whether the cells will survive or not (LaCelle, 1969).
The intrinsic deformability of the membrane itself, is
evaluated by measuring the pressure to pull a hemispherical bulge into the micropipette. The latter pressure is independent of the shape of the cell unless it is
already completely spherical, and it is independent of
the contents. The data at the bottom of the figure
shows solid lines which are values for normal cells, and
you can see how remarkably deformable they are. 4
mm H,O negative pressure will deform the membrane,
and only 8 mm will pull the whole red cell into the
pipette. For comparison, 50 mm H,O pressure is required to deform a lymphocyte. The dotted line shows
HS cells. Both P and P , are very abnormal. In each
case, there is a population which is only slightly different from normal, and a second population which is
strikingly different from normal. Many of the cells in
the abuormal range are not spherical, though, so there
is an intrinsic abnormality of membrane deformability
apart from change in shape.
The Role of ATP in HS

Fig 6 is a plot of deformability against time in an
in vitro incubation. Normal red cells are represented
by the dotted line. There is even in normal red cells, a
small but significant loss of deformability between four
and six hours when ATP falls about 30 percent. This
occurs without any change in shape. Between six and
12 hours there is little change, but thereafter as ATP
falls to about 20 percent the cells become very rigid.
HS cells are somewhat rigid to start with and as they
become ATP-depleted they become more rigid than
normal cells similarly depleted. However, many
changes occur during metabolic depletion and in order
to try to factor these out, we have prepared ghosts
reconstituted to contain specific metabolites. There is
no difference between the deformability of a ghost and
that of the intact cell from which it was prepared.
Ghosts from depleted cells have the same rigidity as
the dep!eted intact cell does itself. ATP, calcium or
magnesium added outside the cell have no effect on it.
They must be present in~de. Incorporation of ATP or
EDTA instantly restores a depleted cell to the properties of a fresh cell. Magnesium will reverse it to a significant extent, but not completely. If we take a normal
fresh cell which has a value of about 4 mm H ,O for P,
and incorporate 10-4 M calcuim, it becomes very
rigid; the deforming pressure goes up to 350 mm H ,O.
Of the various normal intracellular metabolic intermediates, ATP is specific; 2, 3-DPG, NAD and NADP
are without effect.
Fig 7 is from studies of stored cells (La Celle,
1969) and illustrates the correlation between the P ,
value, and survival. After storage for increasing periods, the cells become increasingly rigid. P , has an ex56

cellent correlation with survival, and one can predict a
50 percent survival at P , values of 100.
If one reconstitutes HS cells with ATP they are
restored to the properties of fresh normal cells! Incubation of intact HS cells with adenosine will do the
same thing and it will also restore their permeability to
normal. If you prepare reconstituted ghosts, and alter
the two most critical parameters-ATP and calciumyou find that at an ATP/ Ca ratio which is comparable
to that in normal intact red cells (a ten-fold excess of
ATP over calcium), normal red cells are very deformable as seen in the lower curve of Fig 8. At an ATP / Ca
ratio of 2.5/ 1, normal cells begin to become increasingly rigid. The HS cell is much more sensitive to a
decrease in the ATP/ Ca ratio as seen in Fig 8.
pH and Oxygen Tension

Returning to the relation of decreased deformability
and the spleen, two additional local factors deserving
of mention are pH and oxygen tension. pH has a
rather dramatic effect on intrinsic membrane deformability, and Murphy ( 1967) has suggested that
the spleen has a pH as low as 6.8. A pH of 6.8 compared to 7.4 essentially doubles the rigidity of red cells.
The other important local intrasplenic environmental factor relates to oxygen tension. A great deal of
interest has been focused on oxygen dissociation
curves, particularly in hemolytic states. Hematologists
have once again discovered that the main purpose of
the red cell is to transport oxygen to the tissues, and
that this vital property may be drastically altered in
disease states, either in a compensatory or a non-useful
fashion . It is known now that organic phosphates
(DPG in particular) will bind to deoxyhemoglobin,
but ATP will also bind to deoxyhemoglobin. Potentially a cell that was sufficiently deoxygenated might
have resultant binding of ATP to the hemoglobin and
might become quite rigid. That, in fact, is actually
what happens.
Normal mixed venous pO, is 40 mm Hg, which
poses no threat to a normal red cell. However, when
one gets down below pO, of 25 mm Hg, normal red
cells become very rigid, just as if they either had had
calcium incorporated or were severely ATP-depleted.
This rigidity is instantly reversible, just by re-oxygenating the cell. Cells from patients with hereditary spherocytosis are more rigid than normal cells at arterial
pO, values but they undergo a sharp increase in rigidity
at pO, < 40 mm Hg. Thus, relative hypoxia within
the pulp may be an additional very important splenic
parameter. Both low pO, and pH may constitute two
environmental parameters that the already somewhat
rigid HS red cell encounters acutely upon entering
the splenic pulp that will convert it from a cell that
is just able to negotiate the circulation to a cell that is
very rigid.
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It has been suggested (Weed and Bowdler, 1966;
Weed, LaCelle and Merrill , 1969) that red cell membranes contain a muscle-like protein which has solgel contractile potential when exposed to sufficient
calcium. This would explain how calcium-membrane
interaction within the cell produces a very rigid,
sphered cell. Normally there is very little calcium
in the red cell, and whatever is present is chelated by
ATP. Magnesium would be expected to compete
for the calcium site on the membrane, thereby explaining how magnesium can protect against the
calcium. The ATP level, however, will be affected by
the oxygenation of hemoglobin, and if the p02 falls
below a criti ~al level, hemoglobin will remove some
free ATP and interfere with the role of the latter in
preventing intracellular calcium from interacting with
the membrane. Although evidence suggests the existence of a red cell membrane calcium pump which is
ATP dependent, the latter operates over a long
period of time, while the deoxygenation changes are
acute and rapidly reversible. Based on the calciumATP curves for the hereditary spherocyte, it is suggested that the fundamental abnormality in HS cells
may relate to an altered membrane protein with a
higher affinity for calcium than that of normal red
cells. Such a proposed difference in membtane affinity for calcium need be the only difference between
a normal cell and hereditary spherocyte. Thus, at
normal ATP levels, the HS cell would be unable to
prevent calcium interaction with the membrane and
it need not have higher calcium, lower magnesium,
or abnormal ATP levels as it circulates. The whole
sequence of events after entry into the low pH, low
p02 splenic pulp might simply be an exaggeration of
the calcium interaction seen in severely ATPdepleted normal erythrocytes.

LANGLEY GR, FELDERHOF CH: Atypical autohemolysis in
hereditary spherocytosis as a reflection of two cell populations: relationship of cell lipids to conditioning by the
spleen. Blood 32: 569, 1968
MURPHY JR : The influence of pH and temperature on
some physical properties of normal erythrocytes and
erythrocytes from patients with hereditary spherocytosis.
J Lab Clin Med 69: 758, 1967
NAKAO M, NAKAO T, y AMAZOE S: Adenosine triphosphate
and maintenance of shape of human red cells. Nature 187 :
954, 1960

REED CF, SWISHER SN: Erythrocyte lipid loss in hereditary spherocytosis. J Clin Invest 45: 777, 1966
WEED RI, BOWDLER AJ: Metabolic dependence of the
critical hemolytic volume of human erythrocytes. Relationship to osmotic fragility and autohemolysis in hereditary spherocytosis and normal red cells. J Clin Invest 46:
1137, 1966

WEED RI, LA CELLE PL, MERRILL EW: Metabolic dependence of red cell membrane deformability. J Clin
Invest 48 : 795, 1969
WEISS L : The structure of bone marrow. Functional interrelationships of vascular and hematopoietic compartments
in experimental hemolytic anemia: an electron microscopic
study. J Morph 117: 467, 1965

Summary

In addition to its accentuated pattern of rigidity at
decreasing ATP/ Ca ratios, the hereditary spherocyte
poses a special challenge within the splenic pulp because of its shape. In addition to the geometric requirement for deformability, the spleen also poses a
challenge to HS cells because of its pH, and probably
also the p02 within the splenic pulp. Thus, it is
suggested that splenectomy is essentially curative in
hereditary spherocytosis because it removes an organ
with unique anatomic requirements for red cell passage as well as an adverse environment of lower
pH and p02.
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Paroxysmal Nocturnal
Hemoglobinuria-New Thoughts*
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Introduction
The illness I am going to discuss bears some relationship to what we have been discussing previously
-that is, basically the problem is one of hemolysis
brought about by a defect in the red cell (Dacie,
1967). However, it differs in several major respects
from the other hemolytic anemias under discussion.
First, the defect is not congenital but rather acquired.
Also, there may be 100 million to 200 million people
with a glucose-6-phosphate dehydrogenase deficiency,
but mercifully paroxysmal nocturnal hemoglobinuria
(PNH) is rarer. The incidence is probably not as low
as has been suspected, but increases as one looks for
the disease. In our own clinic we have, within the last
three years, found 16 patients with PNH, some by
referral to be sure. It is important to identify the patients with PNH because of the implications that are
inherent in treating these patients.
Clinical Presentations of PNH
PNH is probably one of those diseases that is badly
misnamed. With its present name, people tend to think
of PNH only when the patient comes to the physician
complaining of passing dark urine in the morning
which clears by noon. Under this definition, hardly
twenty percent of those patients with PNH would be
ordinarily identified.
It has become apparent that there is a great deal
more wrong with the hematopoiesis of patients with
PNH than was originally thought. This defective
hematopoiesis has two characteristics which may be
manifest in different proportions in different patients.
On the one side, the predominant problem may be
marrow hypoplasia, not simply of the red cells but
also of the white cells and of the platelets (Lewis and
Dacie, 1967). The other hematopoietic problem is
that the cells that are made are defective. The manifestation easiest to investigate is, of course, the defect

* Presented at the 23rd Annual Stoneburner Lecture
Series, February 19, 1970, at the Medical College of
Virginia, Richmond.
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in the red cell which renders it sensitive to the lytic
action of complement. This is traditionally demonstrated by the acidified serum test (Ham and Dingle,
1939). This defect in the red cells leads to hemolysis,
which then leads to hemoglobinuria. It has become
apparent in recent years, though, that the white cells
and platelets are likewise defective (Aster and Enright,
1969).
The classic clinical presentation of the patient with
PNH is, of course, hemoglobinuria (Table I) ; when
it is paroxysmal and nocturnal, it is a striking finding.
But, as I have said, if we relied upon this symptom
we would detect, I suspect, not more than twenty
percent of the patients with the disease. When the
symptom is present, the morning urine may be very
dark indeed and the evening urine may not be clear.
The amount of hemoglobinuria may vary greatly from
day to day. One of our patients who was also a wine
connoisseur, reported his urine in terms of the wine it
most nearly resembled. If the color resembled the
color of Chablis, he was pleased but when it looked
like Port, he became apprehensive.
The more usual presentation of PNH is chronic
hemolysis without, at least to the patient's eye, hemoglobinuria. In any patient with chronic hemolysis, one
ought to look for the presence of PNH.
As we mentioned, the bone marrow hypoplasia may
be a major part of the illness, and PNH may grow out
of patients with bone marrow hypoplasia as a primary
event. The bone marrow hypoplasia may be due to
drugs, as it has become apparent that some patients
taking chloramphenicol may, as they recover, show the
manifestations of PNH (Quagliana, Cartwright and
Wintrobe, 1964). The cytopenia in PNH patients may
be simply leukopenia, and/ or thrombocytopenia, without much anemia. But when the patient is carefully
observed, and blood is carefully examined, the defect
in the red cells may be demonstrated.
Iron deficiency is a common presentation of patients with PNH. Usually the reticulocytosis is higher
than one would expect for a similar degree of iron
deficiency in patients not hemolyzing. This is one of
MCV QUARTERLY 6(2): 58-63, 1970
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the few causes of hemolysis in which the loss of iron
is a major problem, and, therefore, iron deficiency is
not uncommon.
Venous thrombotic phenomena are not uncommon
in patients with PNH, possibly because of the release
of thromboplastic substances during intravascular
hemolysis. These thromboses are not simply the usual
arteriosclerotic variety, such as coronary thrombosis
or cerebral thrombosis. In PNH the thrombi are
usually venous and result in unusual syndromes. Adbominal venous thrombosis may occur in the portal
vein, the splenic vein, or most characteristically the
hepatic veins, leading to the Budd-Chiari syndrome.
The presentation of the hepatic vein thrombosis may be
very insidious in its onset, but many patients that die
of PNH, have evidences of hepatic vein thrombosis.
Cerebral vein thrombosis can lead to very bizarre
neurological syndromes due to cerebral venous or
sinus thromboses.
Finally, a most interesting complication of PNH has
been the occurence of acute leukemia. Dr. Dameshek
predicted many years ago that acute leukemia might
well occur in these patients, and indeed it has been
reported in three patients (Dameshek, 1967) . In all
three, the leukemia is acute myelogenous and the PNH
defect in the red cells disappeared with tqe onset of
leukemia.
Diagn o sis: Demonstra t ion of t he Red Cell Defect
How do we make the diagnosis of PNH? We now
define the disease in terms of the red cell defect which
is manifest as an abnormal sensitivity of the red cells
to lysis by complement. It is present in patients with
PNH, by definition, and leads to the problems of the
hemolysis on which we will now base most of our
remaining discussion.
The sensitivity to complement lysis may be detected
in several ways. In Fig 1, I have illustrated the
way we do this (Rosse and Dacie, 1966) .. To generate
this graph, cells are sensitized with an antibody, anti-I
cold agglutinin in this case, and are lysed with different amounts of normal human serum as a source of
complement. In the ordinary complement titration
using sheep cells, differences in the amount of lysis
reflect not differences in the red cells, since sheep cells
are assumed to be always the same, but rather differences in the amount of complement present. In the
complement sensitivity lysis test illustrated here, the
amount of complement present at a given dilution of
serum is the same since normal human serum is used,
so that differences in lysis will therefore reflect not
differences in the amount of complement, but differences in the sensitivity of the cells to lysis by complement in the presence of antibody.
The cells from a normal patient form a single
straight line in this test when one plots the amount
of complement present on a logarithmic scale against

TABLE I
Clinical Presentation and Complications of Paroxysmal
Nocturnal Hemoglobinuria
1. Nocturnal hemoglobinuria.
2. Chronic hemolytic anemia.
3. Pancytopenia - aplastic anemia.
leukopenia
thrombocytopenia
4. Iron deficiency.
5. Acute myelogenous leukemia.
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the logarithm of the fraction lysed over the fraction
unlysed (please forgive that way of expressing the data;
it has been a tradition since 1916, at least, for plotting
this sort of thing in order to obtain a straight line) .
The straight line with normal cells indicates that there
is a single population of cells with respect to complement sensitivity. The graph also illustrates that it requii;es very large amounts of complement in order to
lyse these cells. When PNH cells are examined in the
same system, a double curve is obtained. One population of cells is nearly normal, although almost never
entirely normal with respect to their complement lysis
sensitivity. Another population of cells, called the
complement-sensitive cells, are extremely sensitive to
lysis by complement; that is, they require very small
amounts of complement to lyse the cells. The proportion of cells in each population will vary from
patient to patient.
It does not really make any difference what antibody one uses in order to demonstrate this phenomenon. In Fig 2 the same thing is demonstrated
using a rabbit antihuman antibody. Here again, the
normal is a single straight line, and both sensitive and
insensitive populations in PNH cells are demonstrated.
In this instance, the difference between the complement sensitive and the complement insensitive populations is not quite so striking as with the anti-I, but is
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Fig 2-The lysis of normal and PNH cells by rabbit antihuman red cell antibody and human serum.
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nevertheless apparent. From this and other data
(Rosse and Dacie, 1966), we have concluded that the
increase in immune lysis under these circumstances is
not an effect of antibody but rather is due to the fact
that the cells have increased sensitivity to the effect
of complement.
What do we mean by increased sensitivity to the
effect of complement? We mean simply that the completion of the complement sequence is more efficient.
In the normal human red cell, the complement sequence appears to be very inefficient; ie, for every
complement sequence that is begun, few go through
to completion-probably less than 1 in 500 on the
normal cell. In the PNH cell, the chances of a complement sequence, once begun, going through to completion are very much greater although there is still a
considerable amount of inefficiency in the system.
The nature of the defect which leads to this
complement sensitivity is, at the present time, totally
unknown. There is a very interesting set of compounds
which can render cells which are normal to appear
somewhat similar to PNH cells. These are the compounds that contain the reactive thiol groups such as
glutathione, cysteine, and so on. The concentrations
of these compounds that are required are often very
high, however, and the exact relationship of the effect
of these compounds to the defect in a PNH cell is not
at all certain at the present time.
What is the relationship of this complement sensitivity to the phenomena with which we are more
familiar, ie, the diagnosis of PNH from the in vitro
tests that we use, or the clinical syndrome that we
observe in the patient? The diagnosis of PNH is not,
under ordinary circumstances, made by generation of
the complex curves which I have shown. Rather, at
least historically, this diagnosis has been made by the
Ham test, or the acidified-serum lysis test. In the Ham
test, one simply acidifies normal serum and incubates
the cells of the patient to observe whether hemolysis
takes place. It was early observed, by Ham himself,
that anything that destroyed complement (that is, heating the serum, adding agents which would chelate
calcium, and so on) would destroy the ability of that
serum to hemolyze the cells of patients with PNH.
Further evidence that there is a relationship between
the complement lysis and lysis observed in the Ham
test is obtained from electron microscope pictures.
When the cells of patients with PNH are lysed in
acidified serum and examined on the electron microscope, small, round, 100 A defects with the heaped-up
edge which are characteristic of destruction of the
membrane by complement are observed (Rosse, Dourmashkin and Humphrey, 1966).
What initiates the lysis in the Ham test is not at
all certain. There is no demonstrable antibody present
in the normal serum. It is thought that fluid-phase
activation of complement may be sufficient to bring
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about the lysis of the cell. In the early days, it was
proposed that another immune system related to
properdin was responsible for the initiation of complement lysis, and this may still have a certain
amount of validity although the exact nature of this
system is not at all certain (Hinz, 1966) . Nevertheless, the difference between the normal cells and
PNH cells is probably not a difference in the amount
of complement that is added to the cell, but in the
efficiency with which the complement sequences are
able to be completed in order to bring about lysis of
the cell.
It was early observed by Dacie and others that
the amount of lysis in the Ham test was highly variable from patient to patient. When we examined the
relationship between the amount of lysis in the Ham
test and the proportion of complement-sensitive cells
present in patients with PNH, we found that, in general, the percentage lysis in the Ham test is less than
the proportion of complement-sensitive cells. In addition, different specimens of normal serum may tend
to lyse different numbers of cells. In most instances
the complement-sensitive population is not entirely
lysed on the first exposure to normal acidified serum.
However, on exposure a second or third time, the
entire complement-sensitive population maY, be lysed.
If the complement-sensitive population is very small,
the lysis may not be detected in the Ham test; this
has occurred in three patients in our experience. In
general the Ham test is a reasonably good screen,
although it is rather cumbersome when done with all
controls. It does detect most patients with PNH, but
does not quantitate very well the proportion of the
complement-sensitive population.
In addition to the false negative test, there is a
"false-positive" acidified serum lysis test. This occurs
in a group of patients, first described in detail by the
Crookstons in Toronto (Crookston, et al, 1969) and
by Vervilghin in Belgium, who have a congenital
defect in erythropoiesis, characterized by a dyserythropoietic anemia, multi-nucleated red cell precursors, and a membrane defect. The membrane
defect is manifest in three ways. First, it makes the
cell more complement-sensitive than normal, but the
complement sensitivity is distributed in the single
population, and the complement sensitivity increase is
five to six times normal rather than 30 times normal
as seen in PNH. Second, an antigen is exposed on the
red cell surface which is not present on normal cells,
and to which normal people have isoantibodies. The
reaction of a naturally occurring antibody present
in most normal serum, together with a modest increase in complement sensitivity, renders the acidified lysis test positive with these cells. However, the
serum of these patients does not contain the antibody,
and therefore their own cells will not lyse in their
own serum, despite acidification.

More recently, Drs. Hartmann and Jenkins at
Nashville have introduced the sucrose lysis test, which
likewise appears to depend upon complement lysis
(Hartmann and Jenkins, 1966). The reduction in
ionic strength increases the efficiency of several of
the steps in the complement sequence. Therefore, by
incubating the cells in the presence of normal serum,
the complement-sensitive cells in PNH will lyse. With
this test there is a much better correspondence between the percentage of cells in the complementsensitive population, and the amount of lysis that
one obtains, although the degree of variabiHty is
somewhat greater than in the acidified serum test.
To date, we have not found any false negatives in
patients with PNH having small complement-sensitive
populations which do not lyse in the sucrose lysis
test. There are, on the other hand, instances of falsepositives of which one must be aware. The cells of
patients with immune hemolytic anemia in which
the antibody can fix complement may lyse, if the cells
are incubated in their own serum and sucrose. However, if the cells are incubated in someone else's type
compatible serum, lysis will usually not occur.
We have related the in vitro phenomena that we
commonly associate with PNH to the complementsensitive population. In order to relate these to
in vivo phenomena, we have investigated the life
span of the red cells in PNH. If the complementsensitivity has anything to do with the hemolysis that
one observes, then there should be a difference in the
life span of the complement-sensitive cells, compared
to the complement-insensitive cells.
If the life span of the red cells is determined using
glycine-2-C,, as a cohort label, the complementsensitive cells are seen to be destroyed extremely
quickly in a random fashion. The half-time of this
random destruction is in the order of four to six days,
indicating that the life span of an individual complement-sensitive cell may be extremely short. The
complement-insensitive cells are also lysed in a random fashion to a far greater extent than normal.
Ordinarily, less than five percent of normal cells are
lysed before reaching senescence. In PNH, probably
25 percent of the complement-insensitive cells are lysed.
Those cells that miss the random destruction process
are destroyed at approximately 110 to 120 days. The
complement-sensitive cells do not become complement
insensitive, since as the complement-sensitive population is lysed and falls, the amount of label in the
whole population falls, indicating that the cells in
the complement-sensitive population are born bad
and die young.
We have also studied the red cell life span of both
populations of cells with DFP32, Again, the life span
of the complement-sensitive cells was much shorter
than that of the complement-insensitive cells, reaffirming that the complement-sensitive cells are de61
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stroyed more rapidly than are the complementinsensitive cells. However, the life span of the
complement-insensitive cells is shorter than normal,
again demonstrating that these cells are not normal.
So, we can see then that the lysis of the complementsensitive cells is an important in vivo correlation to
an in vitro demonstration of complement-sensitivity.
Determinants of the Rate of Hemolysis
One might ask, on what does the daily rate of
hemolysis depend? In Table II, we have listed some
of the things which appear to determine the amount
of hemolysis in patients with PNH. In the first place,
probably the most important parameter is the proportion of complement-sensitive cells. Among most
patients with PNH, the sensitivity to complement' of
this population is nearly the same. In general, those
patients with a high proportion of complementsensitive cells have a higher rate of hemolysis. On
the other hand, an occasional patient does have a
complement-sensitive population which, instead of
being 15-25 times more sensitive than normal, is
5- 7 times more sensitive. These patients have less
hemolysis and less difficulty with th~ disease. Thus, on
rare occasions, the decreased sensitivity of the
complement-sensitive population may spare the patient
some of the trial and tribulations of the disease.
On occasion, the complement-insensitive cells may
also be markedly abnormal. If this population is more
sensitive to complement than usual, then the rate of
hemolysis may in part depend upon destruction of
cells in the population.
Another important determinant of the amount of
hemolysis is the rate of erythropoiesis. The proportion of precursors of cells in the complement-sensitive

TABLE II
Determinants of Hemolysis in Patients with Paroxysmal
Nocturnal Hemoglobinuria
1. Cellular Abnormality.
a. Proportion of complement-sensitive cells.
b. Sensitivity of complement-sensitive cells.
c. Sensitivity of complement-insensitive cells.
2. Rate of Erythropoiesis.
a. Response to iron therapy.
b. Response to androgen therapy.
3. Initiating Mechanisms.
a. Immunologic phenomena.
i. infections-especially viral
ii. vaccinations
b. Drugs- ? heparin.
c. Unknown.
i. nocturnal-acting.
ii. others.
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Fig 3-The effect of iron therapy on the rate of hemolysis
in a patient with PNH.

population is far greater than the proportion of these
cells in the peripheral blood. Therefore, each day a
large number of complement-sensitive cells are delivered to the circulation. If the ability to make red
cells is increased, the number of complement-sensitive
red cells that are delivered to the circulation, and thus
the number that are susceptible to hemolysis is increased. Thus patients who are iron deficient with
PNH may have a bout of hemoglobinuria when given
iron because of the increase in erythropoiesis.
Fig 3 illustrates a patient with iron deficiency who,
after initial studies, was given intrav.e nous iron. The
reticulocyte count did not increase until four to five
days later. It was only when the reticulocyte count began to increase that there was an increase in urine
hemoglobin. As the reticulocyte count rose, the amount
of urine hemoglobin rose precipitously. During this
time, the hematocrit rose and the percentage of complement-sensitive cells rose somewhat. At this point,
the patient began to have abdominal pains, a fairly
frequent complication of a hemolytic episode in patients with PNH, probably due to minor thromboses
in the mesentery and the gut wall. The patient was
transfused, and the reticulocyte count and the urine
hemoglobin fell . He was next given iron dextran and
did not have a hemolytic response because erythropoiesis had been suppressed by elevation of the hematocrit by transfusion. Thus we were able to demonstrate that the hemoglobinuria which follows iron
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therapy is not due to a toxic effect of the iron, but
rather due to a sudden increase in erythropoiesis. We
have seen the same effect in patients given androgens,
but the hemolytic episode is not so abrupt or so
dramatic as in iron therapy.
Other determinants initiating hemolysis are not well
known. Some are immunologically related, since the
red cells are susceptible to immunologic lysis. One
would expect that if immunologic reactions were
going on in the patient, hemolysis might be increased.
This is, in fact, true. Certain virus infections, especially the Hong Kong flu, vaccinations, especially
typhoid vaccinations, and some bacterial infections
have been incriminated as precipitating crises in
hemolytic epjsodes.
The cause of the nocturnal variation is totally unknown. It was originally thought that maybe there
was an accumulation of acid during sleep which
would then mimic the acidified serum lysis test. This is
probably not true. It has also been suggested that the
diurnal variation might be related to diurnal variations
in erythropoiesis. This is difficult to demonstrate, but
it may be true. Most of the time, we do not know
why patients with PNH have a paroxysm of hemoglobinuria.
Summary

I have tried to summarize some of the facts we
know, and some of the questions we need to ask
in a disease which, although it is not common, probably is not as rare as we once thought. Once the
diagnosis is made, one must be very careful in tending
to the patients, since there are instances in which they
react much differently than would normal peopleeither by the hemolytic episode or with other complications. This is especially true with regard to surgery, which may be extremely dangerous in these patients. The post-operative course may be complicated
by thrombosis, infections, and other forms of morbidity. Identification of these patients is important,
simple, and relatively helpful in their care.
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The New Hemoglobinopathies*
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In 19iO a Chicago physician, Dr. J. B. Herrick,
called attention to a peculiarly formed red cell which
he observed in the blood smear of an anemic West
India .Negro student (Necheles, Allen and Finkel,
1969). Linus Pauling, a physical chemist, demonstrated in 1949 that the protein portion of the hemoglobin molecule found in patients having sickle cell
disease differed from that found in normal adults. Ingram ( 1957) further defined the molecular defect in
that sickled hemoglobin differed from normal adult
hemoglobin in one amino-acid residue per half molecule. The specific molecular identification of the defect
in sickle cell anemia was that of valine replacing the
normally occurring glutamic acid in the number 6 position of the beta chain. This finding provided inspiration
and technical knowledge whereby over 100 different
hemoglobinopathies have now been described. The
clinical explorations which have resulted from studies
of mutant hemoglobin have allowed definition of a
variety of syndromes whose manifestations require
explanation in terms of the effects of molecular distortion on physiqlogical processes. The complex patterns
of inheritance which lead to amino-acid substitution
in either the alpha or beta chain dictate a variety of
structural alterations which may modify hemoglobin
affinity for oxygen, afford protection against falciparum malaria, and provoke changes in microcirculation which influence renal and splenic function.
Whether abnormal hemoglobins induce these changes
is determined at least in part by the site of replacement,
changes on external surfaces exerting little effect, and
the co-existence of abnormalities elsewhere in the
molecule. The discovery of various hemoglobinopathies
has demonstrated that specific molecular defects may
express themselves in various pathophysiological manifestations. For instance, sickle cell anemia, a single
molecular defect of the beta chain in which valine is
substituted for the number 6 amino-acid glutamine,
presents a wide spectrum of clinical manifestations. A
marked dissociation between the degree of anemia and

* Presented at the 23rd Annual Stoneburner Lecture
Series, February 19, 1970, at the Medical College of
Virginia, Richmond.
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the occurrence of other complications may be found.
More detailed pathophysiological studies of patients
with hemoglobinopathies should be performed to gain
a better understanding of the expression of molecular
disease.
Classification of Hemoglobinopathies
A better understanding of the hemoglobinopathies
can be obtained if they are broken down into various
categories. Table I shows these different types of
hemoglobinopathies. The first is a defect in the rate
of synthesis of a specific polypeptide chain. The most
frequently considered clinical disease in this category
is that of thalassemia. In this group of hemoglobinopathies, there is either a defect in the synthesis of
one or more alpha chains or one or more beta chains.
These molecular defects result in specific clinical
syndromes. Beta thalassemia minor may range in
severity from completely asymptomatic elevations of
one of the minor hemoglobin components to a syndrome consisting of splenomegaly, intermittent jaundice, and mild anemia. The peripheral blood in
patients with thalassemia minor shows hypochromia,
microcytosis, anisocytosis, and poikilocytosis. Target
cells ate quite common and the red cells show a
decreased osmotic fragility. Beta thalassemia major
is a more severe disease and is characterized by hypochromic anemia, splenomegaly, and normoblastemia.
These patients are severely affected and have signs of
severe anemia and phenotypically show expanded
facial bones and increased pigmentation. Alpha thalassemia is usually incompatible with life and results
in hydrops fetalis.
The second major categorization of the hemoglobinopathies are those hemoglobins in which a biochemical
alteration in hemoglobin structure has occurred. The
first significant subdivision within this category consists of patients with sickle cell disease, hemoglobin
C, hemoglobin D, and combinations of hemoglobin S
with other hemoglobinopathies such as hemoglobin
SC, SD, and AS.
The next sub-category includes the unstable hemoglobin hemolytic anemias (UHHA). The unstable
hemoglobin hemolytic anemias are characterized by the
MCV QUARTERLY 6(2): 64·78, 1970
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presence of hemolytic anemia -· from infancy. Heinz
bodies are usually seen in the red cells of patients with
this type of anemia. Splenomegaly is usually pr:esent
and when splenectomy is performed the peripheral
blood shows a marked increase in the number of red
cells containing Heinz bodies. Dacie (Dacie et al,
1964) reported studies on five patients with mild
anemia which he characterized as hereditary Heinz
body anemia. A distinctive characteristic of this
group of patients with hemolytic anemia was the presence of Heinz bodies in · a blood suspension stained
with methyl violet. When hemolysates prepared from
washed red cells of all five patients were heated to 50
C for one hour, easily visible precipitates developed. Since •this time, numerous hemoglobinopathies
characterized by hemolytic anemia and thermal lability of the hemolystate have been demonstrated. On
paper or starch gel electrophoresis at an alkaline pH,

the abnormal hemoglobin band is seen as a minor
component moving more slowly than hemoglobin A.
It is extremely difficult to demonstrate these hemoglobinopathies on conventional paper or Agar gel
electrophoresis. Carrell and Lehmann ( 1969) have
reviewed in detail the unstable hemoglobin hemolytic
anemias. It is felt that the globin of the unstable hemoglobins precipitates because it is no longer stabilized
by firm heme to globin bonding. Hemoglobin Zurich
is an example of the unstable hemoglobin hemolytic
anemias in which there is a replacement of the nonheme linked histidine beta 63 by an arginine amioacid. This hemoglobinopathy is characterized by an
increased susceptibility of the individual to hemolysis
as a result of taking sulfonamides. Other examples of
the unstable hemoglobin hemolytic anemias consist of
Ube-I disease. This was described in 1963 in a fifteenyear-old Japanese girl. This has subsequently been

Table I.

HEMOGLOBINOPATHIES
I.

A defect in the rote of synthesis of a specific polypeptide chain
(Alpha and Beta Thalassemia)

II.

A biochemical alteration in hemoglobin structure
A.
Sickle cell disease, Hb. C, D, and combinations of
S with other hemoglobinopathies
B.
The unstable hemoglobin hemolytic anemias (U H H A)
Hb. Sabine, Zurich, Ko ln, Ube-I, Gunhill, and
Freiburg .
C.
Hemoglobins with increased affinity for oxygen
J Capetown, Chesapeake, Yakima, Kempsey, Rainser,
Hiroshi no
D.
Hemoglobins wi th decreased oxygen a ffinity - Hb.
Seattle and Kansas
E.
Hemoglobins unable to combi ne with oxygen - methemoglobin
1) Hb. m disorders - Boston, Saskatoon, luate, Milwaukee
2) Oxidant drugs
3) Diaphorose enzyme de fi c iency DPN dependant system

Ill .

Defect in polypeptide synthesis with stru c tural alterations (sickle/~
Thalassemia disease)
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shown to be similar to hemoglobin Koln which is characterized by blocking of the 93 amino-acid cysteine in
the beta chain.
Schneider (Schneider et al, 1969) described
hemoglobin Sabin disease in which there is a
substitution of the beta chain at the 91 amino-acid
of a lucine amino-acid by a praline residue at
helical position F7 of the beta polypeptide chain.
Other hemoglobinopathies in this group are those of
hemoglobin Sydney (Raik, Hunter and Lindsay, 1967;
Carrell et al, 1967) in which variant a substitution of
valine for alanine at the beta 67 position occurs. Santa
Ana (Opfell, Lorkin and Lehmann, 1968), Gun Hill
(Bradley, Wohl and Rieder, 1967), Torino (Beretta et
al, 1968), Hammersmith (Dacie et al, 1967), Genova
(Sansone, Carrell and Lehmann, 1967), and numerous
other hemoglobinopathies have been described in this
category. On a molecular basis, the instability of hemoglobin molecules is thought to result from either a defect in the heme-binding site, a change in the overall
globin confirmation, or a defect at the site of subunit
interaction where the alpha and beta chains react together (Carrell and Lehmann, 1969). It has been
pointed out that the concentration c f amino-acid substitutions of the unstable hemoglobins in the heme
globin binding site is striking. Of the 11 positions cited
by Perutz ( 1965) as being most closely related to the
heme group, seven are found to be replaced in the unstable hemoglobins. A molecular change which would
alter the stability of the heme globin binding sites
would result in instability of the hemoglobin molecule.
Substitutions of amino-acids lining the heme pocket or
crevice by others that are too large, alter the distribution of electric charges, or permit formation of abnormal cross links within the molecule, decrease its
stability with resultant precipitation of hemoglobin
within the red cell and associated hemolytic anemia.
Another group of changes consists of the substitution
of praline for lucine residues. This changes the overall
globin conformation with loss of stability of the molecule. Another aspect leading to stability of the globin
heme molecule is the site of subunit interaction. It
appears that it is necessary that heme and globin be
bound together for normal solubility and function of
hemoglobin.
The instability of hemoglobin H and Barts which
are tetramers of normal beta and gamma chains respectively, has been previously demonstrated. Substitutions in the area of subunit contact promote dissociation to monomers which are inherently unstable.
The third sub-grouping within this category of alterations in hemoglobin structure consists of those
hemoglobins associated with increased affinity for
oxygen. Charache (Charache, Weatherall and Clegg,
1966) investigated hemoglobin Chesapeake, an alpha
chain variant, which was found to have an increased
oxygen affinity. This hemoglobin is characterized by a
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substitution at the 92 residue of the alpha chain of
lucine for arginine. The amino-acid substitutions in
hemoglobins with increased oxygen affinity have been
found in two areas. One is the area of contact between the alpha 1 and the beta 2 subunits in the
tetramer; the other is near the C-terminal portion
of the beta chain. Hemoglobin Rainier (Stamatoyannopoulos, Yoshida and Adamson, 1968) is the substitution of histidine for invariant residue 23 tyrosine in
the beta hemoglobin polypeptide chain. Hemoglobin
Chesapeake, Yakima, Cape Town, and Kempsey all
have changes in the region between the F and H
helical segments (Jones et al, 1967). These areas
provide the end chain contact between the polar
groups of the alpha and beta chains and are involved in alpha-beta chain interaction. Substitution
in these areas seems to alter the normal respiratory
movements of the subunits such that oxygen .affinity
is increased. It should also be noted that four of these
hemoglobinopathies have remarkably decreased n
values with nearly normal effects.
The fourth sub-grouping within this major category is that of hemoglobins associated with decreased
oxygen affinity characterized by hemoglobin Kansas
(Reissmann, Ruth and Wohours, 1961) in which there
is a substition of asparagine at the 102 residue of
the beta chain by threonine. It is also a result of a
substitution in the area of alpha 1, beta 2 contact.
The heme and globin components of the polypeptide
are linked together by the iron of the heme binding
to a specific histidine residue. This occurs at position
number 87 in the alpha chain and number 92 in the
beta chain. In addition, the histidine residue at number 58 in the alpha chain and number 63 in the beta
chain are bound to the iron of the heme by either
an oxygen molecule in oxyhemoglobin or a water
molecule in desoxyhemoglobin (Necheles, Allen and
Finkel, 1969).
Four of the five hemoglobin M's are produced by
substitutions of the invariant histidine residues on
either side of the iron atom in the heme area (Conley
and Char ache, 1969) . The presence of oxygen tends
to change the iron to the ferric form producing
metbemoglobin, a compound that cannot combine
reversibily with oxygen. The substitution of tyrosine
for histidine renders ferric iron so stable that the
usual intracellular enzymes cannot reduce it to the
functional ferrous (oxygen binding) state.
The maintenance of heme iron in a functional
(Fe ++ )state requires metabolic machinery for reducing iron in ferric form (Fe++ + ) . This is accomplished by a dipyridine nucleotide. DPN (NAD) dependent methemoglobin reductase is a means by which
the diaphorase enzyme acts to convert methemoglobin
(Fe++ + Hb) to functional hemoglobin (Fe++Hb).
Conversion of one or more of the four ferrous atoms
in the hemoglobin molecule to ferric category leads to
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an increased affinity of the remaining ferrous atoms
for oxygen.
Thus, amino acid substitutions and heme-globin
interactions are important in the molecular behavior
of hemoglobin. In addition, cell constituents influence
the oxygen affinity of hemoglobin. Benesch (Benesch
and Benesch, 1967) has shown that the affinity of
hemoglobin may be increased or decreased by its interaction with organic phosphates. Increased intracorpuscular levels of 2-3-Diphosphoglycerate (2,
3-DPG) combine reversibly with deoxyhemoglobin,
shifting the oxygen dissociation curve to the right.
Charache (Charache et al, 1970) has shown that the
concentration of 2-3-DPG is increased in hemoglobin SS erythrocytes as compared to hemoglobin AA
red cells. This may partially explain the decreased oxygen affinity of hemoglobin SS. In addition, increased
levels of 2-3-DPG have been found in low oxygen
tension states and may be an important compensatory
mechanism in hypoxemia.
The third major category of the hemoglobinopathies

are those in which there is a defect in polypeptide
synthesis with a structural alteration combined with
an inability of the individual to synthesize certain of
the alpha or beta polypeptides. An example of this is
sickled-beta thalassemic disease.
Recently we described an example of methemoglobin anemia associated with a Coombs positive
hemolytic anemia. This patient (G.R.) was found to
have increased levels of methemoglobin in his red
cells during a severe hemolytic episode. However, the
majority of his methemoglobin was extracellular consisting of hemoglobin which had been converted to
methemoglobin. The patient showed multisystem degeneration and died in hepatic and renal failure.
Methemoglobin has a characteristic spectral absorption
curve which can be employed in its identification.
Fig 1 shows a spectroscopic analysis of this patient's plasma. The methemoglobin is treated with
cyanide to form cyano-methemoglobin and the change
in light absorption at 632 m/L is measured. This
method is quite specific except for the M hemoglobins

I - Plasma 1: 30 dilution with 0.1 M P04, pH 6.4

2-Plasma + 25,l 596 KCN (pH t )
3- Plasma+ additional 25-l KCN ( pHt)

2

700mµ

660

630 620

600

580

560

Fig I-Spectroscopic analysis of plasma from patient G. R. with hemolytic anemia and free methemoglobin.
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which have anomalous spectroscopic properties. A
simple screening method for this hemoglobin can be
performed by obtaining three tubes of hemolysate or
plasma. One tube is shaken with room air and if it
does not turn red with adequate oxygenation, this
is an indication of an abnormal hemoglobin. Potassium
cyanide should be added to the second tube and if it
turns red this indicates the presence of methemoglobin.
Sulfhemoglobin produces a dark band at 618 mµ.
which is difficult to distinguish from that of methemoglobin in the hand spectroscope. However, it can be
recognized by the fact that it is not removed by the
addition of cyanide. Hydrogen peroxide (3 percent)
causes both of these bands to disappear. Addition of
potassium cyanide and hydrogen peroxide to hemolysates is a simple screening procedure. A more specific
identification can be obtained with a spectroscopic
examination as demonstrated in Fig 1.
Methemoglobin reduction in normal cells may be
accomplished by four known systems. These are
ascorbic acid, glutathione, DPNH diaphorase, and
TPNH diaphorase. Glutathione is maintained in the
reduced state by glutathione reductase, an enzyme
chiefly active with TPNH but also capable of using
DPNH as a substrate. The DPNH diaphorase is by
far the most active reducing methemoglobin.
Another new hemoglobinopathy which has enabled
us to gain insight into both the molecular and
pathophysiology of sickle cell disease is that of hemoglobin Memphis/ S disease. This was initially discovered by Lorraine and Alfred Kraus at the University of
Tennessee (Kraus et al, 1966; Kraus et al, 1967). This
hemoglobinopathy is characterized by a normal and
mutant alpha chain with an alpha .23 glutamine substitution for glutamic acid at residue 23 of the alpha
chain. They have identified two hemoglobin S molecules-one consisting of a// {3.5, and hemoglobin
/ /3." in two subjects.
Memphis/ S consisting of a,M
These patients, homozygous for hemoglobin S and
heterozygous for hemoglobin Memphis, have very mild
sickle cell disease suggesting that the serious consequences of some hemoglobinopathies may be ameliorated by structural changes at other chain positions.
Following the initial investigations by Kraus, we found
a third patient with homozygous hemoglobin S heterozygous for hemoglobin Memphis who exhibited a similar profound dissociation between the degree of his
anemia and the presence of serious complications. Special attention has been directed toward elucidating
the effect of this hemoglobin on blood viscosity in an
effort to account for the benignity of the process
(Cooper et al, 1969).
Our interest in this area was stimulated by (J.P.) a
53-year-old Negro male who has had episodic abdominal and musculoskeletal pain since childhood and
has been repeatedly hospitalized for treatment of
anemia (Fig 2). Despite shortness of breath and
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Fig 2-Patient J. P., 53-year-old Negro man with hemoglobin Memphis/ S disease.

need for frequent blood transfusions, he worked as a
farm laborer until four years ago when pulmonary
insufficiency forced his retirement. He is 5' 1" tall,
weighs 105 lbs., and his blood pressure ranges from
130- 190 systolic and 85- 100 diastolic. Funduscopic
examination reveals slightly distended retinal veins.
Slit lamp studies have shown no comma-shaped or
curlicue segments of conjunctiva! vessels and no
sludging. He exhibits signs of mild pulmonary emphysema and a Grade IV ejection systolic murmur was
heard at the apex. The liver was smooth and nontender and was felt 5 cm below the right costal
margin. The spleen was nonpalpable. Double distal
interphalangeal palmar creases were present in each
middle finger and on the left fifth finger.
Admission laboratory data shows a urine specific
gravity of 1.010; hemoglobin 9.5 gm/ 100 mg.;
hematocrit 27 vol percent; RBC 3.1 million/ cu ml;
MCV 100 µ. 3 ; MCHC 33 vol percent; reticulocytes 524.6 percent. The creatinine clearance was 59 ml per
minute. The serum folate levels were 19 ng/ 100 ml;
serum iron 149 mcg/ 100 ml and iron binding capacity
244 mcg/ 100 ml. Hemolysis began at 0.34 percent
sodium ch!OFjde and was complete at 0.28 percent in
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an unincubated sample; with incubation, marked resistance to hemolysis was exhibited at lower concentrations of sodium chloride (Fig 3).
Hemoglobin electrophoresis revealed no hemoglobin
A with hemoglobin either in the S or F forms (Fig 4).
Alkali denaturization showed fetal hemoglobin to be
6 percent. Bone marrow aspiration yielded a marrow
which was 100 percent cellular showing marked erythroid hyperplasia and many sickled red blood cells
(Fig 5). Peripheral blood smears contained many
sickled cells and nucleated erythrocytes (Fig 6).
Poikilocytosis was prominent and Howell Jolly bodies
were present. Liver function studies disclosed no evidence of abnormality. An oral cholecystogram demonstrated many small gallstones and a chest film showed
mild left ventricular hypertrophy. Radiographic bone
survey revealed diffuse osteoporotic and osteosclerotic
changes as well as concavity of the vertebral bodies
consistent with sickle cell anemia. No bone infarcts
were seen and at no time could the spleen be visualized
by X-ray. Serum bilirubin was 2.6 mg/ 100 ml of which
2.0 mg/ 100 ml was conjugated. The lactate dehydrogenase was 1980 units and the direct and indirect
Coombs tests were negative.
Routine hematological data were derived by standard techniques. Sickling was ascertained using Sherman's test and minimal concentration gelling of
hemoglobin solution was determined according to the
method of Singer. Numerous isotopic studies consisting of 51Cr labeled erythrocytes, 51Cr labeled platelets,
and heat-treated 51Cr labeled erythrocytes were employed. Hemoglobin electrophoresis was done on starch
gel and cellulose acetate using a discontinuous buffer
at pH 8.6. Individual erythrocytes were stained for
fetal hemoglobin which was then quantitated by alkali
denaturization using Betke's method. After electrophoresis, hemoglobin was characterized by chain separation, tryptic digestion with peptide mapping, a nd
amino acid analysis of aberrant polypeptides according
to Kraus (Kraus, Miyaji and luchi, 1966). Whole blood
viscosity was determined with the falling ball viscometer. Oxygenated a nd deoxygenated blood viscosities were also determined by using a modified
Brookfield viscometer. Renal function studies were
determined and the effect of hyperosmolar solution on
the patient's hemoglobin was also studied.
Fam ily studies were performed and the results
showed a co-dominant inheritance pattern. The Sherman test (Table II) demonstrated 4.5 percent sickled
cells in arterial blood and 21.5 percent in venous
blood. Venous blood from homozygous SS patients
contains 30- 60 percent sickled forms and 5- 20 percent sickled forms in the arterial blood. A minimal
gelling concentration of 27.2 gm/ 100 ml was obtained for S hemoglobin and 35.6 gm/ I 00 ml for
hemoglobin Memphis/ S (Table III). The patient's
deoxygenated blood viscosity was determined by the
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HEMOLYSIS BEGINS : 0 .44% NaCl
HEMOLYSIS COMPLETED: 0.28% NaCl
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90
80
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Fig 3-Tncubated osmotic fragility of J. P.'s RBC.
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Fig 4- H. J . Electrophoresis with cellulose acetate strips
pH 8.6.
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Fig 5- Bone marrow aspiration showing hemoglobin
Memphis/ S sickled erythrocyte.

Table II.
MO DIFIED SHERMAN TEST
% SICKLED CELLS (200 CELLS COUNTED)
o:_Acx_A I

fJ SJJ s o:.Ao:.AljJAJJS ct.A o:.M IfJ sfJ s

VENOUS

30 - 60

<1%

21.5

ARTERIAL

5 - 20

0

4. 5

Table III.
THE LO WEST G ELLIN G PO INT CON CENTRATION
O F HEMOGLO BINS CONTAINING HEMO LYSATES
\gm% S)
a Aa A
BOWMAN G RAY

MEMPHI S•

CHI CAGO"

70

I/3 SfJ s

27. 0 gm/ IOO ml
S± .54

19- 24 gm/ 100 ml

aAaM

lfJ SJJ s

(XAa_A / fJAfJS

35.4 gm/ IOO ml
S± 2. 18

26.8 gm/ 100 ml

21.B gm/ 100 ml
S± l.4

13 . 2 gm/ 100 ml
S±l .4

.

Krous - Trans. Ass . Amer. Physicia ns, 1967

u

Singer, K. & Singer, L. Blood, 1953

falling ball method (Fig 7). The result showed that
the viscosity was 3. 7 centipoise units in contrast to
2.77 centipoise units for hemoglobin AA blood and
4.9 centipoise units for hemoglobin SS blood. For
oxygenated blood, comparable values were 3.2, 2.73
and 3.71 centipoise units.
When the Brookfield viscometer was used, no difference in viscosity of oxygenated and deoxygenated
hemoglobin AA blood was found, while patients with
sickle cell trait displayed an increase of 1 ± 0.46 centipoise units in deoxygenated blood. Blood viscosity
increased approximately 27 centipoise units from the
oxygenated to the deoxygenated state at all shear rates
for homozygous SS and SC disease (Fig 8). Although the propositus is homozygous for hemoglobin
SS, his blood viscosity increased by only 1.1 ± 0.1
centipoise units with deoxygenation. The difference in
viscosity between oxygenated and deoxygenated blood
from hemoglobin AA subjects was not significant. For
sickle cell trait, the difference at all shear rates was
> 0.1 and < 0.5 significance level. The difference for
hemoglobin Memphis/ S was > 0.01 and < 0.001. The
difference in viscosity of deoxygenated blood between
hemoglobin Memphis/ S and sickle cell anemia was
signicant at > 0.001 percent level (Fig 9). However, the difference between hemoglobin Memphis/ S
and AS disease blood both with oxygenation and deoxygenation was not significant.
Renal function studies were performed during Mannitol diuresis, sodium loading, and water diuresis (Table IV) . During Mannitol infusion Cosm TcH,o, UV,
and urine flow were decreased in comparison to normal subjects and individuals with hemoglobin SS. With
sodium loading, glomerular filtration and renal plasma
flow were abnormally low and the filtration fraction
was high reflecting a proportionately greater decrease
of the latter. Because of diminished glomerular filtration, filtered sodium was decreased but U N,V was not
suppressed indicating a decreased tubular re-absorption of sodium. Filtered sodium was decreased secondary to suppressed filtration during water loading
but U N, V was greater than in normal hemoglobin SS
subjects. TN• was considerably depressed. Tc"'° was
decreased, indicative of restriction of tubular diluting
activity.
Hemoglobin gelling point of the propositus required
a much higher concentration of hemolysate than that
which was necessary with hemoglobin SS. The quantity of hemoglobin S necessary for gel formation is
decreased by the presence of hemoglobin A and C.
Because our patient demonstrated a high gelling concentration in contradistinction to subjects with sickle
cell anemia or sickle cell trait, the gelling point must
be altered as a result of the structural change in the
hemoglobin molecule resulting from the alpha 23 glutamine substitution.
Changes in blood viscosity revealed by using the
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Brookfield viscometer appear more accurate and
graphic than rheologic activity defined by the falling
ball viscometer (Wells, Denton and Merrill, 1961 ) .
Blood is a non-Newtonian fluid (the relationship between shear stress and shear rate in such a fluid is
non-linear), so the uniform shear rate during
measurement provided by the Brookfield device permits more precise determinations. With the falling
ball, shear rate varies continuously from 0 at the capillary tube and within the fluid not in contact with or
near the ball to some maximal value at the surface
of th e ball or at the wall of the tube. In addition, the
shear rate under these conditions is dependent on the
dimensions of the instruments necessitating correction
for all but the lowest degree of non-Newtonian behavior. Viscosity is also temperature dependent. Our
studies were performed at 37 C.
With the Brookfield instrument we found the viscosity in hemoglobin Memphis/ S disease to be similar
to that found in sickle cell tra it disease but significantly lower than in norm al subjects when the hem atocrit was adjusted to 42-49 vols percent. The difference
fo und in viscosity of oxygenated a nd deoxygenated
blood in these two conditions was significant but the

differences between sickle cell trait and hemoglobin
S/ Memphis were not. Thus, the alpha chain variant
decreases the viscosity of hemoglobin S to the range
found in sickle cell trait.
Sickle cell disease may result in a variety of renal
lesions: impairment in urine concentrating ability,
medullary necrosis, hematuria, and the nephrotic syndrome. Frequent examinations of the urine from our
patient failed to demonstrate erythrocytes, the typical
features of medullary necrosis were not delineated by
intravenous pyelography, and proteinuria was less
than 100 mg/ day. The renal concentrating defect in
sickle cell disease is characterized by a failure of TcH'2o
to increase progressively with hypertonic saline loading with retention of the capacity to attain maximal
levels in response to Mannitol infusion. Our patient
was unable to increase the Tctt 2 o during Mannitol diuresis, probably reflecting chronic rena l disease. This
was additionally manifested by depressed glomerular
filtration and marked diminution in tubular sodium
re-absorption in response to sodium loading and water
diuresis. Diluting capacity response following oral or
parenteral water loading was also impaired, a feature
characteristic of chronic renal disease. While it could
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Renal Function Studies.

Table IV.

TcH 20 DURING 100k MANNITOL DIURESIS

v•
Hb

X

ml/min

UV*
mOsm/min

Cosm*
m!/mih

TcH20*
ml/min

16.7
4.13

6,434
1,130

21.63
3.56

4.9

AA
SD

±

SS
SD

±

16.0
3.04

6,170
1,030

20.2
3. 15

4. 3
0.20

M/SX
SD ±

12.2
0.88

4,300
326

13.7
0.84

1.46
0 . 28

x

0.39

EFFECT OF SODIUM LOADING ON TUBULAR SODIUM TRANSPORT

v
Hb

ml/min

X

AA
SD

±

SS
SD

±

M/S~

SD

±

FNa*
meq/min

UNaV*
meq/min

TNa*
meq/min

4.24

134.4
6.31

17.0
2.60

1. 31
0.40

15.7
1.76

16.5
3.56

170
5.0

22.09
0.93

1.22
0.27

20.87
1.70

12.2
0.98

59.9
4.2

7.9
0.89

1. 33
0.07

6.5
1. l

15.3

x

GFR*
ml/min

RPF*
ml/min

196.6
15.7

EFFECT OF WATER DIURESIS ON TUBULAR SODIUM TRANSPORT

v
Hb

ml/min

x

GFR
ml/min

FNa
meq/min

UNaV
meq/min

TNa
meq/ min

0.38
0.1

16.71
0.41

97.8
0.5

13.4
1. 9

0.41
0.10

21.56
2.1

98. l
0. 11

18. 9
4.1

0.73
0.13

6.75
0.25

88.5
1.8

5.6
1. 2

AA
SD ±

14.8
2.1

123.8
6.1

17.09

SS 5(
SD ±

19.6
3.9

168. 8
17.2

22.0
1.7

M/S~
SD ±

13.03
2.1

59.8
3.9

0.45

7.7
0.40

TNa/FNa*
%

CH20*
ml/min

TABLE IV: Renal function studies of J. F. P. with Hb M/S disease compared to previously reported
studies of patients with Hb. AA and SS Hatch et. al. J.C. I.Vol. 46, No. 3, pp. 336-345, 1967.
•Abbreviations - V= urine flow; UV= solute excretion; COsm= osmolar clearance; TcH20= free water
reabsorption; GFR= glomerular filtration rate; FNa= filtered sodium load; UNaV =urinary sodium
excretion; TNa= tubular sodium reabsorption; RPF= renal plasma flow; TNa/FNa= fraction of t~e
filtered load of sodium reabsorbed; CH20 =free water clearance. Values corrected to 1. 73 M BSA.
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be argued that these changes could result from Memphis hemoglobinopathy or that hemoglobin SS patients
of comparable age might present similar findings, the
weight of clinical evidence seems to favor chronic
renal disease. Renal biopsy failed to reveal the vascular congestion and the accumulation of sickled cells
usually found in glomerular capillaries. Instead, glomerular hypercellularity with endothelial proliferation
and arteriolar nephrosclerosis with arteriolar thickening were found. Thus, it is not possible to assume that
the alpha chain variation modifies the renal concentrating defect of sickle cell disease, although these
studies are suggestive and typical clinical features of
sickle cell disease have not been observed. Younger
and older subjects with hemoglobin Memphis/ S (with
and without hemoglobin S) without chronic renal disease will have to be examined to clarify this point.
The pathological changes of sickle cell disease are
thought to be a result of a formation of sickled cells
under conditions of deoxygenation with increased viscosity, vascular stasis, and occlusion of the microcirculation. Charache and Conley ( 1964) demonstrated that the viscosity of deoxygenated blood varied
directly with the percentage of sickle cells and exponentially with the hematocrit, concluding that the
clinical manifestations of sickle cell anemia could be
attributed to intravascular sickling. To account for
the occasional patient who has a more benign course
even with marked sickling and increased viscosity,
protective extracorpuscular factors were postulated.
Recent studies by Murayama (1964; 1966) and
Perutz (1965; Perutz and Lehmann, 1968) of effects of amino acid substitution on the functional
activity of hemoglobin may afford explanation of these
clinical variations. Murayama proposed that the substitution of a glutamic acid residue at the number 6
position by a valyl residue results in an intramolecular
hydrophobic bond with the N-terminal valine; a cyclic
structure on the beta chain is formed which can lock
into the alpha chain. Muirhead and Perutz (1963)
demonstrated that the beta chains of reduced hemoglobin are 7 Angstrom units further apart than those
of the oxygenated form. Thus, the reduced beta chains
of hemoglobin/ S would fit into the alpha chains which
are not affected by decreased oxygen tension, forming
a rigid tactoid. Murayama postulated that the binding
sites produced by cyclization at the N-terminal part
of the beta chain must fit precisely with the binding
sites on the alpha chain. When the binding sites on
the beta chain move closer together on oxygenation,
the key of the beta chain no longer fits the lock of the
alpha chain. Murayama demonstrated by polarized
light, magnetic orientation, and electron microscopy
that microtubules of hemoglobin/ S were linearly arranged with resulting stacking up of molecules. The
previous patients reported with hemoglobin Memphis/ S
disease have been found to have sickled red cells, but

our patient has been shown to have normal viscosity
with deoxygenation. This molecular defect on the alpha chain must modify the lock so that less rigid tactoids form.
Perutz (Perutz, Kendrew and Watson, 1965) h~s
suggested that the presence of histidine, glutamic acid,
or aspartic acid is necessary for the formation of corners or non-helical regions on globin molecules, and
has found that one of these amino-acids is a constituent
of every corner and occurs in an adjacent area of
every non-helical region. Perutz's model of hemoglo-

27
25
23
21
19

Ci::

~

HEMATOCRITS ADJUSTED TO 33 VOL ."!.
DEOXYGENATION ' 30 MIN . 95"1. N2_5'J'.C02
OXYGENATION ' 15 MIN . 100"1.02
35•c

17

~ 15

<;;
Cl

~ 13

::;;

11

DEOXYGENATEDaAcxA/thi 5
. . . OXYGENATED cxAcxA//JS/JS

9

..... DEOXYGENATEDcxAcxA/jJS,aC
· - - OXYGENATED CXACXA/jlsjlc

7

DEOXYGENATED ex AaA1jJAjJA

-

_""'l~~@! ..... oxYG ENATED a AcxAtpAjJA

....... DEOXYGENATEDcxAaA/jl AjJS

.111.- -A OXYGENATED cxAaA /fJAjJS

3
12

6

30

60

RPM

Fig 8-Viscosity Measured with the Brookfield Viscometer.

STATISTICAL ANALYSIS
aAaM/pSpS_ OXYGENATED
DEOXYGENATED >-01 < . 001

15

VB .

cxAaA1jJApS- OXYGENATED vs .
DEOXYGENATED>-1 < .05

13

DI FF -tv1scos ITY
a.Aa.A/jJApS vs. a.Aa.M/jJApS

~"
0:

<:i

7

NOR MAL VISCOSITY
>.S <· 3
BLOOD
(HEMATOCRIT 42-49 HEMATOCRIT 33 vol.%
vol.%)
..... OXYGENATED cxAcx M //Jsjls

<.>

e--e DEOXYGENATEDa.Aa.M,,pSpS

:;; 5

..:.. .... OXYGENATED cxAaA /fJS jJA

..._9

..."-

iO

Cl

"'

......... DEOXYGENATEOaAcxA/pSJ)A
3

6

12

30

60 RPM

Fig 9-Brookfield Viscometer.
73

HEMOGLOBINOPATHIES

bin describes the 23rd residue of the alpha chain interacting with Number 21 histidine, stabilizing the corner between the alpha and beta helical regions. The loss
of stability at this position with glutamine substitution
for glutamic acid must result in the change in tertiary
conformation. Thus, the instability of the alpha Memphis and beta chain interaction appears to decrease
rigidity of the "lock and key" mechanism-resulting
in normal viscosity, increased gelling concentration and
decreased sickling in the deoxygenated state. Finding
whether or not the alpha chain defect can completely
modify sickle cell disease must await the discovery of
homozygous hemoglobin Memphis/ S disease. The
heterozygous alpha chain defect by itself is not symptomatically expressed.
Additional studies have been performed measuring
the effect of hyperosmolar solutions on the viscosity
of various hemoglobinopathies. Perillie and Epstein
( 1963) reported the effect of hypertonic solutions on
the various hemoglobinopathies. They reported that
sickling occurred within a few seconds in all patients
with sickle cell anemia and sickle cell variants when
their blood was mixed with hypertonic saline. An increase in the sickling in the blood of patients with
sickle cell anemia (SS disease) was first observed in
osmolality of 600 mosm/ kg. As the concentration of
salt solution increased, the percentage of sickle cells
reached a maximum at 600 to 1,000 mosm/ kg. It did
not usually increase with further increase in extracellular tonicity. The same phenomena was observed in
patients with sickle cell trait, but the sickle cells were
less numerous than in subjects with sickle cell anemia.
They proposed that in patients with sickle cell
anemia, sickling may take place in the capillaries of
the renal medulla but that this is partly related to another property of this tissue-its hypertonicity. Thus,
sickling would increase the viscosity of blood entering
the medulla and, therefore, the resistance to blood
flow through the medullary capillaries would be increased. They postulated that by decreasing intermolecular distances within the red cell, intracellular dehydration induced by hypertonicity might be expected
to enhance the additional tendency to sickling produced by hypoxia or acidity. Ham (Ham et al, 1968)
reported on a series of studies investigating
the effect of various solutions on the viscosity
of red cells. His group found that red cells fixed
in glutaraldehyde or formaldehyde were more viscous
than normal cells and the flow properties were more
Newtonian in behavior, thus being less dependent on
shear rate. These authors showed that hyperosmolar
solutions increased the rigidity of the red cells with
an increase in viscosity. They reported that the increase in viscosity, decreased filtration, and resistance
to packing and morphological changes were identical
for oxygenated blood for dogs, normal humans, sickle
cell trait blood, and sickle cell anemia erythrocytes.
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They found no increase in sickling as the osmolar solutions were increased. When red cells from sickle
cell trait and homozygous SS disease were suspended in
600 mosm sodium chloride and then reduced, the viscosity was maximal or became unmeasurable because
the cells behaved like a gel. They postulated that the
hypertonicity of sodium resulted in increased viscosity
of all cells but did not cause sickling of oxygenated
blood. This increase in viscosity could result in decreased flow in the vasa recti with rising concentrations
of the sodium chloride. The decreased rate of flow
would lead to lowered p02 and pH and these in turn
could result in sickling in both homozygous and heterozygous hemoglobin S patients. Hatch (Hatch, Culbertson and Diggs, 1967) stated that although vascular
damage undoubtedly plays an increasingly important
role in sickle cell nephropathy with advancing age, it
does not explain adequately the renal concentrating
defect that is present almost from birth. He proposed
that indirect evidence suggests a possible increase rather than a decrease in medullary blood flow because
of an inability of patients with sickle cell disease during hypertonic saline diuresis to exceed the maximum
clearance of water as obtained during Mannitol diuresis. Thus an increase in medullary blood flow would
produce a loss in renal concentrating ability through a
decrease in medullary solute concentration.
We measured the viscosity of the various hemoglobinopathies at different osmolalities with a Brookfield
viscometer (Table V). The viscosity was measured at
6, 12, 30, and 60 rpm on blood suspended in plasma,
in 300 mosm sodium chloride solution, 600 mosm solution, 800 mosm solution, and 1,000 mosm solution
concentrations (Table VI). Oxygenated cells suspended
in plasma with an hematocrit of 33 vols percent
showed no significant difference between the viscosity
of hemoglobin AA and AS. However, there was a significant increase in the viscosity of hemoglobin AA,
AS, and HS blood at the 0.01 level when compared
to Memphis/ S and SS hemoglobin. Oxygenated blood
at 300 mosm concentration showed a significant increase of hereditary spherocytosis erythrocytes and
hemoglobin SS blood as compared to Memphis/ S and
hemoglobin AS and AA. At 600 mosm, hemoglobin
SS and hereditary spherocytosis blood showed a significant increase at the 0.01 level in viscosity as compared to hemoglobin AA, AS, and Memphis/ S. With
800 mosm solutions, hemoglobin SS and hereditary
spherocytosis (HS) showed a significant increase in
viscosity over hemoglobin Memphis/ S and hemoglobin AA and AS. At 800 mosm solution, Memphis/ S
showed increase in viscosity over hemoglobin AA and
AS at the 0.05 level. At a 1000 mosm solution, hemoglobin AA and AS showed significantly less increase
in viscosity than Memphis/ S, SS, or hereditary spherocytosis. There was no significant difference between
Memphis/ S, SS, and hereditary spherocytic red cells.
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Table V.

OS MOLALITY
PLASMA
HCT 33 Vol.%

OXYGENATED

AS
SS
~
Viscosity in Centipoise Units

AA

DEOXYGENATED

AS
~
!:M1
Viscosity in Centipoise Units

H.S.

RPM

AA

H.S.

6

4.0

4.2

5.2

5.6

4.3

6

4. 1

6. 1

14.1

6.8

3.7

12

3.8

3. 9

5.3

5.0

4. 1

12

3. 8

4. 3

13.0

6.2

3.8

30

3. 7

3.9

5.2

4.7

3.9

30

3. 6

4.0

12 . 2

5.7

3.6

60

3.6

3.8

5. 1

4.6

3.8

60

3.5

3.7

11.7

5.7

3.5

6

2.7

2.7

13.3

4.3

12.5

6

3.0

3.5

20.3

6.0

14.1

12

2.8

2. 5

10.0

4.2

10.3

12

2.9

3.5

13.0

5.8

11. 3

30

2.4

2.4

5.8

3.8

5.7

30

2.7

3.6

8.8

5.6

6.7

60

2.4

2.4

4.3

3.8

4.1

60

2.6

3.7

7. 1

5.7

4.7

6

3.9

5.8

25.7

5.9

24.5

6

2.7

2.8

5.8

8.5

5. 3

12

3.9

4.3

18.3

5.2

'15.5

12

2.8

2.9

6.5

84.

4.7

30

3.0

3. 7

10.5

4.8

8. 2

30

2.7

3.0

7.9

8.5

4. 2

60

2.6

3.0

7.2

4. 4

5. 8

60

2.7

3. 1

8.3

8.6

3.9

300 m OSM

600 m OSM

T able VI.

OS MOLALITY
PLASMA
HCT. 33 Vol. %

OXYGENATED

AS
SS
~
Viscosity in Centipoise Units

DEOXYGENATED

RPM

AA

AA
AS
SS
M/S
Viscosity in Centipoise Units

800 m OSM

6

3.7

5.8

12.4

7.9

23.0

6

4.6

7.6

10.5

11.6

7.4

12

3.7

5.5

9.8

7.2

14.2

12

4.5

5. 3

7.8

11. 1

6.1

30

3.4

4.2

8.5

6.3

7.7

30

4.3
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In the oxygenated blood at varying osmolalities from
300 to 1000 mosm solutions, hemoglobin SS and HS
blood behaved in a similar manner. Hemoglobin AA
and AS did not show increasing viscosity with increasing osmolar concentrations, as previously reported by
Hamm and his group. Hemoglobin Memphis/ S did
show an increasing viscosity with increasing osmolalities. Hemoglobin SS and red cells from patients with
hereditary spherocytosis showed a similar pattern
which was of a much greater magnitude than that of
Memphis/ S. The same type of studies were performed
with deoxygenated blood. The hemoglobins listed in
order of ascending viscosity suspended in plasma were
hereditary spherocytic red cells, hemoglobin AA, hemoglobin AS, Memphis/ S, and SS disease. At 300
mosm solution under deoxygenated conditions hemoglobin AA and AS showed significantly less increased
viscosity as compared to Memphis/ S or as compared
to HS or SS blood. At 300 mosm solutions, hemoglobin HS and SS behaved similarly and showed a significantly higher viscosity than the other hemoglobinopathies. Hemoglobin Memphis/ S showed increasing
viscosity with increasing osmolar solutions and at 600,
800, and 1000 mosm concentrations was significantly
higher than any of the other hemoglobinopathies.
Sherman tests were performed on the various hemoglobin solutions at varying osmolar concentrations
and showed that there was no increase in the number
of sickled cells in hemoglobin AS or SS disease at increasing osmolar concentrations, similar to the results
obtainel by Ham and his group at Case Western
Reserve. Hemoglobin Memphis/ S showed an increased
number of sickled cells in hyperosmolar solutions, but
this was a constant number throughout all of the osmolar solutions. The consistent finding was that the
red cells were spherical and crenated with numerous
spicules.
These data suggest that there may be an association
between hereditary spherocytosis and sickle cell disease. A group of investigators from Japan (Matsuda
et al, 1969) reported a case of nephrotic syndrome in
a ten-year-old Japanese boy with hereditary spherocytosis. They pointed out that spherocytosis and sickle
cell anemia have some features in common such as abnormal shape, short erythrocyte survival, persistent
icterus, and occurrence of crises. In addition, there
may be some association between hereditary spherocytosis and sickle cell anemia in reference to a marked
increase in viscosity with hyperosmolar solutions in
oxygenated blood. It has been pointed out by Jensen
( 1969) that the repeated sickling and unsickling of a
cell may cause repetitive fragmentation with proportionally greater membrane than volume Joss which
eventually will result in the production of a spherocyte.
This situation would be most likely to happen during a
sickle cell crisis in which the cells would be subjected
to maximal damage. This may also explain the varying
76
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results reported in patients with hemoglobin SS when
subjected to hyperosmolar solutions.
Some investigators have suggested the use of low
molecular weight dextran in the therapy of patients
with sickle cell anemia. We have measured in an in
vitro situation the effect of various dextran 40 and
dextran 70 concentrations on the viscosity of hemoglobin SS disease (Fig 10, 11, 12). Our findings suggest that dextran actually increases the viscosity of
hemoglobin SS disease. Oski (Oski et al, 1965) reported that low molecular weight dextran was of no
benefit in the therapy of sickle cell crisis.
Eisenberg ( 1969) reported that low molecular
weight dextran had no specific effect on blood viscosity. However, it did prevent erythrocyte rouleau
formation and aggregation. It is also known that the
infusion of low molecular weight dextran is associated
with acute renal failure in at least fourteen patients.
Mailloux (Mailloux et al, 1967) produced acute
anuria in experimental animals with low molecular
weight dextran. They postulated that a reduction in
filtration pressure combined with a marked increase
in urinary viscosity generated by the dextran may lead
to tubular stasis and subsequent tubular blockade.
Laszlo (Laszlo, Obenour and Saltzman, 1969)
studied the effect of hyperbaric oxygenation on erythrocyte sickling during sickle cell crisis. His group at
Durham studied five patients during crises. They
found that the percentage of circulating sickle cells
did decrease during hyperbaric oxygenation. However,
there was no improvement of the sickle cell crisis and
there was no tendency toward improved renal concentrating ability during the hyperbaric oxygenation. A
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New Concepts in the Management of
Neonatal Jaundice: Use of Enzyme
Induction and Phototherapy*
HAROLD M. MAURER

D epartment of Pediatrics,
M edical College of Virginia,
Richmond 23219

Io the last two years two new methods for treatment of neonatal hyperbilirubinemia have been successfully introduced. The first consists of administration of phenobarbital to newborn infants and to
pregnant women for at least two weeks prior to
delivery. The second consists of exposing the neonate
to light. Before these treatments were available, only
with exchange transfusions (which are time consuming, expensive, and carry a risk of about one to
55 percent even in experienced hands) or, very rarely,
with dialysis could one predictabl y lower the concentration of serum bilirubin.
Why do newborn infants have hy perbilirubinemia,
and why are we so concerned about controlling the
bilirubin level ? The life span of a newborn infant's
red blood cell is shorter than that of an adult. As
senescent cells a nd their fragments become sequestered
in the reticulo-endothelial system the hemoglobin
molecule is split into two fragments: globin which is
brought into the protein metabolic pool, and heme
which is further catabolized. Microsomal heme
oxidase, a rate limiting enzyme, then acts on heme to
form biliverdin as the principal product. Biliverdin is
further reduced and degraded to indirect-reacting
unconjugated, lipid soluble bilirubin. Most of the
bilirubin is reversibly bound to albumin. In this form
it can be distributed in blood to a variety of tissues.
A small fraction of circulating bilirubin is unbound
in a dissociation equilibrium with albumin bound
bilirubin. Normally, it is the unbound bilirubin fraction that continuously diffuses across the surface of the
liver cells. The bilirubin is taken by the cell membrane lipids and transferred to proteins within the
liver cell. Similar processes occur in fat cells, epidermal cells and neurons. Bilirubin can be pulled
out of cells by increasing the albumin concentration
of plasma. Within the liver cell bilirubin is separated
from protein and conjugated. Normally, the conjugation process helps to maintain the diffusion of biliru-

* Presented at the 23rd Annual Stoneburner Lecture
Series, February 20, 1970, at the Medical College of Virginia, Richmond.
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bin into cells by lowering the intracellular concentration of protein bound bilirubin. The conjugation
process involves the transfer of an active glucuronide
moiety from uridine diphosphoglucuronic acid
(UDPGA) to bilirubin by the microsomal enzyme,
uridine diphosphoglucuronyl transferase (UDPGT).
The conjugated bilirubin is water soluble and is subsequently excreted into the bile or urine.
It has long been felt that physiologic jaundice in
the neonatal period is due, at least partly, to low content of UDPGT in the livers of newborn infants.
However, recent animal studies suggest that there may
be adequate amounts of enzyme present. Approximately 50 percent of full-term and a greater percentage of low-birth-weight infants have physiologic
jaundice.
Jaundice may occur for a number of other reasons.
The most common causes, and the most dangerous
with respect to risk of bilirubin encephalopathy, are
those related to hemolysis or accelerated breakdown
of mature red blood cells. Isoimmunization due to
fetal-maternal ABO or Rh incompatibility is the leading cause of hemolytic jaundice. Other causes include
sepsis, erythrocyte enzyme deficiencies and congenital
spherocytosis. Jaundice may also arise from defects
in hepatic uptake of bilirubin, as occurs in Gilbert's
disease. Further, defective conjugation of bilirubin
in hepatic microsomes may lead to jaundice. Approximately 1 percent of breast fed newborn infants develop severe hyperbilirubinemia, which persists for
three to 12 weeks. Milk from mothers of these infants
can inhibit to a very significant degree glucuronyl transferase activity in vitro. These inhibitory milks contain pregnane-3-( alpha), 20 (Beta)-idol which is produced in the actively secreting mammary tissue. Also
leading to jaundice are disturbances in hepatic excretion of bilirubin, as occur in the Dubin-Johnson and
Rotor's syndromes.
Kernicterus or bilirubin encephalopathy occurs almost exclusively in newborn infants with severe
indirect-reacting hyperbilirubinemia. Jn the nursery
they show opisthotonis; lethargy; flaccidity or spasticity; high-pitched cry; and poor suck, moro and grasp
reflexes. If they survive the newborn period they may
be mentally retarded or have choreoathetosis, cerebral
palsy, deafness or evidence of minimal brain damage.
When they succumb to this condition in the neonatal
period, the brain usually shows localized yellow staining. Strong evidence suggests that this is due to free
indirect-reacting lipid soluble bilirubin which readily
crosses biologic membranes including the blood-train
barrier. Although in normal plasma the free indirectreacting bilirubin is minute, it may be increased in
hemolytic disease of the newborn in the presence of
organic anions which compete with the pigment for
binding sites on albumin, or in acidotic states where
the binding of albumin for bilirubin is reduced. It
80

has ·Jong been realized that such factors as asphyxia,
hypoglycemia and hypoproteinemia may increase
susceptibility to kernicterus.
There is considerable evidence that bilirubin causes
decreased cellular oxygen uptake; it also inhibits
oxidative phosphorylation while producing characteristic morphologic changes in large neurons in tissue
culture, such as enlargement of the mitochondria.
The search continues for a reliable guide to define
what constitutes a dangerous concentration of serum
bilirubin. As a working guide to the need for exchange
transfusion, these figures continue to stand up well:
20 mg/ 100 ml for the full-term infant with erythroblastosis, 18 mg percent for the premature infant
with erythroblastosis, and 20-25 mg/ 100 ml for the
non-erythroblastotic infant. It continues to puzzle and
frustrate clinicians that kernicterus can occur sporadically in premature infants with low serum bilirubin
concentrations, and that some full-term infants with
serum concentrations above 30 mg percent are amazingly resistent to its development.
Control of Hyperbilirubinemia by Enzyme
Induction

Yaffe and associates (1966), and Crigler and Gold
(1966) independently reported the first clinical trials
of phenobarbital for treatment of congenital nonhemolytic jaundice. In Yaffe's patient, treatment with
15 mg of phenobarbital three times daily lowered the
serum bilirubin concentration and jaundice disappeared. When treatment was stopped, the serum bilirubin concentration rose to its original high levels;
reinstitution of therapy again decreased serum bilirubin
levels and jaundice disappeared. Parallel studies by
Yaffe on salicylamide, metabolized like bilirubin,
showed that the defective capacity to conjugate glucuronide before phenobarbital became normal after treatment. In Crigler's case, the size and rate of turn-over
of the bilirubin pool was measured before and during
phenobarbital treatment. Results indicated that phenobarbital enhanced the excretion of the bilirubin rather
than causing its redistribution into extr·~-vascular pools.
A large body of data showing the stimulatory effects
of drugs such as phenobarbital on the metabolism of
normal body constituents led to its trial in the above
two patients. Studies during the past decade have
shown that the activity of enzymes in liver microsomes is markedly increased when animals are treated
with various hormones, drugs, insecticides, and carcinogens (Conney, 1967). This increased activity appears to represent an increased concentration of enzyme protein and is referred to as enzyme induction.
The induction of liver microsomal enzymes is important pharmacologically, for it leads to an accelerated
transformation of drugs in vivo and so alters the duration and intensity of drug action in animals and man.

H. M. MAURER

TABLE 1
Stimulators of Microsomal Enzyme Activity
Drug
Pharmacological Action
Hypnotics and sedatives

Anesthetic gases

Central nervous system
stimulators
Anticonvulsants

Tranquilizers
Antipsychotics
Hypoglycemic agents and
related sulfonamides
Anti-inflammatory agents
Muscle relaxants

Barbiturates
Glutehimide (Doriden)
Chlorobutanol (Chloretone)
Urethane
Carbromal (Adalin)
Pyridione (Persedon)
Methyprylone (Nodular)
Ethanol
Chloral hydrate
Paraldehyde
Nitrous oxide
Methoxyflurane
Halo thane
Ether
Nikethamide (Coramine)
Bemegride
Methylphenylethylhydantoin
(Mesantoin)
Diphenylhydantoin
(Dilantin)
Paramethadione (Paradione)
Phenaglycodol (Ultran)
Meprobamate
Chlordiazepoxicte (Librium)
Chlorpromazine
·
Triflupromazine
Promazine
Tolbutamide (Orinase)
Carbutamide
Phenylbutazone
Orphenadrine
Carisoprodol
Zoxazolamine

TABLE 2
Effects of Enzyme Inductiop in Man
1. Alters metabolism of other drugs; eg, dilantin,

coumarin, griseofulvin, aminopyrine
2. Stimulates biiirubin metabolism
3. Enhances metabolism.of steroids

More than 200 drugs, insecticides, carcinogens and
other chemicals are known to stimulate the activity of
enzymes in the liver. Examples are shown in Table 1.
Enzymes can be stimulated by different types of drugs:
barbiturates and other hypnotics and analgesics, tranquilizers, antihistamines, oral antidiuretic agents, and
uricosuric agents. The characteristic pharmacological
actions of these compounds on the organism are extremely diverse, and there is no apparent relationship
between their actions or structure and their ability to
induce enzymes.
The quantity of inducer necessary to have an appreciable effect on the enzymes varies considerably.
It has been shown that phenobarbital given to lactating
rabbits increases the levels of enzymes in the nurslings
at doses that do not effect the behavior of the offspring.
Phenobarbital acts by stimulating varied pathways of
metabolism through liver microsomes, causing oxidation-reduction reactions, glucuronide formation and
de-esterification. When the enzyme that acts on a
drug or substrate is induced, the drug or substrate is
metabolized more rapidly. Enzyme induction alters
not only duration but also intensity of drug or substrate action.
Several test systems are available to determine
whether a compound can induce enzymes. These include enzyme assay of liver fractions, measurement
of duration of drug action, measurement of drug or
metabolite in blood or urine, and examination of the
hepatic parenchymal cell under the electron microscope. Evidence indicates that increases in enzyme
activity by drug represent an induction of more enzyme protein rather than an altered affinity of the
enzyme for the substrate.
Several effects of enzyme induction in man have
been noted and are listed in Table 2. Phenobarbital
stimulates the enzymatic metabolism of coumarin,
dilantin, griseofulvin, doridren, digitoxin and aminopyrine. Further, it stimulates bilirubin metabolism
and enhances the urinary excretion of 6-beta-hydroxycortisol.
Recent studies have shown that phenobarbital facilitates hepatic metabolism and biliary excretion of bilirubin in animals, as seen in Table 3. The administration
of phenobarbital stimulates: 1) bilirubin glu,curonyl transferase activity in liver microsomes, 2)
the disappearance of exogenously administered bilirubin from plasma, 3) hepatic uptake of bilirubin, 4)
bile flow and biliary excretion of bilirubin, and 5) the
proliferation of smooth membranes of the endoplasmic
reticulum. These observations suggested to Yaffe et al
1966), and Crigler and Gold (1966, 1967) that
phenobarbital might have therapeutic value in human
diseases of hyperbilirubinemia.
Encouraged by these studies in congenital nonhemolytic jaundice, we investigated the effect of phenobarbital on neonatal jaundice (Maurer et al, J 968) .
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Bilirubin formed in utero by the fetus can cross the
placenta and be excreted by the maternal liver. After
birth, however, the infant's hepatic bilirubin clearance
is not sufficient to prevent its accumulation during
the first week of life. We wanted to know whether
careful treatment of pregnant women with phenobarbital for at least two weeks before delivery could
enhance the metabolism of bilirubin in the newborn
infant and reduce neonatal serum bilirubin levels. We
chose to treat the pregnant women rather than the
newborn infants with phenobarbital, to · determine
whether enzyme induction could be accomplished in
the fetus in utero and to avoid a delay in induction of
enzyme activity which might be anticipated if treatment was started at birth.
Thus, 12 pregnant women were treated with sodium
phenobarbital, 30-120 mg per day for two weeks or
longer prior to delivery (Table 4). Subsequently, concentrations of total serum bilirubin in their offspring
and in 16 control babies were compared during the
first four days of life. Premature babies and those
sensitized by maternal-fetal Rh or ABO in compatibility were excluded from this study. All but one
of the women received injection of 1.5 percent
mepivocaine hydrochloride for continuous epidural
analgesia during labor and delivery. Medications normally administered to some of the pregnant subjects
were not controlled, but evaluation of the medications
given to the control and the phenobarbital groups
showed no significant difference.
Table 4 lists the dose and duration of phenobarbital
treatment received by each of the pregnant women,
and shows the maximum level of serum bilirubin observed in their infants in the first four days of life.
The highest level of neonatal serum bilirubin in the
phenobarbital group was 4.7 mg percent, whereas 12
of 16 control babies had peak serum bilirubin levels
above this value. Since all but two of the women were
treated with the same daily dose of phenobarbital, it
was not possible to determine what dosage regimen
most effectively Jowers the concentration of serum
bilirubin.

TABLE 4
Schedule of phenobarbital treatment during pregnancy
and its effect on the maximum level of total serum bilirubin
in the neonatal period*
Group and dose of
Maximum neonatal
Duration of
serum bilirubin
phenobarbital
(mg/ day)
treatment (days) level (mg/ HlO ml)
Controls:
0
Phenobarbital:
60
60
60
60
60
60
30
60
60
60
120

0

1. 3-10.4

14
14
14
14
22
24
30

4.2
2.8
2.7
2.7
3.6
1.1
1.8
1.6
4.7
1.0
1.2
4.4
(2 . 7 ± 0.4t)

31

40
60
105
11 yr.

60

(5 .9 ± 0.5t)
* The value of serum bilirubin for each subject represents
the maximum obtained for that subject during the first
4 days of life.
t Mean ± S.E.

TABLE 5
TABLE 3
Effect of Phenobarbital on Bilirubin Metabolism
in Animals
1. Stimulates bilirubin glucuronyl transferase activity

in liver microsomes
2. Stimulates clearance of exogenously administered
bilirubin from plasma in animals
3. Stimulates hepatic uptake of bilirubin
4. Stimulates bile flow and biliary excretion of
bilirubin
5. Stimulates proliferation of smooth membranes
of the endoplasmic reticulum

82

Effect of phenobarbital received during pregnancy on
concentration of total serum bilirubin in the neonatal
period*
Serum bilirubin (mean ± S.E.) (mg / 100 ml)
Day
2
3
4

Control
3.8
5.0
5.7
5.2

±
±
±
±

0.4
0.6
0.7
0 .8

Phenobarbital
2. 1 ±
2. 5 ±
2.2 ±
1.8 ±

0 .4
0.4
0 .4
0 .4

* Each value represents the mean and S.E. obtained on
each day for the control and phenobarbital groups.
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In Table 5, the mean daily concentrations of serum
bilirubin are compared in control infants and babies
of phenobarbital treated women. Daily levels of serum
bilirubin were significantly low in the phenobarbital
group. The maximum mean value for serum bilirubin
in these infants was 2.5 mg/ 100 ml; this concentration
occurred on the second day of life. In control babies,
however, the maximum mean level of serum bilirubin
was 5.7 mg/ 100 ml; this value was found at three
days of age. The level of serum bilirubin in each group
was not related to the type of feeding received.
All babies in the study were vigorous at birth and
thereafter.
These data suggest that the administration of phenobarbital for two weeks or longer before delivery altered
the usual course of physiologic hyperbilirubinemia.
Serum bilirubin levels were reduced and maximum
serum bilirubin values occurred earlier in babies born
to women treated with phenobarbital. The low concentration of serum bilirubin in these babies suggests
that phenobarbital, acquired by the fetus transplacentally, enhanced the hepatic metabolism and biliary excretion of bilirubin in the fetus and the newborn infant. Our findings were confirmed by Trolle ( 1968).
One question that immediately comes to mind is
whether phenobarbital may be harmful to the pregnant woman or to her newborn infant. A la'rge number
of women with epilepsy or pre-eclampsia have been
treated with phenobarbital for at least two weeks during pregnancy without recognizable difficulty. Regarding the danger phenobarbital may cause a newborn
infant, in our series no difference was detected in the
behavior of infants of treated and untreated mothers.
Similarly, no differences have been detected in other
series. Trolle ( 1968) measured the serum phenobarbital level in some of his babies, and in no case did
the concentration exceed 21 mg/ ml, which is well below the sedative level.
Another consideration is the possibility that phenobarbital could displace bilirubin from alfmmin. This
could lead to a diffusion of dissociated bilirubin from
the blood and interstitial fluid to the intracellular
fluid, thus increasing the risk of development of
kernicterus. In this regard we did not see increased
skin jaundice in those babies born to phenobarbital
treated women, nor did Trolle in his series. In addition,
we made serial measurements of the reserve binding
capacity of serum for bilirubin, using the HABA dye
method, and found no difference in the serum binding
capacity between the control and phenobarbital treated
groups. Our findings, in conjunction with those reported by Yaffe and Crigler, indicate that the decrease
in serum bilirubin concentration after phenobarbital
treatment cannot be considered dangerous. All the
observations suggest, therefore, that phenobarbital may
be of therapeutic value in controlling neonatal hyperbilirubinemia.

Control of Hyperbilirubinemia by Phototherapy
Lucey, Ferreiro and Hewitt ( 1968) reported a
controlled study which showed that early prolonged
exposure of premature infants to artificial light might
prevent or at least modify the degree of hyperbilirubinemia. Cremer, Perryman and Richards (1958) of
Australia first demonstrated that serum bilirubin concentrations of some newborn infants could be reduced
by exposure to sunlight or artificial blue light. Several
groups of English, South American, French and
Italian workers subsequently reported very favorable
experiences with this method of treatment. This therapy had not found acceptance in the United Statesprobably due to doubts as to its effectiveness, concern
that the photodecomposition products might be toxic,
and unawareness of many reports in the foreign literature.
Lucey ( 1968) tested the effectiveness of artificial
blue light in preventing hyperbilirubinemia among 111
premature infants. Treated infants from 12 to 144
hours of age were placed in light; serum bilirubin concentrations were then carried out. The control and
treated infant groups were comparable with respect
to birth weight, gestational age, fluid intake and weight
loss. The results showed a statistically significant difference between the two groups on the fourth and sixth
days of life. No differences were noted in the sleeping
and feeding habits of the infants in the light treatment
group.
How does light affect bilirubin metabolism? The
level of indirect reacting bilirubin present in a solution
of human albumin and bilirubin decreases when it is
exposed to light of certain wavelengths. As the level
of bilirubin decreases, first biliverdin and then a series
of not yet fully characterized related substances appear in the solution. The best available evidence suggests that the derivatives of photo-oxidation are in
part pyrrolic pieces of bilirubin resembling dipyrrole.
There is to date no published animal data supplying
any convincing evidence of the toxicity of the products of photo-decomposition. The studies of Ostrow
( 1968) using radio-labelled C,., bilirubin in Gunn rats
clearly demonstrate that these products are rapidly
excreted in the bile and urine, and that they are
indistinguishable from the normal products found in
Gunn rat bile and urine. It appears, therefore, that
photodecomposition is a normal alternate route of
excretion of bilirubin and is increased or activated in
newborn infants by the use of light.
In jaundiced infants exposed to light, the presence
of icterus in shielded areas of skin suggests that the
photo-oxidation occurs in the skin. Too, biliverdin
which is produced in the test tube, when a bilirubinalbumin solution is exposed to light is not observed
in the skin or plasma of light-treated infants.
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Potentially, light may have an effect on bilirubin
metabolism at several different points in its in vivo
metabolism (Behrman and Hsia, 1969). Light might
affect the microsomal heme oxidase system, which
might increase the amount of bilirubin carried in the
serum and presented to the liver. It might alter the
albumin binding sites for bilirubin, making it easier
for bilirubin to escape in the tissue. It might affect
the protein receptors for bilirubin within the liver cells
or other cells. Light might stimulate a variety of
mitochondrial enzymes, including UDPGT. It might
affect the yet poorly characterized bilirubin and other
excretory mechanisms in the liver.
Other biological effects of light have also been noted.
Ultraviolet light causes capillary dilation as in sunburn,
activates tyrosinase which results in skin darkening,
and causes a photo-chemical transformation of ergosterol to active forms of vitamin D. Further, there are
indirect effects that, though less well known, are of
potential concern. The duration of light exposure in
young animals can tum on or markedly delay the onset of puberty. Light has a profound effect on biologic
rhythms such as body temperature, food consumption,
physical activity and adrenal cortical secretion. In
animals, light has a profound influence on gonadal
weight and ovulation. Newborn piglets exposed to
light without the use of eye shields have developed
retinal detachment.
Although no obvious acute clinical toxicity has been
recognized in light-treated newborn infants, no organized retrospective or prospective follow-up study of
change in neurologic and behavioral sequelae is
available. There is still considerable doubt nd concern about all the potential biological effects of light
on bilirubin metabolism in humans and in animals.
Additional knowledge of these matters is critical in
evaluating the potential dangers of phototherapy.
Most investigators have started phototherapy soon
after birth; others have started at 12 to 72 hours after
birth or when jaundice was first noted. Therapy has
been continued for varying periods of time, continuously or intermittently through the sixth day of life.
At the Medical College of Virginia, the light is placed
over the isolette containing the infant and treatment
is continued for 96 hours. The light chamber consists
of ten GE#20 daylight bulbs attached to an aluminum
and steel frame. The lamps emit most strongly in the
blue-yellow wavelengths form 400 to 500 mU, and are
most effective in rapidly photo-oxidizing bilirubin
from 420 to 440 mU. Blue lamps and cool white
lamps, with slightly different wavelength emissions, are
also used. Red lamps emitting wavelengths above 600
mU are not effective; lamps that emit the lower ultraviolet wavelengths are less effective and more dangerous to the eyes than visible light. The infant's eyes
are covered with a simple bandage; no clothing is
placed on the infant so as much skin as possible is
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exposed to light. The intensity, duration, and pattern
of light exposure has varied considerably among the
groups of infants who have been subje,c.t ed to phototherapy by different investigators. The intensity of
light has ranged from 100 to 500 footcandles. At the
Medical College of Virginia 200 footcandles are used.
During a symposium on bilirubin metabolism in the
newborn infant held in Chicago in June, 1969, an
attempt was made to delineate tentative guidelines
in light therapy (Behrman and Hsia, 1969). The following guidelines were formulated:
1. The etiologic diagnosis for jaundice should be
established, as far as is practical, before starting
any therapy including phototherapy.
2. Phototherapy should not be used prophylactically
in term infants.
3. Phototherapy should be used for infants in whom
the risks of hyperbilirubinemia are thought to
out-weigh the risks of phototherapy.
4. Infants who, when first seen, have sufficient indications for an exchange transfusion should
not have their transfusion delayed for trial of
phototherapy.
5. Phototherapy should not be started until an abnormal rise in serum bilirubin has been demonstrated. In general, the serum indirect bilirubin
concentration should be at least 10 mg percent
at the time phototherapy is initiated.
6. Wavelengths between 300 and 600 mU from
200 to 400 footcandles should be effective in
reducing serum bilirubin concentrations in many
premature infants.
7. Eyes of the infant should be shielded with patches
to protect the developing macula. In order to
avoid corneal ulceration, it is also critical to make
sure that the eye is closed and remains closed
when patched.
8. Body temperature should be monitored to minimize the risk of over heating.
A number of questions with respect to phototherapy
still remain unanswered. There is no evidence that
jaundiced premature infants treated. with light have
fewer developmental abnormalities than untreated infants, that there is a decreased need for exchange
transfusion in premature babies with hyperbilirubinemia due to isoimmunization or sepsis, or that light
therapy is effective at high bilirubin levels. No organized follow-up data are as yet available regarding
sequelae of light therapy. No information is available
to evaluate optimal duration of light exposure or
determine whether exposure should be continuous or
intermittent. No good comparison is available to judge
the relative effectiveness and safety of blue versus white
or daylight lamps in photo-oxidizing bilirubin in humans. Data available comparing the effectiveness of
light in the Negro and in the Caucasian is limited and
inconclusive. No data is available comparing the effec-
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tiveness of light versus phenobarbital versus a combination of light and phenobarbital for treatment of
hyperbilirubinemia.
With these questions in mind, we (Dr. David
Draper, Dr. Orestes Valdes and myself of the department of pediatrics; Dr. Ali Hossaini ofthe Blood Bank;
with the cooperation of the pediatric house staff at the
Medical College of Virginia) have embarked on a
comprehensive study of phenobarbital and light therapy. The study is designed to compare light versus
phenobarbital versus a combination of light and phenobarbital for the prevention and treatment of hyperbilirubinemia in low-birth-weight infants. The comparisons will include the effectiveness of each on
Negroes compared to Caucasians; effectiveness of each
in hyperbilirubinemia due to hemolysis and other
causes; effectiveness of each when hyperbilirubinemia
is complicated by respiratory distress syndrome, intestinal obstruction and hypoglycemia; and effect of
each on the need for subsequent exchange transfusions
in infants who have previously received such transfusions. In addition, a long-term follow-up to determine possible sequelae of these treatments is planned.
In the study, low-birth-weight newborn· infants are
treated with either phenobarbital alone at a dosage of
five mg/kilo/gram per day for five days, ~xposure to
light for 96 hours at 200 footcandle intensity, or a
combination of phenobarbital and light. Only preliminary data are available at the present time and are
shown in Table 6. Of seven untreated control patients,
six had serum bilirubin levels over 10 mg percent
during the first five days of life. However, three of
eight phenobarbital-treated infants, none of the seven
light-treated infants, and none of the seven phenobarbital and light-treated infants had serum bilirubin levels above this value. The Figure shows the mean daily
serum bilirubin levels in each group. Beginning with
the second day of life there is a marked difference in
serum bilirubin levels between the controls and the two
light-treated groups. Infants who received phenobarbital alone showed a lowered serum bilirubin level
beginning on day four. Infants who received only light
therapy showed slight rebound bilirubinemia after the
light was discontinued. Though we must be cautious
in drawing firm conclusions from these preliminary
data, two points seem clear. Phenobarbital and light
treatment each modify the course of hyperbilirubinemia in the premature infant. Light reduces the bilirubin level more quickly and more dramatically than
phenobarbital treatment since the latter probably depends upon enhancement of hepatic microsomal enzyme activity, which takes several days to occur. At
the present time, the data are insufficient to determine
if the addition of phenobarbital to light offers an advantage over light alone. One might suspect, however,
that the combination might produce a sustained reduction of serum bilirubin level and avoid the rebound

phenomenon seen on the fifth day with light alone.
In our study, only one of the infants who received
phenobarbital became lethargic, but the lethargy persisted even after the drug was discontinued. No side
effects from light therapy were recognized, and a
funduscopic examination in the nursery in the majority
of children failed to reveal any abnormalities.
Summary

All the observations suggest that phenobarbital and
light may be of therapeutic value in controlling neonatal hyperbilirubinemia. In pregnancies in which one
might anticipate increased bilirubin formation by the

TABLE 6
Peak total serum bilirubin levels of low birth weight
newborn babies during the first 5 days of life
Group

Total No. of
Babies

Controls
PB*
Light
PB +Light

No. Above
10mg / 100ml

7
8
7
7

Percentage
85.5
37.5
0
0

6
3
0
0

* PB-Phenobarbital
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Figure-Effect of phenobarbital (5 mg/kilo/day, orally)
and light (200 footcandles, daylight bulbs) on daily total
serum bilirubin levels of low birth weight newborn babies.
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newborn baby, the use of phenobarbital during pregnancy and in the neonatal period, and exposure of
the infant to light may provide methods other than
exchange tranfusion to reduce the concentration of
serum bilirubin in the infant. Clinical trials should
proceed cautiously, however, since phenobarbital is
known to stimulate the activity of liver microsomal
enzymes that metabolize, steroids, hormones, and
other normal body substrates. It is not known whether
this effect would be harmful if it occurred in the human fetus or neonate. Pediatricians should consider
phototherapy in the same cautious manner as they
would the use of a new drug available for the treatment of newborn infants. Considering the state of
ignorance on this subject, research into the long-term
effects of phototherapy is clearly needed.
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Hemolytic Anemias*
ALI A. HOSSAIN!

Department of Pathdlogy,
Medical College of Virginia,
Richmond 23219

All hemolytic anemias feature shortened red cell
survival due to premature hemolysis of the cell. For the
purposes of this presentation, we may classify the
hemolytic anemias, most broadly, according to the
mechanisms leading to hemolysis.
Intrinsic Mechanisms
Hemolytic anemias due to intrinsically defective
erythrocytes are essentially of three types. First are
those anemias in which the red cells are defective due
to lack of an essential factor, eg, pernicious anemia
in relapse. The second type includes those in which
the red cells have an abnormal shape because of an
inherited error in the chemical makeup of the hemoglobin molecules; eg, sickle cells, elliptocytes, spherocytes, and the target cells. Last are those anemias in
which the red cells are defective in their basic enzyme
systems, as in paroxysmal nocturnal hemoglobinuria
(PNH) (bithermal auto-hemolysins) with acetylcholinesterase deficiency, or primaquine sensitivity with
glucose-6-phosphate dehydrogenase ( G6PD) deficiency.
Such anemias due to intrinsically defective erythrocytes, including those in which the red cells are defective in their basic enzyme systems as iq PNH, pose
no problem for the Blood Bank. In these cases there
is no antibody involved, and compatible group and
type specific blood is abundantly available and effective in raising the hemoglobin level of these patients. However, should the reticulocyte count exceed five percent, a direct Coombs test (DCT) may
be obtained which complicates matters for the Blood
Bank, unless the reticulocytosis is brought to the attention of the Blood Bank staff.
Another complication may occur if the specimen
sent for blood group, type, and crossmatch is obtained
shortly after hemolysis has occurred. Should the
serum contain hemolysins, they might not be detected in the crossmatch unless certain precautions
are taken. If missed, incompatible blood may be issued
-adding insult to injury.

* Presented at the 23rd Annual Stoneburner Lecture
Series, February 20, 1970, at the Medical College of
Virginia, Richmond.
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Extrinsic Mechanisms
Those hemolytic anemias which are due to extrinsic
factors may be classified, further, as non-immune or
immune. Non-immune mechanisms include a) drugs
and chemicals (phenylhydrazine, naphthalene, lead,
snake venoms); b) physical agents (heat); c) bacteria
and parasites (hemolytic streptococci, Clostridium
welchii, Bartonella, plasmodia); and d) acquired sensitivity to penicillin, methylodopa, Keftin®, or fava
plant as examples. Some of the agents in this. last
group serve to lyse the cells, either through duect
action or by formation of antibodies.
These hemolytic anemias due to extrinsic factors
of the non-immune variety present no transfusion
problem for the Blood Bank. However, it ~~st b.e
realized that in those conditions where a positive direct or indirect Coombs test is obtained (as in acquired
sensitivity to methyldopa, penicillin, phenacetin) a
situation may arise whereby blood may be needed in
an emergency; because of this incompatibility the release of blood may be delayed, to the detriment of
the patient. Therefore, it is essential th~t such ~on
ditions be recognized within a short penod of time.
The administration of blood thereafter becomes as
easy as the transfusion of any patient in the previous
category.
In drug sensitivity cases, however, it must be realized that the hemolytic anemia will cease once
the drug administration is stopped, and the DCT
usually reverts to negative. Worrledge, Carstairs,
and Dacie (1966) studied 30 patients who developed
hemolytic anemia while taking methyldopa (Aldomet®). Cessation of therapy led to immediate hematological remission. Peculiarly, the auto-antibo~ies
had Rh specificity, instead of being directed. agamst
methyldopa or one of its derivatives. In pat1ent.s. on
methyldopa, in which the DCT beco1!1-es pos1t1ve,
warm auto-antibodies may be detected m the serum
so that all donors appear to be incompatible. However, despite the presence of such incompat~bility,
infused red cells show normal survival. Revers10n to
a negative Coombs test enables the Blood Ban~ to
obtain and prepare compatible blood for the patient
without difficulty or worry. It is essential, therefore,
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that the drug causing the hemolytic anemia be withheld.
Sodium cephalothin (Keflin®) is another drug
which sometimes causes neutropenia and often a DCT
which appears to be causally related to hemolytic
anemia. The clinical significance of the DCT in these
patients is primarily one of its complicating blood
banking-as high as 75 percent of such patients, depending on the dose administered, may give an incompatible minor crossmatch on a non-immunologic
basis.
Another antibiotic which complicates blood banking, and may be a cause of hemolytic anemia, is
penicillin. In contrast to cephalothin, penicillin produces both a DCT and indirect Coombs test (JCT).
This means that the major crossmatch, in addition to
the minor crossmatch, is incompatible. In a review of
allergic drug-induced hemolysis, Dausset and Contu
( 1967) found penicillin to be the offending drug in
14/ 34 cases. Another difference between these two
related antibiotics is that an eluate which will react
with penicillin as well as cephalothin-coated cells may
be prepared. No such eluates may be prepared from
the . sera of patients receiving cephalothin.
Another drug known to rarely cause hemolytic
anemia on an immunological basis is phenacetin
(acetophenetidin). This drug also produces a number
of side effects: direct dose dependent hemolytic anemia, methemoglobinemia, sulfhemoglobinemia, and
(rarely) a severe hemolytic anemia in G-6-PD deficient individuals. Patients who develop sensitivity to
the drug produce antiphenacetin antibodies which can
directly (although weakly) agglutinate red cells, and
produce and JCT and an active eluate. The addition
of phenacetin to the patient's serum neutralizes the
antibodies in the presence of complement after two
hours of incubation. A basic difference between Keflin®
and penicillin sensitivity, and phenacetin sensitivity is
the failure of normal erythrocytes to absorb phenacetin.
Quinidine, quinine, p-aminosalicylic acid, stibophen,
and sulfomethrazine have been cited as rare causes of
hemolytic anemia.
Varying mechanisms of action have been postulated
for these drugs. The cause-effect relationship of these
drugs is dependent on the in vitro demonstration of
enhancement of the JCT in the presence of the offending drugs. It seems that the mechanism of immunologic hemolysis induced by some drugs may be different than that produced by others. In 1965, Levin
summarized the mechanism leading to drug sensitivity
with antibody formation as a drug or a drug degradation product combining with tissue protein to form
a complete antigen. These provoke formation of antibodies which possess structural specificity toward
either the drug hapten, the aminoacid residue binding
hapten to protein, or the structural configuration of
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the protein moiety. If the drug attaches to the red
cell membrane proteins first, the formed antibodies
sensitize the red cells and lead to their destruction.
According to Ackroyd ( 1952), this is the mechanism
of immune hemolysis in penicillin sensitivity. A variation of this scheme has been proposed which suggests that cephalothin causes a positive OCT by binding pre-existing plasma proteins to erythrocytes. Another mechanism of cell destruction has been advanced by Miescher and Cooper (1960) who suggest
that drug and antibody combine in the plasma with
secondary and non-specific fixation to the cell.
The hemolytic anemias of immune origin may be
the result of the presence of a) iso-antibodies or isohemolysins, or b) auto-antibodies or autohemolysins.
Hemolytic anemias caused by auto-antibodies are
acquired. From the standpoint of mechanism they
may be classified as primary idiopathic (occurs in
patients in whom no primary disease can be demonstrated), or secondary symptomatic (is associated
with some other disease; eg, malignant lymphomas,
leukemia, virus pneumonia, infectious mononucleosis,
or collagen disease). From the standpoint of serology,
the auto-antibodies may be classified as warm antibodies, with best reactivity at 37 C; and cold antibodies, with maximum reactivity at lower temperature.
In turn, the cold and warm antibodies may be subclassified into normal and pathogenic. The presence of
both of these kinds of antibodies is shown best by
the DCT, which is the distinguishing feature, and
by auto-agglutination. Patients with the pathogenic
type of either the cold or warm type are said to have
auto-immune hemolytic disease or anemia. Most antibodies eluted from the cells of patients with the
warm type of auto-immune hemolytic anemia detect
an antigen associated with the Rh agglutinogen complex.
Hemolytic anemias due to iso-antibodies and isohemolysins are, in the majority of cases, easy to deal
with; cells lacking the corresponding antigen are
usually relatively easy to find, and compatible blood
may therefore be transfused. However, certain isoantibodies are directed against an antigen that is
present in a high percentage of the population; should
blood be requested, particularly in large amounts, it
would be very difficult to obtain the required number
of units of compatible blood. For example, in order
to find two units of compatible blood for a patient
with anti-k antibody, the blood of 1,000 donors
must be crossmatched since the percentage of Cellano
negative individuals is only 0.2 percent. Other examples of this type of incompatibility may be cited.
It is immensely difficult to transfuse patients with
paroxysmal cold hemoglobinuria. These patients show
a positive DCT, free plasma hemoglobin, and free
antibodies in their serum. These antibodies are of
anti-P, or anti-Tj• specificity. Since the corresponding
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Tj' antigen is present on the red cells of more than
99.9 percent of people, it is obvious that to find a unit
of compatible blood more than 1000 randomly selected donors must be crossmatched.
The transfusion of a patient with the warm antibody type of auto-immune hemolytic anemia is also
a formidable problem. The cells of such patients give
a positive DCT and, infrequently, an ICT. A positive
ICT in these patients is associated with a poor prognosis.

Anti-e Antibodies
Anti-e is one of the most disliked antibodies when
found in a patient with auto-immune hemolytic
anemia who is. in need of blood transfusion, for three
main reasons:
1. It is a warm antibody; the administration of
incompatible blood is certain to be detrimental to the
patient who obviously can do without an additional
load of plasma hemoglobin.
2. This antibody is directed against a very common antigen. After crossmatching 50 units · of blood,
one may find one unit of compatible blood if lucky.
For each additional unit requested, 50 units must be
crossmatched.
3. The adverse effect of the antibodies on the
supposedly compatible red cells is often demonstrated
clinically by the frequency of hemolytic transfusion
reactions in patients having auto-immune hemolytic
anemia in general; and in patients having auto-immune hemolytic anemias due to anti-e reacting not
only with e-positive cells but also, although much more
weakly, with e-negative cells. Consequently, although
e- negative cells may have a near normal life span following initial transfusion, subsequent transfusions of
these patients result in the appearance of a higher
titer of antibodies. This complicates f1,1ture crossmatching tests. One other result of failure to apply
extreme restraint on the use of blood in such cases
is the exhaustion of the limited supply of the rare
R,R. blood. Hence, when such blood is needed as a
life-saving measure, it is often not available. The
first case study-auto-immune hemolytic anemia due
to anti-e, secondary to chronic lymphocytic leukemia
( CLL )-typically illustrates this point.
L.C. a Negro male diagnosed as having CLL in
January, 1966, was taking chlorambucil until January,
1968. In October, 1968, he was found to have anemia
with a hemoglobin of 4.5 gm percent. A sample of
blood sent to the Blood Bank showed the following
results:
Blood Group:
Direct Coomb's Test:
Most Probable Genotype:
Antibody Identification:

0 Rh, (Pos.)
Postive ( 1 +)
RlR2 (CDe/ cDE)
Anti-e. Detectable only by
the Coomb's technique

Blood was requested, and three units of R2R2 (cDE/
cDE) were released and administered.
It is obvious that prior to transfusion the direct
and indirect Coombs tests were weak. Although
e-negative blood was transfused, both the DCT and
ICT became progressively stronger-as evidenced by
a rise in antibody titers from one in pre-transfusion
to eight in post-transfusion blood sample. As the
number of transfusions increased, the patient's serum
became increasingly incompatible not only with the
blood of e-positive donors, but also with that of
e-negative donors. Just before his demise, L.C. received the last two units of R.R2 which we were able
to obtain from t;he rare bloods stored in a frozen state
at the New York Blood Center.

Anti-I Antibodies
A patient with auto-immune hemolytic anemia of
the strictly cold antibody type, which does not agglutinate cells at 37 C, presents a lesser problem. Usually
the antibody involved is of anti-I specificity. Dacie
reported finding cold auto-antibodies rather than
warm ones in about 20 percent of cases of idiopathic
acquired hemolytic anemia and in about 30 percent
of cases secondary to such conditions as CLL. Further,
an upper respiratory tract infection associated with a
group of organisms known as pleuro-pneumonia-like
organisms was found in all cases in which acquired
hemolytic anemia followed an attack of primary
atypical pneumonia. Anti-I antibodies are directed
against an antigen which is much more prevalent than
the e antigen. In order to find a unit of compatible
blood, the Blood Bank would have to crossmatch the
serum of the patient against the blood of 4,400 randomly selected people. However, as mentioned earlier,
such patients are a lesser problem in transfusion
mainly because the majority of the patients show an
antibody which reacts below body temperature only;
therefore, when absolutely essential such patients
may be safely transfused, provided transfusion is given
conservatively.
The advisability of transfusing these patients, conservatively and only when absolutely essential, is
based on the fact that continued transfusion of such
patients may eventually result in production of the
antibodies which are reactive at body temperature.
Blood administered to these patients has a reduced
life span and may invoke a hemolytic transfusion reaction which, in turn, may produce warm reacting
antibodies. Such patients have an abnormal immune
response and the antibodies, although cold, are pathogenic.
A few of the patients with auto-immune hemolytic
anemia due to anti-I have antibodies which react
initially not only in the cold but also at 37 C. Transfusion of such patients with incompatible blood must
be avoided unless it is to alleviate debilitating symp89
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toms or is a life saving procedure. Such patients are
susceptible to antibody production when repeatedly
challenged with the corresponding antigen.
Therefore, the sooner and more frequently these
patients are transfused, the sooner the stage is reached
when transfusion of incompatible blood is no longer a
life saving measure. One can be more liberal in the use
of blood for such patients if the very rare ii genotype
blood is available. To our knowledge no individual
living in the Richmond, Virginia area belongs to this
phenotype. Since these patients are kept relatively
comfortable with the judicious use of immunosuppressive therapy and avoidance of exposure to cold,
the use of hemotherapy may be avoided for a considerable period of time. The successful blood management of such a patient is represented in the second
case study.
D.O. was a 60-year-old white female who had been
in good health until ten days prior to hospital admission on October 25, 1965. At that time she noted
severe headaches and weakness of her lower extremities with ataxia; she developed nausea, vomiting, and
fever. She was diagnosed as having bronchopneumonia
and was treated accordingly. She was also found to
have severe anemia with a hemoglobin of 5.4 gm
percent. History showed no melena, hematuria, or
epistaxis and she had noted bruising only during the
two weeks prior to admission. She had no history of
jaundice. Family history was non-contributor. Later
she was referred to William T. Dabney of the Medical
College of Virginia, who found her to have a moderately enlarged spleen. Cr51 red cell survival time and
studies showed a T 1/ 2 of 14 days (normal 25-35
days), and a slight increase in the spleen to liver ratio
with normal splenic localization index. A blood sample sent to the Blood Bank on December 29, 1966
showed the following: .
Blood Group:
Direct Coombs Test :
Indirect Coombs Test:
Antibody Specificity :

0 Rh0 (Neg.)
Weakly Positive
Positive, Titer-1 :4
Anti-I

The anti-I antibodies were found to react not only
in the cold but also at 37 C. The Blood Bank accordingly advised withholding transfusing until absolutely
essential. This patient was treated and kept on a
maintenance dose of prednisone. The transfusion of
blood has been avoided purposefully until the present,
despite the fact that her hemoglobin has been 6-7
gm percent. Dr. Dabney saw her again in January,
1970 and found her active despite her anemia. The
DCT was repeated 15 times between December, 1966
and January, 1970. Reactivity ranged between negative and 1 + strong with the last test, like the first one,
being only a weak positive. The failure of the
Coombs test to become stronger after four and onehalf years may be the result of non-transfusion. This,
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as suggested previously, indicates the value of withholding blood transfusion in such cases.
Anti-i Antibodies
Another case exemplifying a transfusion problem
in hemolytic anemia is that caused by a high titer
of anti-i antibodies in patients with IM. Last year
we reported the fourth case of IM complicated by
severe, but transient, auto-immune hemolytic anemia
due to anti-i, as seen in a third case study.
R.P. was a 20-year-old white male who had been
in good health until six days prior to admission to the
Medical College of Virginia Hospital. On that day,
he was involved in an automobile accident. Examination of the patient at the referring hospital emergency room immediately following the accident revealed no serious injury, with negative X-rays, and
he was released. Four days later he began to have
some vomiting and pain in the right side of the abdomen, which continued until the day of admission.
The next day he developed dark urine and a mustardcolored stool. At this time, one day prior to admission, he was found jaundiced with a bilirubin level
of 7.6 mg percent, a hemoglobin of 8.0 gm percent, and a hematocrit of 22 percent. There was
marked tenderness in the right upper quadrant and
a possible epigastric mass. He was referred to the
Medical College of Virginia Hospital for further
evaluation and admitted on April 20, 1968. The
past medical history was not remarkable except for a
prior appendectomy. Examination showed a pulse of
120/ min and a blood pressure of 130/ 90. He was
jaundiced with some abdominal distress. Eyes showed
marked icterus. The abdomen showed tenderness in
the right upper quadrant and there was a small, illdefined , tender epigastric mass. The spleen was barely
palpable. Prior to admission the patient had never
received blood, blood components, antibiotics, or
other drugs. He denied exposure to any chemicals,
and there was no history of allergy to drugs or chemicals. The rest of the accessory history was not remarkable. A tentative diagnosis of liver hematoma
was made, and surgery to relieve it was entertained.
For this purpose eight units of blood were requested.
Because of difficulties encountered in blood grouping,
typing, and crossmatching, blood was withheld until
studies were completed to clarify the discrepancies.
The difficulties consisted of a discrepancy between
cell grouping which showed him to be group AB
and serum grouping which showed him to be group
0 . The DCT using broad spectrum Coombs serum
was strongly positive ; his serum agglutinated 60
randomly selected group A bloods and all members of
two commercial panels of cells. Using appropriate
techniques, the blood group of the patient was found
to be A,B. Initial laboratory studies on admission
showed a hemoglobin of 5.2 gm percent, and a
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hematocrit of 15 percent which steadily fell to 4.5 gm
percent and 12 percent respectively over the next eight
hours. The white cell count was l 3,500/ mm3 ; the
differential showed 54 percent polymorphonuclear
leukocytes, 31 percent lymphocytes and 14 percent
considered monocytes. Nucleated red cells were also
present. Blood chemistry studies included amylase-70
(normal 150) Somogyi units, alkaline phosphatase
18 (normal 0.8 to 2.9) Bessay-Lowry units, LDH 570
(normal 20 to 68) International units, and SGOT 225
(normal O to 40) Karmen units. Total protein was
6.9 gm percent with 56 percent albumin and A/ G of
1.27: 1. Plasma hemoglobin was 210 mg percent, and
the urine was strongly positive for bile and contained
160 mg of pemoglobin. On the second day of admission, a liver radiosotopic scan revealed a moderately increased size and decreased uptake in both lobes,
and increased concentration in the spleen which was
enlarged. Because of the immunologic reaction which
is indicated by the DCT, hemoglobinemia and bilirubinemia, he was started on prednisone. The red cell
count on this day was 1.92 mil/cu mm, and the platelet
count was 364,000/ cu mm. The peripheral blood
smear showed nucleated red cells, shift to the left,
and 50 percent lymphocytes with one-half appearing
as pathological lymphocytes. The bone marrow
showed good myeloid, erythroid, and megakaryocytic
cellularity with moderate increase in erythroid/ myeloid ratio and a slight increase in reticuloendothelial
cells. The stain for iron was strongly positive. On this
day he received two and one-half units of whole blood
without untoward reaction. Permission to release
blood was based on compatibility tests with patient's
serum after absorption with own cells. Blood was released which showed incompatibility no stronger than
a selfcontrol by the saline and albumin methods, and
which was negative by the Coombs test. The following
day, April 22, the patient showed a clear urine but the
urine became hemoglobinuric almost immediately after the administration of two more units of blood. A
heterophile agglutination test was performed, and the
unabsorbed serum showed a 1 : 448 titer which remained unchanged after guinea pig kidney absorption,
and became negative after beef cell absorption. Further laboratory studies using rare cells of the phenotype ii and absorption-elution techniques indicated
that the antibody causing the incompatibilities was of
anti-i specificity. This antibody occurs rather commonly in patients with IM, although in low titer. As
such it reacts strongly with cord blood and only
weakly, if at all, with adult blood at 4 C only. Therefore, it is usually of no clinical significance and does
not present crossmatching difficulties. Ho:-vever, ':h~n
it does it is important to identify the antibody w1thm
a shor; period of time. This shows the immunohematologist that it is advisable to release b~ood for these
patients, since transfusion problems which may occur

may be outweighed by the complications of withholding blood.
Albumin Autoagglutination Phenomenon

The last case posing a transfusion problem which
I present is a rare phenomenon which may coexist in
a patient with hemolytic anemia. This phenomenon has
been termed the albumin autoagglutination phenomenon. The first example was reported by Weiner
( 1956).
V.P. was a seven-year-old white female patient.
Three weeks prior to admission to the Medical College of Virginia Hospital the patient had followed a
truck spraying 30 percent dichloro-diphenyl-trichloroethane. She had also been exposed to dog spray insecticide and had been given chloromycetin in March and
April, 1964 for pharyngitis. She was admitted to a hospital on July 6, 1964 with 5 gm/ 100 ml of hemoglobin
and jaundice. She was successfully transfused with
250 ml of whole blood without crossmatching difficulties. On July 10 she was transferred to the Medical
College of Virginia Hospital with a hemoglobin level
of 6.8 gm/ 100 ml. She was diagnosed as having acquired hemolytic anemia, possibly on the basis of inhalation of an insecticide. Despite the fact that blood
was urgently needed, due to difficulties in the albumin
phase of the crossmatch the Blood Bank could not release the blood requested. Further studies showed that
this case was an example of the non-immune autoagglutination phenomenon. On this basis, on July 17 the
patient was successfully transfused with 125 ml of
packed red cells compatible in the Saline and Coombs
tests, although very strongly incompatible in the albumin test. Admittedly, this phenomenon is rare. Rarity,
however, does not detract from its practical significance, since blood required in an emergency for such a
patient may be withheld on the presumption that it
contains specific high-protein active antibodies.
Transfusion Criteria

It is worth remembering that transfusion could lead
to complications, particularly in patients with autoimmune hemolytic anemia. Therefore, the longer the
transfusion is avoided, the longer the complications of
blood transfusion are delayed and the better the prognosis. I~ all hemolytic anemias, the anemia per se is
not an indication for transfusion, and transfusions are
given only when the symptoms justify. Transfusions
are not means of maintaining the hemoglobin levels
in the normal range.
Does every severe anemia always demand transfusion? The answer to this vital question is NO. This
answer is based on the fact that in patients with extremely marked anemia, transfusion may easily overload the circulation and precipitate cardiac failure.
Therefore, it is mandatory that whenever the chance
91

TRANSFUSION PROBLEMS

exists that the patient will respond to some other form
of treatment, transfusion of blood should be avoided.
An ideal example is the patient with pernicious
anemia in relapse. It is commonly agreed that transfusion of such patients should be avoided unless ( 1)
there is hemorrhage associated with thrombocytopenia and (2) the patient has pneumonia or some
other infection which may interfere with the response
to Vitamin B12• Inhalation of 100 percent oxygen by
such patients may effectively raise the 0 2 carrying
capacity of the blood, to tide them over a short period
of extremely severe anemia. A blood with 3 gm Hb
percent normally carries about 4 ml oxygen per 100 ml,
while the inhalation of 100 percent oxygen increases
the oxygen content of the plasma by an increment of
2 ml oxygen per 100 ml. This means that such treatment may effect an increase equivalent to 1.5 gm Hb
percent, which in the case of the patient with 3 gm
Hb means a rise to a level of 4.5 gm percent. Should
these patients be transfused, the transfusion rate
should not exceed 0.5 ml/lb of body wt/ hr. Sharpey-Schafer ( 1945) suggested that it would be wise to
limit the volume of transfused blood to 500 ml/48
hrs (preferably as PRC) and to take various measures
to reduce right auricular pressure, such as keeping the
patient propped up in a sitting position. The central
venous pressure should be observed and any rise
should be an indication for slowing or stopping the
transfusion. Other safety measures are ( 1) warming
of the patient and (2) administration of a diuretic.
Summary

In this presentation I have attempted to present
some of the transfusion problems that face the Blood
Bank and the physician treating the patient. I have
briefly discussed methods of recognizing the complicating factors, interpretation of their clinical significance, and the proper hemotherapeutic management
of such cases. Finally, I hope that this presentation is
a convincing thesis for a better understanding of the
Blood Bank and its problems, since the patient's welfare is better served when there is a rapport between
the clinicians and the Blood Bank staff.
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Immune Suppression in
Auto-Immune Hemolytic Anemia*
JOHN H. MOON
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The acquired auto-immune hemolytic anemias represent a diversity of disease states in which the most
constant immunologic finding is a positive direct
anti-human globulin test (van Loghem, 1965; Swisher
et al, 1965). This is true of the symptomatic variety
of acquired hemolytic anemia as well as the idiopathic
form. The positive Coomb's test has been seen in
association with primary atypical pneumonias, occasionally in favism, in some bacterial and drug induced hemolytic anemias, in patients with malignancies
of the lymphoid tissues, and in collagen-vascular disorders-chiefly SLE.
The original hope that the direct Coomb's test would
be negative in all forms of hereditary hemolytic disease
and thus differentiate them from acquired forms of
hemolytic anemia has not been borne out.
Acquired auto-immune hemolytic anemias vary
widely in the severity of the hemolysis, in the association of additional pathologic states and in the comparative clinical influence of these factors. Those cases
of auto-immune hemolytic anemia that are associated
with self-limiting viral diseases such as infectious
mononucleosis, measles or bacterial infections, usually
subside with the primary disease. Forms· of Coomb's
positive hemolytic anemias associated with drug therapy can usually be eliminated by withholding the
offending drug. In instances where the Coomb's
positive hemolytic anemia is associated with benign or
malignant tumors or cysts, surgical correction of the
abnormality may result in permanent hematologic and
serologic remission. It has also been observed that a
positive Coomb's test may occur in association with
pernicious anemia, folic acid deficiency and iron deficiency anemia. In these circumstances, replacement
of the specifically deficient material may result in complete remission of the hematologic abnormality. This
discussion will concern itself primarily with the idiopathic disease, since immunosuppression is not necessary or desirable in most of the symptomatic varieties.

* Presented at the 23rd Annual Stoneburner Lecture
Series, Febru'lry 20, 1970, at the Medical College of Virginia, Richmond.
MCV QUARTERLY 6(2): 93-99, 1970

Since the diagnosis of an auto-immune hemolytic
anemia of the idiopathic variety is tied to the exclusion of recognizable causative disease, the frequency
with which the diagnosis is made will first depend on
the aggressiveness of the attending physician in looking for secondary causes and secondly, the nature of
the patient population. Since the disease has a peak
incidence in the fourth through seventh decades, a
large pediatric population would diminish the incidence. Likewise, since about 60 percent of the patients
in reported series are women, a largely male clinic or
hospital population would have a similar effect. No
racial discrepancies have been noted to date. In Dacie's
series (1969) followed over a 20 year period, 111/ 210
or 52 percent adult patients with a positive direct
Coomb's test were classified as idiopathic, whereas
only 18.2 percent of Pirofsky's 234 cases were idiopathic ( 1969). A positive direct Coomb's test is, of
course, central to the diagnosis of auto-immune hemolytic anemia although a positive direct Coomb's may
be present for years with hemolysis.
The demonstration that the globulins coating the
red cells are "true" antibodies is now generally accepted with the proviso that the coating of the red
cells with a protein giving rise to a positive antiglobulin reaction does not necessarily mean that the reacting substance is an erythrocyte antibody. It may even
be complement absorbed as a result of antibody activity. By performing a gamma globulin neutralization
test one can elucidate whether the coating globulin of
the erythrocyte is a gamma globulin, complement or
mixed type. Further evaluation of the protein can be
done with antiglobulin sera specific for lgG, lgM, or
IgA. The great majority of auto-immune hemolytic
anemias will have lgG antibody.
The cardinal points which identify the coating
globulins as antibodies are their transferability to normal red cells; the frequent presence in serum of similar globulins which can be absorbed by normal cells;
and in many instances, their ability to react with specifically identifiable red cell antigens. For instance, in
patients who form warm antibodies, it is often possible
to demonstrate a clear specificity for one or more Rh
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antigens, but the nature of specificity of other antibodies which do not have affinity with Rh antibodies
is yet unknown. It appears probable that an antibody
reacting indifferently with all human cells may be involved. Although the etiology of the auto-immune
hemolytic anemias remains obscure, current theory
(Parker and Vavra, 1969) surmises that somatic mutation leads to the development of forbidden clones of
antibody forming cells which are not susceptible to,
and escape from, the normal homeostatic mechanisms
which prevent auto-antibody formation . The association of auto-immune hemolytic anemias with other
diseases thought to be of an auto-immune nature, such
as disseminated lupus erythematosis and ulcerative
colitis, lends unity to this concept. Chronic lymphocytic leukemia and lymphosarcoma may represent
malignancies of potential antibody forming cells in
which the tumor cells, in some instances, retain their
ability to form antibodies, particularly abnormal ones
which react with erythrocytes. Another possibility is
that the antibodies primarily formed against the abnormal neoplastic lymphoid cells act as antigens; the
antibodies which cross-react with red cells. It also
seems conceivable that the malignant lymphomas

AFFERENT
PHASE

RECOGNITION
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represent an enormous monoclonal proliferation of
lymphoid cells which displace the immunologically
competent cells and interfere with the delicate balance
between the two. This allows the development of a
clone of auto-antibody forming cells. Whichever of
these mechanisms ultimately proves to be true, the
current therapy for auto-immune hemolytic anemias
of a sufficient degree of severity to require treatment
involves attempts at immunological manipulation.
Cu rre nt Con cep t of the Immu ne Respon se

The current concept of the immune response (Fig
l) is divided into afferent, recognition, stimulatory and
effector phases. All phases of this scheme can be
manipulated to produce immunologic tolerance, as we
shall see.
( 1) In the afferent phase it is believed that the antigen is processed by macrophages into highly immunogenic complexes with RA and other cellular constituents.
(2) In the recognition phase the macrophage transmits messenger RNA to "antigen sensitive cells" which
have the morphologic appearance of a small lymphocyte. These cells arise from stem cells in the marrow
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Fig I-The four phases of the immune response (modified from D avis, et al; Microbiology, 1967).
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where they are incapable of responding to antigen.
Upon leaving the marrow they migrate to the thymus
where partial maturation takes place and then seed
peripheral lymphoid tissue where they acquire immunologic competence. Stimulation of these "antigen
sensitive cells" appears to be confined to lymphoid
organs. They do not in themselves produce antibody,
but they give rise to clones of antibody producing
cells as well as to additional antigen sensitive cells.
( 3) In the stimulatory phase exposure to antigen
initiates an immunologic response after a latent period
of four to 24 hours. Mature antibody processing cells
appear to arise from a large immunoblast (hemacytoblast) and reproduce rapidly. Serum antibody arises
logarithmically and gradually declines. Small lymphocytes are also formed, committed to react specifically
with antigen. They seem to be the primary mediators
of cellular immunity and probably carry long term
immunologic memory.
( 4) In the effector phase the small lymphocytes are
responsible for such forms of hypersensitivity as allograft rejection, and contact skin sensitivity.
Responses attributable to serum antibody include
local and systemic anaphylaxis, Arthus phenomenon,
hemolytic anemia and thrombopenia.
Approaches to lmmunosuppression
In clinical immunosuppression the number of options available to the clinician is somewhat restricted
by the clinical setting. Since the immune response in
auto-immune hemolytic anemia is mediated by humoral antibody, attempts at immunosuppression should
be so directed.
Table I shows the theoretical areas where immunosuppression might be possible in immuno hemolytic
anemia. Administration of antigen might be considered
as analagous to desensitization of patients with allergic
asthma. Since the nature of the erythrocyte antigen is
unknown, this approach does not seem feasible at
present. Administration of specific antibody as a form
of immunosuppression has received renewed interest
as a result of the successful use of Rh antibody in the
prophylaxis of erythroblastosis. It seems dubious that
such an approach would prove successful in autoimmune hemolytic anemia for a variety of reasons.
I would like to discuss the types of immunosuppression which have been attempted in auto-immune
hemolytic anemia, paying particular attention to those
methods which are most commonly used in treatment
today (Table II).

Surgical Ablation of Lymphoid Tissue
One of the four major approaches to immunosuppression has been that of surgical abl~tion. Sple~ec
tomy, of course, is the oldest form of .1mmun.olog1cal
manipulation that has been attempted m autoimmune

TABLE I
Approaches to immunosuppression
1. Administration of antigen

2.
3.
4.
5.
6.

Administration of specific antibody
Administration of antilymphocyte serum
Cytotoxic drugs
Radiation
Surgical ablation of lymphoid tissue

TABLE II
Approaches to immunosuppression in idiopathic autoimmune hemolytic anemia
Surgical ablation of lymphoid tissue
A. Splenectomy
B. Thymectomy
C. Thoracic duct drainage
II. Administration of cytotoxic drugs
A. Corticosteroids
B. Alkylating agents
C. Purine antagonists
III. Radiation
A. Total body
B. Local
1. spleen
2. Lymph nodes
I.

hemolytic anemias. The rational behind its first application in 1911 by Michelle was a result of Banti's work
incriminating the spleen as a primary site of blood
destruction. The mechanistic concept of its function in
auto-immune hemolytic anemia is probably still a
prime reason for its removal; but it is included in the
list of immunological manipulations because of the
evidence showing splenic hyperplasia, particularly an
increased production of lymphocytes and plasma cells,
in the spleen. This suggests that hemolysis can potentiate the ability of the spleen to engage in antibody
production. Jandl ( 1965) speculated that the enhanced
immunologic reactivity of the hyperplastic spleen could
take two pathways. In one it could initiate immunologic
responses directed against related or coincidental antigens of the erythrocyte; in the other it could convert
reactions which were intially nonimmune into immune forms. The latter mechanism could possibly permit metabolically modified antigenic determinants to be recognized as foreign. In this manner,
it could supply the background to the auto-immune
state described as an enhanced sensitivity of antibody
forming tissues. Splenic hyperplasia creating these
two antibody producing states could result in an immune relationship which is auto-catalytic and which
would appear as an auto-immune hemolytic anemia.
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The beneficial effects of splenectomy have been amply documented in several series reported since
1911. Therapeutic response has been noted in about
70 percent of the patients treated with half of the patients apparently being cured of their disease (Allgood and Chaplin, 1967). The mortality rate, however,
of splenectomy in patients with auto-immune
hemolytic disease is high and averages about 17 percent in the series reported. There is a further increase
in mortality if splenectomy is delayed for over a year
after the onset of the disease. This high surgical mortality rate has tempered the enthusiasm for splenectomy
in most clinics.
In addition to the immediate surgical mortality of
splenectomy, the predisposition of patients with autoimmune hemolytic anemia to thrombosis may be enhanced by the thrombocytosis occurring after the
spleen is removed. In younger patients, such a thrombocytosis is usually well tolerated, but in the older
age groups with co-existing atherosclerosis, it may
constitute a major hazard to the patient's survival.
The increased frequency of overwhelming infections in
infancy following splenectomy seems to be real, but
since auto-immune hemolytic anemia occurs very
rarely in this age group, it is seldom a consideration. A
more serious difficulty following splenectomy is the hyperplasia which sometimes occurs within the reticuloendothelial cells in the liver leading to progressive hepatomegaly, liver dysfunction and death.
Responses to splenectomy in patients with autoimmune hemolytic anemias secondary to reticuloendothelial neoplasm seem to be somewhat less
frequent than in the idiopathic form of disease. Splenectomy may be of value after patients have failed
on corticosteroids, and Crosby's data suggest that the
remission rates following splenectomy in patients who
are unresponsive to steroids may be as good as those
treated de novo with splenectomy. Several authors
have emphasized criteria which may enable one to select candidates for splenectomy. Among these are the
patients with warm acting, incomplete erythrocyte
auto-antibodies and documentation of splenic sequestration. Several methods of determining significant
splenic sequestration of Cr 51 labeled red cells are in
use including those devised by Korst (1955) , Jandl
(1956), and McCurdy and Roth (1958). All suffer the
same defect, ie, they are not entirely reliable in predicting either response to splenectomy or failure of
response.
Goldberg and his associates have suggested that a
reduced Chromium 51-T 1h may be of importance in
selecting candidates for splenectomy; this seemed
to be the case in their series of 13 patients in whom
11 had good results. It is difficult to know what this
means since all patients with auto-immune hemolytic
anemia have reduced Cr51 red cell survival times and
the response rate is what one would expect. Evidence
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of sequestration of red cells in the liver is a poor prognostic sign and suggests that splenectomy will offer little benefit.
Thymectomy is an attractive approach to immunosuppression in ante-immune hemolytic anemia because
of the central role of the thymus in the maturation
of immunologically competent cells. It is also technically easier than splenectomy and should carry a lower
mortality rate. No data are available on adults treated
in this manner, but in infants there have been two remissions induced with this procedure and one failure.
Thymectomy appears to be of no value when thymoma
is associated with auto-immune hemolytic anemia.
Thoracic duct drainage seems potentially useful
because primary antigen sensitive cells and immunologic memory cells can be removed. Unfortunately,
immunologic impairment is very short lived.
Cytotoxic Drugs

The administration of cytotoxic drugs is a second
approach to immunosuppression. The inmmnosuppressive effects of corticosteroids resemble those of
x-irradiation in that they produce lymphocytolysis
particulary in the germinal centers of lymph nodes
and spleen with resultant lymphocytopenia. The mechanism by which the cell damage is effected is unknown.
They are also active in suppression of delayed hypersensitivity but their effect on serum antibody synthesis is less impressive.
Because of the high surgical mortality associated
with splenectomy in auto-immune hemolytic disease,
the observed lympholytic activity of adrenocorticoids
was investigated in 1951 by Dameshek in auto-immune
hemolytic anemias.
In a series reported in 1956, Dameshek and
Komninos claimed that 90 percent of the cases of autoimmune hemolytic anemia would show an initial therapeutic response to corticosteroids. Of these, 65 percent
were complete remissions and in an additional 25 percent a definite response was obtained. Two-thirds of the
cases, however, relapsed when corticosteroids were
discontinued. Subsequent series have shown similar
results. Horster reported a 6.8 percent cure rate with
corticosteroids, and remissions lasting over a year in
about a third of the cases after discontinuation of
corticosteroid therapy. About half of the patients
could be maintained in remission only while corticosteroids were continued. Pirofsky's data suggests
that the corticosteroids, too, are less effective in the
auto-immune hemolytic anemias associated with
reticule-endothelial malignancy. The dosage of corticosteroids necessary to induce remission has been variable in the series reported but in the average adult,
300 mg of cortisone per day or it's equilvalent of prednisone, triamcinolone, or dexamethasone, appear to
be an effective dose level. If using corticosteroids is
effective, time of onset of the evidence for reduced
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hemolysis is rapid. Response is usually clearly apparent within the first one to two weeks, although a few
patients will respond as long as 21 days after therapy
is begun. In the patients who respond slowly, the
response tends to be less good and it is difficult to
remove such patients from steroid coverage.
Hematologic remission may occur while the direct
anti-globulin tests remain positive. In idiopathic autoimmune hemolytic anemias, there may be reduction
in spleen size, although this effect is not as marked in
the symptomatic varieties of the disease. Since the
side-effects of steroids are not inconsiderable, reductions from the high dose levels initially used, should
be made as soon as possible, and the minimally effective dose of corticosteroid should be used as the maintenance dose. Even with maintenance, a significant
number of relapses will occur within the first six
months, although the relapse is usually of gradual onset. If the patient is being seen at frequent intervals,
there is normally sufficient warning to increase the
amount of steroid. In a few patients, prednisone may
gradually be discontinued over a period of five or six
months and the patients will remain in remission.
Alkylating agents include such compounds as the
nitrogen mustards, sulfur mustards, sulfonate esters
and ethylenimines. They are chemically highly reactive and are capable of combining irreversibly with
DNA, proteins and other essential macromolecules in
the cell.
Cyclophosphamide, a latent compound activated in
vivo after tissue phosphorylases cleave the cyclic
phosphamide moiety to expose the alkylating radicals, has been shown to be a very promising immunosuppressive agent. It appears to be capable of reducing the antigen sensitive cell population, blocking
cellular proliferation during the inductive phase and
is ever active in reducing antibody synthesis. Hersh
found it to be the most effective immunosuppressive
agent among the various alkylating agents. I am unaware of any published reports on its effectiveness in
auto-immune hemolytic anemias, although there are
isolated reports of remission induced by other alkylating agents (Taylor, 1963).
Purine and pyrimidine antagonists are another approach included among the cytotoxic drugs. In 1957,
Stertzle and Holub suggested that 6-Mercapto-purine
(6-MP) might interfere with antibody synthesis, but
were unable to confirm it in the test system that they
were using. This was independently confirmed in extensive studies by Schwartz and Dameshek (Schwartz
and Dameshek, 1959; Dameshek and Schwartz, 1960;
Schwartz, Eisner and Dameshek, 1959; Schwartz and
Dameshek, 1960) who demonstrated that 6-MP could
suppress antibody formation in rabbits immunized with
Bovine albumin. In addition, 6-MP apparently could
induce a state of immunologic unresponsiveness in
adult rabbits and could suppress transplantation rejec-

tion of skin graft although not completely at tolerated
doses. Further studies on the mechanism by which 6MP was capable of inducing this effect led to the conclusion that the drug had its primary effect on the lymphoid hemocytoblast (immunoblast) and morphologic
studies of lymph nodes subsequent to 6-MP after a
homograft administration revealed extensive disruption
of the lymphoid follicles (Andre et al, 1962). Borel also
showed suppression of IgG response with prolonged
administration. Studies were extended (Schwartz
and Dameshek, 1962) to include cases of human auto-immune hemolytic anemias treated with
6-MP or Thioguanine with a favorable effect in three
of six cases. 6-MP and thioguanine have been sporadically reported since (Demis, Brown and Crosby,
1964; Shearn, 1965 ; Hitzig and Massimo, 1966) to
cause remissions in auto-immune hemolytic anemia.
The primary limiting factors to the administration of
these agents is bone marrow toxicity (Demis, Brown
and Crosby, 1964). Azothiaprine (an imidazole subsituted 6-MP) is converted to 6-MP in vivo. It has
been used in the auto-immune hemolytic anemias alone
and in combination with corticosteroids with some success. Its spectrum of immunosuppression is similar to
6-MP but it appears to have a better therapeutic ratio
(Frisch and Davis, 1962; Frisch, Davis and Milstein, 1962) and produces less bone marrow suppression. It also produces fewer G.I. symptoms when
given orally.
It seems probable that these agents do not show
cross resistance with corticosteroids, and failure on the
latter does not necessarily militate against induction
of remission with the former. Response rates are difficult to access on the basis of the limited number of
cases reported, but the drugs are somewhat less effective than corticosteroids. This may merely reflect the
fact that the patients are further advanced in their
disease.
Fig 2 shows the clinical course of a 79-year old
white man, who was first seen here in August 1964
for treatment of progressive anemia of four months'
duration. Physical examination was essentially unremarkable. His laboratory data revealed a hemo~lobin
of 7.8 gm percent, reticulocyte count 29 percent,
MCV 96, MCH 32, MCHC 34, and Bilirubin 2.2
mg percent with 0.3 mg percent direct reacting fraction. Coomb's test was weakly positive. Cold agglutinins were positive in a titre of 1 : 64. Chromium51 red
cell survival was 7 1h days, and the spleen to liver
ratio was 0. 72. This patient was started on prednisone
40 mgs per day with a prompt rise in his hemoglobin
concentration, as shown in Fig 2. His hemoglobin
was maintained well until steroid toxicity forced the
reduction of his dose of prednisone. Three months
later his hemoglobin gradually fell to levels of seven
to eight grams percent. He required an interim hospitalization in September 1966, at which time his
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Fig 2- The clinical course of a 79-year old white man being treated for progressive anemia.

hemoglobin was 8.5 gm percent, reticulocyte count
was 40 percent, cold agglutinins were positive at a
titre of 1: 1, 280, and Coomb's was strongly positive.
He was seen again in consultation and the recommendation was made that he be offered splenectomy.
Because of his age and the patient's wishes this was
not done, and he was instead started on 6-MP in a
dose of 25 mg per day, which was continued uninterruptedly until the time of his terminal hospitalization
in August 1969. We have only random blood counts
available for this period of almost five years, because
he was being followed elsewhere. He was admitted in
August 1969 because of massive G.I. bleeding. At
that time his hemoglobin concentration was 5.5 gm
percent with a reticulocyte count of 16 percent. Prednisone, which had been continued at a low dose level
of 5 mg per day was increased because of the uncertainity as to whether the marked fall in his hemoglobin concentration was the result of bleeding or an accelerated rate of hemolysis. His upper G.I. series was
normal. His barium enema revealed some diverticula
in the colon. His Coomb's test was strongly positive
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and his cold agglutinin titre was too high to read.
Serum protein electrophoretic pattern was essentially
normal, except for a questionable blip in the slow
gamma region. Immunoelectrophoretic assay of his
serum revealed an lgM level of 1,168. lgG and lgA
levels were normal. He was started on leukeran,
12 mg per day on September 11, 1969, which was
continued through October 5, 1969, when it had to be
discontinued because of leukopenia of moderate degree. His G.I. bleeding continued throughout his hospital illness, and he was transfused several times when
his hemoglobin concentration fell to dangerous levels.
It was not apparent, in this particular patient, who had
what we would classify as cold agglutinin disease, that
his immunologic process was altered either by the
long-term administration of small doses of 6-MP or by
the relatively aggressive therapy with chlorambucil at
the time of his terminal illness.

Radiation
The primary effect of total body irradiation appears
to be on DNA of lymphoid and other sensitive cells.

J. H. MOON

Unfortunately, when used alone, high doses are required which are lethal in themselves. At present there
seems to be no place for total body irradiation in the
clinical context of auto-immune hemolytic anemias.
Local irradiation has proven to be a more effective
approach to immunosuppression. Since splenectomy
is an efficient form of treatment for autoimmune hemolytic anemia it has seemed natural to try to circumvent the surgical mortality by splenic irradiation.
Results have generally been poor. However, some
transient responses have been obtained in secondary
forms of auto-immune hemolytic anemias, particularly
those associated with malignancy of the reticuloendothelial tissues.
As far as tire lymph node is concerned, nodal irradiation seems to offer little promise in auto-immune
hemolytic anemia but there are scattered reports by
Wasserman, Brown, Eisner (Eisner, Ley and Mayer,
1967), and others of a beneficial effect on symptomatic hemolytic anemias from Hodgkin's disease to
radiation of local tumor masses.
Administration of Anti-Lymphocyte Serum

Anti-lymphocyte serum has been shown to be of
value in the treatment of the allograft rejection response but its primary effect seems to be in suppressing
cellular immunity rather than humoral. There is some
evidence that it may abolish immunologic memory and
thus might be of value in auto-immune hemolytic
anemia. We are unaware of any attempts to use the
material in the clinical setting of auto-immune hemolytic anemia.
Prognosis
The outlook in auto-immune hemolytic anemia is
unpredictable but a large number of the patients can
be controlled by judicious therapy with corticosteroids.
Despite the improvement in mortality rates since the
advent of steroids ( 46 percent Dacie's series) the mortality rates are still high-31 percent Dausset and
Columbani and 28.2 percent Allgood. If the disease
cannot be controlled with low doses of steroid which
produce minimal toxicity, splenectomy should be
done. The time at which this should be performed
will require individualization for each patient but, in
general, a failure of corticosteroid therapy at acceptable levels of toxicity will require splenectomy at four
to six months.
If splenectomy fails to halt the immune process or
cannot be done because of the patient's poor condition,
a trial of other immunosuppressive agents may be
attempted or thymectomy may be resorted to. Information at present is not firm enough to recommend a
specific line of approach. On the basis of the experimental data, drug therapy with either cyclophosphamide or azothiaprine would be my personal choice.
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Solar Retinopathy Following the
Eclipse of March 7, 1970:
A Follow-Up*

WALTER J. GEERAETS

Department of Ophthalmology,
Medical College of Virginia,
Richmond 23219.

In the last issue of this journal (Medical College of
Virginia Quarterly 6: 3, 1970) Thomas W. Nooney,
Joseph R. Svoboda, Florencio Ching and I reported
two cases of binocular injury and one case of unilateral
retinal burn of the fovea caused by watching the recent solar eclipse in the Richmond, Virginia area. Since
reporting our local cases, a survey has been completed through other Virginia ophthalmologists of
the occurrence of solar retinopathy throughout the
state. Nine additional cases of ocular involvement were
revealed in the survey and are reported here in table
form. The cases are listed in order of probable severity.
Several persons who observed the eclipse without
protection and reported to an ophthalmologist for fear
of some eye damage showed no evidence of injury.
The relatively low incidence of retinal burns following
this event may be attributed to the efforts made by
television, press and radio to inform the public of potential hazards and methods of eye-sight protection.
Scientific research over several decades, aided by private organizations such as the National Society for
the Prevention of Blindness and the Commission for
the Visually Handicapped, has greatly increased understanding of and ability to predict eye damage by
light.

* I am grateful to the many ophthalmologists throughout the State of Virginia who provided data for this report.
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TABLE
Summary of ocular injuries resulting from wa tching the recent solar eclipse.

Patients
Age /Sex/
R ace

Location at
Time of
Eclipse

Approximate Time
of Observa tion(PM)

14/ F / W

Richmond

1:00

14/ F / W

Waynesboro

Approxi-

mate Duration of
Observation
15-30 sec

•

I :30- 1 :45

20 / M/*

Norfolk

*

15 / M /W

Altavista

from start
to finish

26 / F/W

Charlottesville

62 / M/W

Roanoke

24 / F/W

3-4 times
for 20- 30
sec

Ocular
Findings

Eye
used

OS foveal
lesion with
mild surrounding
edema

OS

OS marked
macular
edema OD
some edema

OU
possibly

rnacular
edema cystic
macular
changes

OS

Protection
used

OS central
scotoma
(2•)

OS 20 / 200
(20 / 70 scan)
OD 20 / 20

OS none
OD closed

chromatopsia

3 / 12 / 70

hazy vision
(fields not
done)

OS 20/ 100- 1
OD 20 / 40

none
('looked
through
mirror')

none

3/ 11 / 70

OS 20 / 80
-20 / 200

none

none

3/9 / 70

•

Other
findings

First seen by
Ophthalmologist

Visual
Acuity

Visual
Fields

intermittent yellow burns
total about OU macula
l / 2 hr

OU

OU central
scotoma
(relative)

OD 20 / 50
OS 20 / 40

none

chromatopsia
(steroid
therapy)

3 / 10/ 70

intermittent OD foveal
edema

OD

OD a bscol.
scotoma
(3--40)

OD 20 / 30
OS 20 / 20

looked
through
pinhole in
cardboard

none

3 / 18 / 70

1 :38

4- 5 see

OS

OS black
spot
(4-5")

OS 20 / 25
OD 20 / 20

none

chromatopsia

3/13 / 70

Danville

1 :30

sufficient
OS 'mottling'
to get light lesion below
burn of
macula
face
about 2x
size of fovea

OS

hazy vision
(fields not
done)

OS 20 / 20
OD 20 / 15

none

none

3 / 12/ 70

22/ M / W

Richmond

1 :30

several sec

maybe mild
macular
edema for
one day

OU

hazy vision
(no field
defects)

OU 20 / 20·

none

(steroid
therapy)

3/8/70

62/ M /W

Salem

Noon

3 see

OS mild
macular
edema

OS

hazy vision

OU 20 / 20

none

none

4 / 3/ 70

28 / F / W

M arion

2:00

2 min

OU 'burning
of eyes'

OU

fields not
done

OU 20 / 20

x-ray film

none

*

9/M /W

Arlington

1 :30

several sec

none

•

fields not
done

OU 20 / 20

none
used telescope with
sun filter
and 3 layers
of exposed
film

3 / 11 /70

*/ M / N

Newport
News

none

•

none

3/ 10/70

•

•

I

•

OS foveal
lesion 1 /4l /2 disc
diameter

hazy vision
(fields not
recorded)

•

none

• Not R eported
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SAMA-A ~~ A Student Honors Day:
Abstracts of Scientific Presentations
Medical College of Virginia, May 1969

Mechanism of Baroreceptor-Induced
Changes in Heart Rate*
MARC D. THAMES (M- 69)

The mechanism of mediation of baroreceptorinduced changes in heart rate is uncertain. According
to the classical view reciprocal changes in parasympathetic and sympathetic efferent activity are involved;
newer studies, however, suggest that increases in
heart rate in response to systemic hypotension are
mediated exclusively by increased sympathetic activity
while decreases in heart rate in response to systemic
hypertension are due solely to increases in parasympathetic activity. To resolve these differences, we
studied dogs unanesthetized, anesthetized with chloralose and urethane, or with chloralose and morphine.
Beta-adrenergic receptor blockade with propranolol
reduced significantly but did not abolish the tachycardia in response to the hypotension induced by
intravenous nitroglycerin. It also reduced significantly
the bradycardia in response to hypertension produced
by intravenous phenylephrine. Parasympathetic efferent blockade with atropine essentially abolished the
tachycardia in response to nitroglycerin and the
bradycardia in response to phenylephrine. In a second
group of experiments, propranolol reduced but did
not abolish the tachycardia in response to bilateral
carotid arterial occlusion. In a third group of experiments, parasympathetic blockade with atropine reduced
but did not abolish the bradycardia in response to
bilateral electrical stimulation of the carotid sinus,
nerves. These results clearly show that baroreceptorinduced changes in heart rate are mediated by reciprocal alterations in cardiac parasympathetic and sympathetic efferent activity.
Preceptor: HERMES A. KONTOS, Division of Cardiovascular Disease, Medical College of Virginia.

* Reprinted with permission from Fed Proc 28: 644,
1969.
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Inhibition of Fibroplasia with Lung
Implants in the Peritoneal Cavity of
the Swiss White Mouse*
KENNETH D. YOUNER CM- 7ll

Well documented observation has shown that
pneumococcal lobar pneumonia undergoes resolution
without the fibroplasia that often follows inflammatory
processes. As noticed by Dumont, neutrophiles invade
the lung alveoli, however, the usual lymphocyte infiltration does not follow. Using pulmonary homografts in dogs, Barnes et al, have shown that intralveolar edema, inflammation and neutrophilic
infiltration occur. However, lymphocytes either do
not appear, or do so only in the peripheral vessels.
An attempt was made to compare the ability of lung
tissue to inhibit fibroplasia using tissue implants into
the peritoneal cavity of a Swiss white mouse. The lung
of a donor mouse and the kidney of the same mouse
were used as the experimental-comparison tissues.
Three variables were considered. First the tissue types
were chosen due to close anatomical and histological
similarity. Each organ has a parenchyma with a basement membrane type structure with a connective tissue capsule surrounding the entire organ. The presence of the capsule, and the possible role it may play
in stopping a lymphocyte infiltration was the second
factor. Each mouse received the entire left kidney and
the entire left lung, each with an intact capsule. Half
of the other lung and half of the other kidney was
also implanted into the same mouse. The remaining
half of each tissue was used as a normal histological
comparison . The third factor is time. Barnes noted
a maximum tissue response at 5-6 days. Therefore,
I used two series. Series of 6 and 12 days were used.
The second series was used to see if any effect the
lung may have on fibroplasia is time dependent. The
whole lung implant gained more weight (used to

* Supported

in part by an A. D . Williams Fellowship
MCV QUARTERLY 6(2): 102-105, 1970
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reflect the amount of fibrosis) than the whole kidney.
However, once the capsule is opened the half kidney
gains more weight than the half lung. With the 12
day series whatever effect the lung parenchyma had
on fibrosis is now gone, for the whole lung and the half
lung both gained more weight than the whole or
half kidney. These weight findings were corraberated
by histological sections comparing the amount of
fibrosis in the implanted tissues.

histologically proven cirrhosis the radiographic arterial pattern was assessed "Normal" in all. It is clear
from our data that the specificity of arterial tortuosity
as a reflection of cirrhosis, a concept generally accepted, does not withstand objective appraisal. In
view of this significant (although negative) observation we are encouraged to continue efforts in seeking
a statistically significant correlation with this angiographic finding.

Preceptor: WILLIAM REGELSON, Department of Medical, Oncology, Medical College of Virginia .

Preceptors: MELVIN VINIK, Department of Radiology; I. NAKONECZNA, Department of Pathology, Medical College of Virginia.

Roentgen Evaluation of the
Hepatic Arterial Bed

Effect of Gravity on the Distribution of
Blood in the Dog Lung

PARHAM R. FOX (M-71)

DAVID H. BRISTOW (M-71)
FRANK MARTORANO (M-7 1)

Angiographic alterations sustained by the hepatic
arterial bed in diffuse parenchymal disorders such as
cirrhosis, and congestion, have heretofore not been
critically evaluated. Tortuosity of intrahepatic arteries,
a readily detectable and often striking angiographic
feature, has generally been considered as indicative,
or even specific for cirrhosis. The influence of ageing, liver size, and other factors, have not been
objectively considered. We have attempted to correlate the gross and histologic appearance of thirty
livers at post mortem with the roentgen appearance
of their barium injected hepatic arteries; this report
constitutes our preliminary results. Diagnostic criteria
of in vivo hepatic arteriography will be subject to
correlative evaluation with the data provided by these
post mortem studies. Liver weight, gross description,
color photographs, and microscopic sections were obtained for pathologic correlation. Pertinent clinical
details were culled from the patients' chart. High
resolution radiographs were randomized and shown to
a panel of three radiologists who assessed and categorized each into the following groups:
1. Normal . . . . . . . . . . . . . . . 14 cases
2. Tortuosity . . . . . . . . . . . . . 10 cases
a. Mild
b. Moderate
c. Severe
3. Hypo-and hypervascularity;
curvilinear stretching . . . . 6 cases

BATTINA GROOME

The distribution of blood was measured in nineteen
anesthetized dogs. Ten were placed vertical, head up,
and nine were placed head down. The dogs were in
the vertical position for at least an hour and a half,
then blood samples- were drawn, the heart was
fibrillated, the thorax entered, the major vessels of
the heart and lung were clamped, the heart and lung
removed together and frozen in liquid nitrogen. Cubes
were cut from the lungs at various levels from apex
to base and were measured on each edge, weighed,
and ground in a colloid mill. Blood pigments were
extracted from the ground cubes and measured to
find blood volumes in each cube. The total volume of
each cube was known and tissue and gas volumes were
calculated with algebraic equations. In the head up
dogs, per cent of blood was three times as great in
the base as in the apex and tissue increase 1.5 times
from the apex to the base. In the head down dogs,
there was no gradient from apex to base of blood or
tissue. One implication of these results is anatomic
difference between the apex and base of the lung.
Preceptor: JoHN L. PATTERSON, JR., Division of
Cardiopulmonary Laboratories and Research, Medical
College of Virginia.

Of the 10 cases radiographically demonstrating
hepatic arterial tortuosity, none showed gross or
histologic evidence of cirrhosis. Of the cases with
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A Study in CPK !so-Enzymes
JOHN ELWOOD OWENS (M-71 )

Heart muscle has three CPK iso-enzymes; CPK, in
smallest amount and nearest the anode on electrophoresis; CPK, in medium amount and in the middle
of electrophoretic pattern; and CPK. in greatest
amount at the cathode end. The four chambers of
the heart and the septum of the heart are apparently
possessive of slightly different levels of concentration
of CPK enzyme, a fact which, upon CPK iso-enzyme
differential analyses of the four chambers and septum
of heart, may be resolved by proving that the fluctuating total level of CPK in a particular area is a
function of a certain specific iso-enzyme of CPK.
CPK, and CPK, appear to be the enzymes that fluctuate not only among the extracts of cardiac muscle
from these five areas of the heart but also among
the extracts of cardiac muscle of different pathological
states. With respect to tissue from the same heart,
there appears to be a decreasing level of CPK, in
going from RA to RV to LA to LV to septum. This
is particularly true in cases where death had heart
involvement. This pattern does not hold true at
present in cases where death had no heart involvement. Results are apparently well-reproducible not
only in different electrophoretic chambers but also
with long intervals of time intervening (i.e., if tissue
and/ or extracts are frozen) . The prospects of this
study include the possibility of diagnosing area of
heart involved in myocardial infarction by serum
analysis of altered CPK iso-enzyme levels.
Preceptor: FRANKLIN LIM, Division of Clinical Pathology, Medical College of Virginia.

Drug Usage in a Medical Ward
JAMES B. BLITCH (M-70)
JEFFREY BIENER (M-71)

Drugs are an essential part of medical therapy and
their use has increased rapidly in recent years. Their
benefits are obvious. Nevertheless, the physician must
be ever aware of their hazards. A six week drug study
under the direction of A. J. Wasserman, M. D. was
conducted in order to assess the use of drugs in a
general medical ward. Drug sheets containing information about dosage, route, instructions, indications,
discontinuation and side effects were kept for every
drug order for each patient during the entire six
weeks. D ata was collected by two medical students
who accompanied the house staff on daily rounds and
questioned each doctor about his patients' medications.
This study included 85 patients with a total of 884
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drug sheets. There was a mean of 10.5 ± 8.2 S.D.
drug sheets per patient with a range of 1 to 47, and
a mean of 6.3 ± 3.7 S.D. drugs per patient with a
range of 1 to 22. 13 % ( 11 out of 85) of the patients
had side effects (this result is similar to that obtained
in other drug studies on side effects). There was no
statistically significant correlation between side effects
and age, sex, number of drugs per patient or number
of days in the hospital. However, a correlation between side effects and number of days in the hospital
may have existed although it was not statistically
significant in this study. In addition, only 5% of the
drugs were discontinued because they were effective
and no longer necessary. 15% of the drugs were
continued at time of discharge, and 8 % were discontinued at time of discharge. These figures cast
doubt on the efficacy of drugs being employed. Concerning route of administration, 52% were p.o., 17%
J.M., 5 % S.C. and 20% I.V. 20% I.V. is a surprisingly high figure. Tabulation of instructions for drug
usage revealed 48 % standard orders, 10% pm, and
40% stat. That 40% of the orders were stat is again
a surprising figure.
Preceptor: ALBERT J. WASSERMAN, Division of Clinical Pharmacology, Medical College of Virginia.

Acquired Absence of Alpha Lipoproteins
and Acanthocytosis in Severely Burned
Patients*
MARVIN ZELKOWITZ (M-70)

Severely burned patients develop decreased to absent alpha lipoprotein (LP) and concommitant "burr
shaped" RBC. In serial observations of all hospitalized
burn patients, only one of 13 having more than 30%
body burn did not develop decreased alpha LP during
the first to the tenth week after the burn, the onset
depending on the severity of the burn. The beta LP
and other lipid measurements tended to be low, although two patients had increased beta LP. Acanthocytic RBC (30-90 % ) were found in each patient with
absent alpha LP, aad the findings were temporally
related. P atients with less than 30 % total body bum
did not develop either abnormality. Neither septicemia,
hepatic failure, or renal failure could be incriminated.
Preliminary studies of the lipid content of RBC membranes from acanthocytic cells suggest that the
phospholipid content is less than that of normal RBC,
but the cholesterol content is unchanged, as is the
distribution of RBC phosphatides. We suggest the
following sequence: alpha LP weep through the
damaged skin in amounts exceeding synthetic capacity;
the RBC phosphatides which are in equilibrium with
the plasma phosphatides are leached from the cells

ABSTRACTS OF THESES

altering membrane lipids and membrane structure with
a resultant change in shape. Thus, an alphalipoproteinemia developing after a severe burn can be associated with burr-cell formation, perhaps because of
membrane lipid changes. These findings contrast with
the absence of morphologic RBC changes in hereditary
an-alphalipoproteinemia (Tangier Disease) and provide another facet to the association between LP and
acanthocytosis.
Preceptor: WILLIAM R. HARLAN, JR., Clinical Research Center, Medical College of .Virginia.
'''Reprinted with permission from Clin Res 17: 35,
1969.

Proteinuria and Glomerular Lesions in
Rats Induced by Sera from Human Renal
Transplant Recipients
R. C. SMALLRIDGE CM-70)
D. B. WALDMAN (M-72)

Glomerulonephritis appears to be due to a variety
of factors, one of which may be circulating antibodies
to glomerular basement membrane. Since some kidney
transplant recipients develop massive proteinuria, a
model was established to see if kidney lesions could
be produced in experimental animals by inoculations
of serum from patients with recurrent proteinuria.
Sera (5-8 cc.) taken after transplant rejection from
5/ 7 transplants produced no proteinuria or histologic
changes in the kidneys of unilaterally nephrectomized
rats. One patient's serum produced massive proteinuria
of 36.6 mg./24 hrs. and 127 mg./24 hrs. in two rats.
(control rats averaged 8 mg./24 hrs.) No significant
changes were observed on microscopic examination.
The serum and acid eluate from the kidney of another
patient produced glomerular lesions with obliteration
of Bowman's space, thickening of the glomerular
vasculature, increased cellularity, and the deposition
of PAS positive material in the region of the glomerular basement membrane. We conclude that transferable serum factors present in some patients with
glomerulonephritis are even pathogenic in rats. Thus
far, we have seen two different effects : ( 1) massive
proteinuria, and (2) obliteration of glomeruli without
significant proteinuria. It is possible that this type of
bioassay will help in determining which patients have
a high risk of recurrent glomerulonephritis following
transplantation, and, more important, that it will distinguish types of glomerulonephritis.
Preceptor: G. MELVILLE WILLIAMS, Department of
Surgery, Medical College of Virginia.
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Contributors

Ali A. Hossaini (Transfusion Problems in Hemolytic Anemias) is associate
professor of clinical pathology and director of the blood bank at the Medical
College of Virginia. He completed his undergraduate studies at the American
University of Beirut, Lebanon, received his M.A. and M.S. degrees from Texas
Christian University, and earned his Ph.D. at Ohio State University. Before coming to MCV, Dr. Hossaini was on the faculty of the department of pathology at
West Virginia Medical Center in Morgantown.

Harold M. Maurer (New Concepts in Management of Neonatal Jaundice: Use
of Enzyme Induction and Phototherapy) is an assistant professor in the department of pediatrics at the Medical College of Virginia. Before coming to MCV,
he was chief of pediatrics at the U. S. Public Health Service Hospital in Norfolk,
Virginia, and then on the attending staff of Babies Hospital and Vanderbilt
Clinic, Columbia-Presbyterian Medical Center. Dr. Maurer received his M.D.
from the State University of New York, interned at Kings County Hospital in
Brooklyn, and trained in pediatrics at Babies Hospital.

Daniel N. Mohler ( Glucose-6-Phosphate Dehydrogenase Deficiency ) is associate
dean and professor of internal medicine at the University of Virginia School of
Medicine. He attended the University of Kentucky and Ohio State University,
then received his medical degree from the University of Virginia. After internship
at Massachusetts Memorial Hospitals and residency at U. Va., Dr. Mohler had
a research fellowship in hematology at the Washington University School of
Medicine, then returned to U . Va. where he has remained on the full-time staff
in medicine.

John H. Moon (lmmunosuppression in Autoimmune H emoly tic Anemia) is an

associate professor of medicine in the department of medicine at the Medical
College of Virginia. He attended the University of Richmond, then the Medical
College of Virginia where he received his medical degree. Dr. Moon interned at
Methodist Hospital, Indianapolis, and returned to do his residency at MCV,
where he has remained in the field of hematology.
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Robert I. Weed (New Thoughts on Hereditary Spherocytosis) is a professor of
medicine and of radiation biology and biophysics at the University of Rochester
School of Medicine and Dentistry; he is also head of the hematology unit. Dr.
Weed received his B.S. and M .D. from Yale University, interned at Strong
Memorial Hospital, and was an assistant resident in medicine at the Yale-New
Haven Medical Center. He held fellowships in hematology with the American
Cancer Society and the U .S. Public Health Service. Dr. Weed is also an associate
editor of Blood.

Wendell F. Rosse (Paroxysmal Nocturnal Hemoglobinuria-New Thoughts) is
associate professor of medicine and of immunology at Duke University. A graduate of the University of Omaha, he received his M.S. in physiology from the University of Nebraska and his M.D. from the University of Chicago. After internship and residency at Duke, Dr. Rosse was a clinical associate at the National
Cancer Institute, a fellow in hematology at the Postgraduate Medical School,
London, and a senior investigator at the National Cancer Institute. Dr. Rosse is
recipient of a Public Health Service Research Career Development Award.

M. Robert Cooper (The New Hemoglobinopathies) received his M.D. degree
from the Bowman-Gray School of Medicine of Wake Forest University. After
his internship at the University of Virginia Hospital, Dr. Cooper returned to
Bowman-Gray where he completed his residency in medicine, was a fellow in
clinical oncology, and is now assistant professor of medicine (hematology and
oncology). His primary research interests are in white cell metabolism, platelet
survival and sequestration, and viscosity changes in hemoglobinopathies.

Walter J. Geeraets (Solar Retinopathy Following the Eclipse of March 7, 1970:
A Follow Up), professor of ophthalmology and associate professor of biophysics
at the Medical College of Virginia, was born in M. Gladbach, Germany. He obtained a doctor's degree in medicine from the University of Bonn, later serving
as a research fellow at the Radiation Institute of that university and as the chief
assistant of the surgical clinics at Bochum, Germany. In 1957 he came to MCV
with appointments in the departments of ophthalmology and biophysics. Dr.
Geeraets is currently director of ophthalmic research and coordinator of the
NIH ophthalmic resident training program at MCV.
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A new service from A. H. Robins
Late in 1969, the A. H. Robins Company, because of their
spec ial interest in gastrointestinal med icine, began distributing to Residents and Interns a series of brochures
entitled G.I. SERIES. This publication was designed to provide a quick, yet comprehensive review of basic
procedures and practices in G. I. medicine - with
particular emphasis on the physical examination as
performed in the office or at bedside. Designed primarily for the student physician, the contents have been,
arranged and programmed for quick reading, rapid comprehens ion and easy review .
An excerpt from the first of the six-part series on physical
examination of the abdomen is shown at right. If you have
teaching responsibilities, limited
quantities of the already published sections of the series are
still available on a " first come ,
first served" basis. Presently
available are Part 1-/nspection,
Part 2-Palpation and Part 3Percussion . Simply write to :
The Medical Department,
A. H. Robins Company,
1407 Cummings Drive,
Richmond , Virginia 23220

the spasm reactors
in your practice deserve
"the Donnatal®effect"
each tablet, capsule or
5 cc. teaspoonful
of Elixir (23% alcohol)

each
Don natal

No.2

each
Extentab®

hyoscyamine
sulfate

0.1037 mg.

0.1037 mg.

0.3111 mg.

atropine sulfate

0.0194 mg.

0.0194 mg.

0.0582 mg.

hyoscine
hydrobromide

0.0065 mg.

0.0065 mg.

0.0195 mg.

phenobarbital
(1A gr.) 16.2 mg.
(warning: may be habit forming)

('12 gr.) 32.4 mg.

(% gr.) 48.6 mg.

A·H·ROBINS
A. H. Robins Company, Richmond, Va. 23220

Excerpt from Part 1, Inspection...,.
Abdom inal profiles
Careful inspection of the profile
of the abdomen from the side may
give the first clue of abnormality,
directing attention to a specific
region and prompting a search for
further signs. While distinction
begins with visual inspection,
palpation, percussion and
auscultation are required to make
an accurate differential diagnosis .

generalized distention,
with umbilicus inverted:
obesity or recent
distention from gas, etc .

generalized distention,
with umbilicus everted:
chronic ascites, tumor,
or umbilica l hernia

scaphoid abdomen,
from malnourishment

distention of lower half:
ovarian tumor, pregnancy,
bladder

distention of lower third:
ovarian tumor, uterine fibroids,
pregnancy, bladder

X = Xiphoid
U= Umbilicus
P= Pubis

The stress-spasm syndrome and the "Donnatal Effect."
Donnatal provi des a predictable, inexpensive way to help the patient who
responds to stress situations with gastrointestinal or other smoothmuscle spasm. The characteristic over-all effect of Donnatal achieves
two essential objectives: calming the patient, pacifying the gut. Outstanding in effectiveness, safety, economy, uniformity of composition
and dosage convenience, Donnatal continues to be prescribed by more
physicians than any other agent in its class.
The Donnatal "spectrum" of usefulness.
Particul arly useful when anxiety and tension accompany, aggravate or
account for smooth muscle spasm, Donnatal is indicated for the symptomatic relief of recurring, persistent or chronic visceral spasm, as in
gastritis, pylorospasm, esophageal spasm, irritable stomach and colon,
nervous indigestion, duodenal or gastric ulcer. Donnatal is also indicated in dysmenorrhea, nausea, motion sickness and nocturnal enuresis . Since Don natal helps reduce gastric hypersecretion, it is useful in
hyperchlorhydria, peptic ulcer and other conditions mentioned above .
For spasm reactors-young and old alike-Donnatal is an ideal choice to
control the syndrome-safely, simply and effectively .
Brief summary: Blurring of vision, dry mouth, difficult urination , and flu shi ng or dryn~s~ of th~ skin may occur on higher dosage levels, rarely on usual dosage. Adrnb1nister. with caution to patients with incipient glaucoma or urinary bladder neck
0 struct1on . Contraindicated in acute glaucoma, advanced renal or hepatic disease
or a hype rsensiti vity to any of the ingredients.

distention of upper half:
carcinomatosis, pancreatic cyst,
gastric dilation
Adapted from DeGowin, E. L.,
Bedside Diagnostic Examination, New York,
The Macmillan Co., 1967.

Whenever anxiety induces or intensifies clinical symptoms

~i

•

rtum®

(chlordiazepoxide HCl)
Quickly relieves anxiety-Helps improve response in
psychophysiologic disorders-Seldom impairs
mental acuity or physical coordination, on proper dosageHas wide margin ofsafety

Before prescribing, please consult complete
product information, a summary of which
follows :
Indications: Indicated when anxiety, tension
and apprehension are significant components
of the clinical profile.
Contraindications: Patients with known
hypersensitivity to the drug.
Warnings: Caution patients about possible
combined effects with alcohol and other CNS
depressants. As with all CNS-acting drugs,
caution patients against hazardous occupations
requiring complete mental alertness (e.g.,
operating machinery, driving).Though physical and psychological dependence have rarely
been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage;
withdrawal symptoms (including convulsions),
following discontinuation of the drug and
similar to those seen with barbiturates, have
been reported. Use of any drug in pregnancy,
lactation, or in women of childbearing age
requires that its potential benefits be weighed
against its possible hazards.
Precautions: In the elderly and debilitated,
and in children over six, limit to smallest effective dosage (initially 10 mg or less per day) to
preclude ataxia or oversedation, increasing

gradually as needed and tolerated. Not recommended in children under six. Though generally not recommended, if combination therapy
with other psychotropics seems indicated,
carefully consider individual pharmacologic
effects, particularly in use of potentiating
drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of
impaired renal or hepatic function. Paradoxical reactions (e.g., excitement, stimulation and
acute rage) have been reported in psychiatric
patients and hyperactive aggressive children.
Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and
protective measures necessary. Variable effects
on blood coagulation h'!ve been reported very
rarely in patients receiving the drug and oral
anticoagulants; causal relationship has not
been established clinically.
Adverse Reactions: Drowsiness, ataxia and
confusion may occur, especially in the elderly

~ Rh®

1!11!] LA°io~TORIES

Division of Hoffmann - La Roche Inc.
Nutley, New Jersey 07110

and debilitated. These are reversible in most
instances by proper dosage adjustment, but are
also occasionally observed at the lower dosage
ranges. In a few instances syncope has been
reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation,
extrapyramidal symptoms, increased and decreased libido-all infrequent and generally
controlled with dosage reduction; changes in
EEG patterns (low-voltage fast activity) may
appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice
and hepatic dysfunction have been reported
occasionally, making periodic blood counts
and liver function tests advisable during protracted therapy.
Usual Daily Dosage: Individualize for maximum beneficial effects. Oral-Adults: Mild
and moderate anxiety and tension, 5 or 10 mg
t.i.d. or q.i.d.; severe states, 20 or 25 mg t.i.d.
or q.i.d. Geriatric patients: 5 mg b.i.d. to
q.i.d. (See Precautions.)
Supplied: Librium® (chlordiazepoxide HCI)
Capsules, 5 mg, 10 mg and 25 mg-bottles of
50. Libritabsu1. (chlordiazepoxide) Tablets,
5 mg, 10 mg and 25 mg-bottles of 100. With
respect to clinical activity, capsules and tablets
are indistinguishable.

Also available: LibritabsM(chlordiazepoxide) 5-mg, 10-mg, 25-mg tablets

